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Lay Summary
Antibiotic resistance is a growing concern in veterinary care. Not only do an-
tibiotic resistant bacteria cause significant harm to animals, they also increase
the risk of antibiotic resistant infections in humans. There is a growing body of
evidence to suggest that antibiotic resistance is associated with particular types
of E. coli ; antibiotic resistant bacteria tend to associate less strongly to E. coli
that are harmful to humans and animals. Instead they associate with E. coli that
are commonly found in healthy humans and animals. Bacteria in general, and
especially E. coli, are extremely adept at sharing DNA, including the DNA which
encodes for antibiotic resistance.
This project utilized E. coli that had been collected from canine patients at
the Small Animal Hospital, Royal (Dick) Veterinary School. Specifically, E. coli
collected from urinary tract infections in dogs that were resistant to three or more
different antibiotics, were compared against E. coli collected from urinary tract
infections in dogs that were not resistant to any antibiotics. At the outset of this
study it was not known how the E. coli had acquired their antibiotic resistance;
or how easily this resistance could be transfered.
The experiments in this study were used to help define the relationship between
the genes causing the antibiotic resistance and the E. coli carrying the resistance.
Ultimately the work focused on particular molecules of DNA called plasmids
which were found to be wholly responsible for spreading the antibiotic resistance
in these isolates at the Small Animal Hospital, Royal (Dick) Veterinary School.
xii
Abstract
This study focused on a group of multi-drug resistant (MDR) E. coli collected
between 2002 and 2011 at the Small Animal Hospital, Royal (Dick) Veterinary
School; isolated from urinary tract infections in dogs. The MDR E. coli isolates
were compared against a group of fully susceptible E. coli, also collected from
canine urinary tract infections.
The MDR isolates were notable for their AmpC β-lactamase resistance pheno-
type (12/18) and resistance genotype (blaCMY-2, 8/12). Phylogenetic comparisons
between the MDR and susceptible groups of isolates showed a large degree of sep-
aration between the two groups. Susceptible isolates strongly associated the the
pathogenic B2 phylogroup (67%), which was expected. The MDR group was
much more mixed, with isolates more associated with commensal A (28%) and
B1 (22%) phylogroups.
Virulence marker abundance, evaluated using an Identibac microarray, showed
a much reduced presence of virulence markers in the MDR group, as compared
with the susceptible isolates. An infection model, using Galleria mellonella lar-
vae, was used to better test the phenotypic virulence of the MDR and susceptible
E. coli isolates. An asymptomatic bacteriurea strain (ABU83972) and a virulent
pyelonephritis strain (CFT073) were used as non-virulent and virulent control
strains of uropathogenic E. coli. The model produced consistent and expected dif-
ferences in lethality between ABU8392 (non-lethal) and CFT073 (lethal) strains.
However, the model showed no differences between the MDR and susceptible
isolates.
Second generation Illumina short-read sequencing and third generation single-
molecule real-time sequencing were used to further dissect the genetic background
of both the E. coli and the MDR genotype. Core-genomic sequence comparisons
of the E. coli showed no clonal relatedness amongst the different MDR and sus-
ceptible strains. Most strikingly, sequencing revealed extensive plasmid carriage
of the MDR genotype.
Plasmid mediated blaCMY-2 was associated with a clonal group of IncI1 plas-
mids. The IncI1 plasmids show favorable sequence comparisons to a plasmid
backbone previously reported in dogs and other animals, with a global distri-
bution. The remaining resistance genes were associated with a group of IncFII
xiii
plasmid sequences. This study highlights a broader range of commensal E. coli,
which have resulted in opportunistic infections in their canine hosts. As such,
they act as a potential reservoir of resistance, which is as yet uncharacterized.
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Aims
• To characterize the resistance phenotype and genotype of multi-drug resis-
tant Escherichia coli isolated from urinary-tract infections.
• To determine if antimicrobial resistance provides the main advantage, al-
lowing establishment of infection in an antimicrobial environment.
• To determine if multi-drug resistant urinary-tract infection Escherichia coli
strains are atypical of uropathogenic E. coli, in that they are less virulent.
• To determine if multi-drug resistance status, particularly plasmid acquisi-
tion, contributes to virulence in either a positive or negative manner.
• To determine if resistance phenotypes are co-selected with virulence factors
or virulence regulation.
• To determine if multi-drug resistance characteristics are detrimental for
viurlence with multi-drug resistance strains generally being avirulent with






A bacterial multi-drug resistant (MDR) isolate is one that is resistant to at least
one antimicrobial from three or more classes of antimicrobials. Such isolates are
often the result of the accumulation of separate antimicrobial resistances and
pose a significant clinical challenge (Magiorakos et al., 2012). Between 2006
and 2011 a number of MDR E. coli infections were identified by the Veterinary
Microbiology Laboratory, Royal (Dick) Veterinary School. Despite their sporadic
nature, these infections were extensively MDR, and notable for their extended-
spectrum β-lactamase (ESBL) resistance. These infections were isolated from a
number of different animals (canine, feline and equine), and had differing clinical
presentations:
• Wound abscesses





All of the animals had been undergoing complex treatments at the time the
infections had been diagnosed; and many of the patients had been prescribed pro-
phylactic antibiotics. It was not known if they were part of an ongoing outbreak,
or the consequence of modern veterinary clinical care. Neither MDR infections
or ESBL infections are commonly identified. Of the 28 MDR infections initially
identified, urinary tract infections (UTI)s were the largest singular group of in-
fections (12/28). It was also the only group of infections that had a suitable
comparator group of fully susceptible isolates that could be used to perform com-
parative studies.
Out the outset it was not known if there was a potential community-associated
reservoir of resistance that the patient had been exposed to. No studies into
the molecular epidemiology of UTIs, MDR or otherwise, had been conducted.
MDR is a consequence of the persistence and accumulation of antimicrobial re-
sistance (AMR) within the clinical environment. It is influenced by a number of
confounding factors:
• The antibiotics prescribed routinely; which act as selection pressures pro-
moting the spread of acquired resistances.
• The bacteria expressing the acquired resistances. Bacterial pathogens, with
diverse ecological niches, affect the diversity and prevalence of AMR.
• The transferability of resistance beyond a single bacterial host, or patient.
The endemic, or epidemic presence of AMR within the clinical environment
is influenced by the transferability of AMR between different bacterial pop-
ulations and also other mammalian hosts.
2
• The etiology of the infections and health status of the host prior to AMR, or
MDR infection. The duration and complexity of antibiotic chemotherapy
(prophylactic or not) and any underlying patient susceptibility to infec-
tion which may increase the persistence of AMR and MDR in the clinical
environment.
Whereas there is a considerable body of published research detailing the effects
and affects of antibiotic chemotherapy and developing resistance in human clinical
care; little, if any, comparable research exists for canine veterinary AMR or any
companion animals. As little is known about companion animal AMR, and almost
nothing was known about the MDR E. coli isolates identified at the outset of the
work presented here, this project focused on the following aims:
• To characterize the resistance phenotype and genotype of MDR E. coli
isolated from the UTIs.
• To determine if AMR is the primary niche adaptation promoting the oc-
currence of these infections in the clinical setting.
• To determine if the MDR E. coli causing UTIs identified in this study are
atypical of uropathogenic E. coli (UPEC); in that they are less virulent.
• To determine if MDR status, particularly plasmid acquisition, contributes
to virulence in either a positive or negative manner.
• To determine if resistance phenotypes are co-selected with virulence or vir-
ulence regulation.
• To determine if the acquisition of MDR favor a particular E. coli genetic
background; either from the intrinsic gut flora (commensal E. coli), or ex-
trinsic pathogenic E. coli.
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To better frame the work laid out in this thesis, the introduction will expand
on the following topics:
• The antibiotics used to treat canine UTI’s. With a particular focus on the
β-lactams, given the preponderance of ESBL resistance:
– The antibiotics used to treat companion animals.
– The sub-set of antibiotics used to treat UTI
• The known epidemiology of AMR and MDR that arises from the clinical
use of antibiotics used in veterinary care:
– MDR and known clinical epidemiology.
– β-lactamase and ESBL resistance.
• The intersection between AMR, MDR and UPEC; with a focus on the trade-
offs between the acquisition of pathogenic and MDR conferring elements.
– UTI
– UPEC
– Urovirulence and AMR
• The wider impacts of veterinary MDR isolates, including One Health.
1.2 Background
The progressive increase of world-wide incidence of AMR bacterial infections is
now the biggest problem facing modern health care. The World Health Or-
ganisation (WHO) cites a growing disconnect between effective national poli-
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cies, and attempts to control the spreading epidemic. WHO policy statements
attach particular importance to stopping the inappropriate or blanket use of
antibiotics and the concomitant stagnation of pharmaceutical development of
novel antibiotics. The poor communication of the health risks posed by AMR
and MDR is compounded by the academic and clinical focus aimed at contain-
ing AMR and MDR remaining at the institutional level, rather than at a na-
tional level for the majority of countries (http://www.who.int/world-health-
day/2011/presskit/whd2011_fs1_natplan.pdf?ua=1).
The Center for Disease Control (CDC) now estimates that 2 million US nation-
als now contract a bacterial infections which is AMR; of which 23,000 will dies as
a direct result. Of the 140,000 healthcare-acquired infections (HAI)’s attributable
to the Enterobacteriaceae, 26,000 will harbor ESBL resistance; leading to 1,700
deaths (https://www.cdc.gov/drugresistance/biggest_threats.html).
MDR, extremely drug resistant (XDR), and pan drug resistant (PDR) bacte-
rial isolates from across a spectrum of genera and species are of utmost concern
to the international health care community (Magiorakos et al., 2012).
Notable and well published examples of the spread of AMR include: MDR tu-
berculosis and methicillin-resistant Staphylococcus aureus (MRSA). More recent
and emerging AMR bacteria such as: Clostridium difficile, vancomycin-resistant
Enterococcus (VRE), carbapenem resistant Enterobacteriaceae (CRE), and Neis-
seria gonorrhoeae. These organisms are no longer treatable using first-line an-
tibiotics.
These concerns have been re-iterated by the European Center for Disease
Control (ECDC). Regular resistance surveillance recorded increased prevalence
of AMR in gram-negative bacteria (with emphasis on E. coli and Klebsiella
pneumoniae), as well as worrying increases in the numbers of MDR ESBL pro-
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ducing isolates (fig.1.1, fig.1.2) (https://ecdc.europa.eu/en/publications-
data/antimicrobial-resistance-surveillance-europe-2013).
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Figure 1.1: Available data for the prevalence of third generation cephalosporin resistance reported to the ECDC by participating
member states in E. coli Europe for the year 2000.
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Figure 1.2: Available data for the prevalence of third generation cephalosporin resistance reported to the ECDC by participating
member states in E. coli Europe for the year 2013
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The WHO, CDC and ECDC emphasize the importance of expanding surveil-
lance efforts in response to the developing threats of AMR and MDR; as well
as improving stewardship and expanding efforts towards the pharmaceutical de-
velopment of novel antibiotic compounds. Fundamentally, if not addressed, the
increasing incidence of AMR can drive increases in MDR, and eventually XDR
and PDR. Though still rare, there now incidences of AMR infections resistant to
all available treatment options (Jain and Mondal, 2008).
The increasing prevalence of AMR infections seen in human clinical care is also
influenced by the use of antibiotics in animals. The UK Department of Health
(DoH) has described veterinary AMR infections as a reservoir of resistant organ-
isms from which MDR strains can be selected for, and maintained. The transfer
of AMR between humans, animals and the environment they share indicates that
surveillance for resistance in just the human clinical setting is inadequate; and
that national surveillance must include animals. Despite this, national AMR




Though recent efforts by the UK government, through the Veterinary Medicines
Directorate (VMD), have acted to reduce the number and frequency of antibi-
otic prescriptions in animals; combined, food producing and companion animals
antibiotic prescriptions amounted to 337 tonnes of antibiotics for 2016 (https://
www.gov.uk/government/publications/veterinary-antimicrobial-resistance-
and-sales-surveillance-2016).
Improved epidemiology of animal-derived AMR, in conjunction with human
clinical data, provides a greater understanding of the potential future impacts of
AMR to: drug discovery and pharmacological developments in antibiotic treat-
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ments (Shryock, 2004); the changing effectiveness of antibiotics and the impact
this has on animal welfare (Mateu and Martin, 2001, Mateus et al., 2011, Wayne
et al., 2011); assess the frequency and efficiency of the transfer of AMR between
humans and animals (Guardabassi et al., 2008, 2004, Phillips et al., 2004). Fur-
thermore, the study of developing mechanisms of AMR in animals can be used as
a model for improving patient outcomes in human clinical care (Mateu and Mar-
tin, 2001). The increased attention that animal derived AMR is now receiving is
vital in protecting the increasingly vulnerable classes of antibiotics that form the
basis for the majority of clinical interventions.
1.2.1 Companion Animal Antibiotics
Few developments in the modern health care can eclipse the impact that antibi-
otics have had on improving clinical treatment outcomes. Along with improved
sanitation and general hygiene, the synthesis of targeted antimicrobial compounds
has saved an inestimable number of lives (Aminov, 2010).
Though the continuing development of antibiotics is mostly influenced by hu-
man clinical care, the veterinary care of companion animals relies on the same
classes of antibiotic compounds; with only few exceptions.
The functional diversity of the different classes of antibiotic, along with syn-
thetic modifications made to individual antibiotics within the different classes;
create a spectrum of activity against different bacterial isolates. This affects the
applicability of a particular antibiotic to a bacterial infection. Inappropriate class
choices, or the usage of an antibiotic whose spectrum of activity does not include
the causative bacterial organism risk the development of AMR.
Despite the diversity of the available antibiotic classes, the development of
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antibiotics has not kept up with developing AMR. The decreased rate of discovery
of novel antibiotics compounds has coincided with an increasing prevalence of
AMR; which increases the vulnerability of first and second-line antibiotics to
resistance.
As the diversity of available therapeutic options has been reduced, the selective
pressures which favor the aggregation of AMR into MDR have increased due to
the over-use of particular antibiotics.
This process is slow and difficult to reverse, and further increases the risk of the
development of AMR against newer antibiotics (Levy and Marshall, 2004). The
stewardship and general prescribing practices of antibiotics used in veterinary
care is not completely known.
The most recent Veterinary Antimicrobial Resistance and Sales Surveillance
(VARSS) report for UK (2016) https://www.gov.uk/government/publications/
veterinary-antimicrobial-resistance-and-sales-surveillance-2016 does
include prescription and resistance data for companion animals (including dogs).
However the report has several shortcomings which limit its use:
• Prescriptions are inferred from total antibiotic sales and are likely overesti-
mated.
• Companion animal resistance is only recorded when the bacterial isolates
are considered a direct threat to public health; estimates are therefore likely
underestimated.
The VARSS report for companion animals includes data collected in a separate
study (Buckland et al., 2016), indicating that 25% of total dog visits to veterinary
practices resulted in the prescription of one ore more antibiotics between 2012
and 2014. The most commonly prescribed antibiotics being either aminopenicillin
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or cephalosporins. Though 60% of the prescriptions included antibiotics listed as
vital to human clinical care (fluoroquinolones, macrolides and third-generation
cephalosporins).
Along with the other classes of antimicrobials listed in the VARSS report, the
β-lactams are a sizable component of the veterinary prescriptions. This is in
concurrence with a previous report into companion animal prescriptions in the
UK (Mateus et al., 2011), which highlighted the use of penicillins (amoxicillin-
clavulanate, amoxicillin) and the cephalosporins (cephalexin and cefovecin) as
being commonly prescribed to companion animals (dogs and cats).
The VARSS report along with data collected by the World Organisation for
Animal Health (OIE) https://www.oie.int/fileadmin/Home/eng/Specific_
Issues/docs/pdf/OIE_list_antimicrobials.pdf details the extent to which
veterinary care is reliant on antibiotics which have limited, or no, current alter-
natives:
• Aminoglycosides: used to treat septicemia, gastrointestinal, respiratory and
urinary tract infections. Widely used and few to no alternatives.
• Cephalosporins (all generations): used to treat septicemia, respiratory infec-
tions and mastitis. Therapeutic alternatives are more limited in spectrum
or cannot be used due to prevalent AMR.
• Penicillins: used to treat septicemia, respiratory and urinary tract infec-
tions. Alternatives are limited and more expensive.
• Fluoroquinolones: used to treat septicemia. Widely used with few alterna-
tives.
• Potentiated-sulfonamides: used to treat a wide variety of bacterial infec-
tions and can be used combinatorially. Alternatives are limited and more
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expensive.
• Tetracyclines: Are applied to a broad spectrum of bacterial infections. Al-
ternatives are limited and more expensive.
Apart from the vulnerability of several of these classes of antibiotics to devel-
oping resistance in animals; all of the antibiotics listed are also indicated for use
in humans. The usage of antibiotics to treat animals that are also used to treat
humans risks the selection of resistant bacteria capable of posing challenges to
both human and veterinary care (de Jong et al., 2012).
While there is some debate over the direct risk to humans resulting from animal
derived AMR; studies reporting such transfers exist for food producing animals
(Founou et al., 2016, Lambrecht et al., 2018), and in companion animals (Schaufler
et al., 2015, Somayaji et al., 2016); including direct transmission between pets
and their owners (Guardabassi et al., 2004, Harada et al., 2012). These reports
suggest that AMR in companion animals can directly contribute to the antibiotic
resistance reservoir which may impact human health.
1.2.2 β-Lactam Antibiotics
The β-lactams are perhaps the most commercially successful antimicrobial class;
represented by several hundred different compounds. The group comprises several
sub-groups including the penicillins, cephalosporins, carbapenems and monobac-
tams. Regardless of their chemical diversity, they possess the same antimicrobial
property: the inhibition of cell wall synthesis by binding of the penicillin-binding
protein (PBP)s.
The success of the β-lactams as therapeutic compounds, is in part, due to
the properties of the molecules which they target. They do not target a single
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bacterial protein, but the whole family of PBPs. This makes successful bacterial
resistance by point mutation alteration of particular PBPs less likely. The PBPs
are also relatively easily accessible; and cytosolic uptake of the drug compounds
by the bacteria is not necessary (Schneider and Sahl, 2010).
As well as their good pharmacokinetic properties, they are well tolerated by
the patient population; with low toxicity and only moderate concern for the rare
development of patient hypersensitivity to them. They have a broad spectrum of
activity against Gram negative and Gram positive bacteria, and are very often
used empirically as first-line antimicrobials of choice to treat the majority of
infections (Finch et al., 2003).
However, such use has not been without consequence. The widespread and
frequent usage of the β-lactams has been strongly correlated with increasing re-
sistance amongst Gram-negative bacteria, in particular. Continued clinical use of
the β-lactams has led to a concomitant rise of acquired and vertically-inherited
resistance, primarily associated with β-lactamase resistance genes. Such resis-
tance (primarily recorded in humans) has been observed in the community and
in health care associated infections (Davies and Davies, 2010).
1.2.3 β-Lactamases
β-lactam antibiotics inhibit bacterial cell-wall synthesis by binding to and inac-
tivating the PBPs, which are required for the assembly and maintenance of the
peptidoglycan layer (Morar and Wright, 2010). Enterobacteriaceae resistance to
the β-lactams can occur via:
• Increased drug efflux.
• Decreased PBP binding affinity.
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• Enzymatic degradation of the β-lactam molecule by the β-lactamases.
Of these different resistance mechanisms, the production of β-lactamase en-
zymes, by the bacteria, is most important (Rubin and Pitout, 2014).
The enzymatic inactivation of the β-lactam antibiotics by the β-lactamases
occurs by the hydrolytic cleavage of the chemically active β-lactam ring. This
can occur via two distinct chemical pathways, which is the foundation for the
classification systems used to classify and differentiate individual β-lactamase
enzymes (Morar and Wright, 2010).
The Ambler classification system divides the various sub-groups of β-lactamase
enzymes based on amino acid sequence (Ambler, 1980). The Ambler classification
scheme identifies four main classes of β-lactamase (A, C, D and B). Classes A, C
and D are separated from class B by the presence of a catalytic serine residue in
the active site. The active sites of class B enzymes (also referred to as metallo-
enzymes) contain a catalytically active metal ion.
A more modern and more functional system, the Jacoby-Bush-Medeiros (JBM)
classification, was introduced to address the paucity of available amino acid
sequence data which the Ambler classification relies on. Under the JBM, β-
lactamase enzymes are grouped by their ability, or inability to hydrolyze differ-
ent β-lactams and the rate by which hydrolysis occurs (Bush et al., 1995). The
JBM classification is more readily capable of accommodating novel β-lactamase
sequences and functional data, and incorporates the existing Ambler classifica-
tions. The most recent classification of known β-lactamases (Bush and Jacoby,
2010) identifies three major groups of β-lactamases:
• Group 1: Serine mediated hydrolysis (Class C) enzymes. Functionally de-
fined by: cephalosporin affinity. Enzymes are not inhibited by clavulanic
acid or tazobactam. Variably resistant to extended-spectrum cephalosporins.
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• Group 2: Serine mediated hydrolysis (Class A and D) enzymes. Function-
ally defined by: variable penicillin and cephalosporin affinities. Mostly in-
hibited by clavulanic acid and tazobactam. Variably resistant to extended-
spectrum cephalosporins.
• Group 3: Metallo-enzymes (Class B). Functionally defined by: carbapenem
affinity as well as broad-spectrum β-lactam affinity. Inhibited by EDTA.
Despite comprehensive attempts to classify individual enzymes into distinct
families through functional and sequence comparisons; there is considerable over-
lap in the inter and intra group capabilities for individual enzymes to inactivate
the various β-lactams (Morar and Wright, 2010).
1.2.4 AmpC β-lactamases
Class C β-lactamases have a distinct evolutionary origin from class A and D
enzymes. The archetypal class C β-lactamase, AmpC, is encoded chromosomally
throughout the Enterobacteriaceae (the expression is not ineducable in E. coli).
The functional origins of chromosomal AmpC are in routine bacterial cell wall
maintenance, as well as the enzymes ability to inactivate β-lactam compounds
(Morar and Wright, 2010).
AmpC was first identified as being distinct from other β-lactamases in the
early 1980’s (Jaurin and Grundström, 1981). AmpC enzymes have hydrolytic
activity against the penicillins, cephalosporins (extended-spectrum or otherwise),
the cephamycins and the monobactams. Unlike the majority of of the class A or D
enzymes, AmpC enzymes are not inhibited by β-lactamase inhibitors introduced
to combat the increasing prevalence of β-lactamase resistance (Bush and Jacoby,
2010).
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The three dimensional structure of AmpC is analogous to class A and D en-
zymes. Though notably, the AmpC active site is capable of binding the larger
and more complex β-lactams such as the cephalosporins and extended-spectrum
cephalosporins.
As with other β-lactamases, the catalytic affinity of individual enzymes can
be extended to new β-lactam compounds through structural modification of the
active site, by altered amino acid sequence; to accommodate bulkier chemical
side-chains associated to the β-lactam ring (Jacoby, 2009).
Chromosomal AmpC (cAmpC) mediated resistance in E. coli can arise through
various point mutations which act to constitutively express AmpC. However,
more commonly, AmpC mediated resistance is horizontally acquired via plasmid
associated AmpC (pAmpC) group enzymes. Though the majority of identified
β-lactamases are class A or D enzymes, novel plasmid mediated AmpC enzymes
continued to be identified (Bush and Jacoby, 2010).
1.2.5 Extended-spectrum AmpC (ESAC) and ESBL
The rate at which novel β-lactamases have been identified has increased since
their initial identification; and continues to accelerate (Bush and Jacoby, 2010).
The initially well defined β-lactamase groups have become increasingly variable
in their resistance profiles through the accrual of beneficial genetic mutations;
expanding or altering their enzymatic affinity towards different β-lactams. The
horizontal transfer of β-lactamase gene sequences to different bacterial hosts via
mobile genetic elements has also increased the diversity of the β-lactamases (Liv-
ermore and Woodford, 2006). As the development of the β-lactams increased to
deal with emerging resistance, so to did the rate of discovery of novel β-lactamases
capable of inactivating these newer compounds.
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The oxyimino-cephalosporins (extended-spectrum cephalosporins), or third
and fourth generation cephalosporins, were developed to combat emerging re-
sistance against existing β-lactams. The addition of a 7-oxyimino group to the
β-lactam ring introduces steric hindrance and shields the β-lactam ring from the
active site (Mammeri and Nordmann, 2007). Shortly after their introduction, the
first β-lactamases capable of hydrolyzing the extended-spectrum cephalosporins;
these enzymes are the ESBLs (Bradford, 2001).
The term ESBL has been applied to any β-lactamase that confers resistance
against the extended-spectrum cephalosporins; and they are horizontally acquired
(Cornaglia et al., 2008). However, further distinction is required to separate
ESBL enzymes from the functionally separate AmpC enzymes which can also
confer resistance to the extended-spectrum cephalosporins. These are referred to
as extended-spectrum AmpC (ESAC) β-lactamase. ESAC enzymes remain un-
inhibited by clavulanic acid, but despite their characteristic extended-spectrum
activity, affinities towards other β-lactams are highly varied (Mammeri and Nord-
mann, 2007).
1.2.6 E. coli and β-Lactamase Resistance
Antimicrobial resistance has been well documented as negatively impacting on
patient morbidity and mortality in human clinical care. Resistance to extended-
spectrum cephalosporins, in particular, has been linked to increased adverse clin-
ical outcomes (Cosgrove et al., 2002, Cosgrove and Carmeli, 2003). Inappropriate
use of β-lactams, particularly third generation cephalosporins, has been linked to
increasing β-lactamase prevalence within the hospital setting (Paterson, 2004).
Currently, the best preventative measures against hospital-acquired infections
rely on infection control, antimicrobial stewardship, and active hospital surveil-
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lance (Owens Jr. and Rice, 2006, Paterson, 2006, Weinstein, 2001). Outbreaks
also impact on hospital resources and increase per-patient health care spending
(Roberts et al., 2003).
The impact on human health care is not just limited to the hospital setting.
AMR E. coli isolates, are also detectable in the community setting (Pitout et al.,
2005, Rogers et al., 2010, Kim et al., 2017). AMR E. coli, capable of nega-
tively impacting human health has also been detected in the wider environment
(Leonard et al., 2018).
In order to effectively limit the potential impact, it is important to correctly
identify the most successful AMR determinants from hospital, community and en-
vironmentally associated infections so that the may be appropriately treated and
prevented from disseminating. A recent update on the prevalence of AMR in the
European Union (EU) (2013-2016), issued by the ECDC (https://ecdc.europa.
eu/sites/portal/files/documents/AMR-surveillance-Europe-2016.pdf), high-
lights concerns over the wide-spread dissemination of resistant and MDR E. coli :
• E. coli is the most frequent cause of bacteraemias and UTIs in Europe; and
is a significant causative agent of both community and hospital-associated
infections.
• 58.6% of E. coli isolates were resistant to at least one of the antimicrobial
groups. There is a notable, increasing trends in third-generation cephalosporin
resistance (and ESBL detection).
• ESBL isolates often possessed acquired resistances to other antimicrobial
classes (fluoroquinolones and aminoglycosides). Some of these infections
are susceptible only to the carbapenems; to which some E. coli isolates are
resistant.
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ESBL mediated resistance is a complicating factor in infections risk manage-
ment and negatively impacts hospital resources and patient morbidity and mor-
tality; though limited antibiotic chemotherapeutic options make it more difficult
to assess the risk to patient welfare (Ramphal and Ambrose, 2006). The antimi-
crobial class of choice to treat ESBL producing infections are the carbapenems.
While they remain largely effective, increased usage of this class of antimicro-
bials may promote the selection for resistant isolates. Were such resistance to
become acquired by MDR E. coli isolates there remains little, if any antibiotics
of choice (Livermore et al., 2011).
ESAC producing E. coli isolates also present a threat to the carbapenems.
Worryingly, ESAC producing isolates that are also resistant to some carbapen-
ems (ertapenema and imipenem) have already been reported; resistance being
conferred by the loss of OmpC and OmpF porins (Mammeri et al., 2008).
Despite the documented threat to human health, posted by β-lactamase re-
sistant E. coli, it remains difficult to assess the threat that these isolates pose to
veterinary care at a national level.
There is little information on the effects of infection control practices within
veterinary hospitals. A survey conducted by (Benedict et al., 2008) concluded
that infection outbreaks are a regular occurrence for veterinary hospitals; and
have identified E. coli as an important causative organism. The authors go on
to speculate that given the lack of: co-ordinated and standardized surveillance
efforts, passive not active surveillance for resistance and no surveillance for en-
vironmental transmission; these are all underestimated problems in veterinary
hospitals.
In general, much less is known about AMR in veterinary practice, compared
to what is known about AMR in human clinical environments. While there
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are regular surveys conducted on the the usage of antibiotics in companion
animals VARSS, Small Animal Veterinary Surveillance Network (SAVSNET)
(http://www.liv.ac.uk/SAVSNET/) and GermVet (Michael et al., 2017), they
do not release data on the incidence of UK wide AMR.
Similar to reports originating from the EU and the UK, a national survey
of veterinary hospital inpatient prescribing practices in the USA (Baker et al.,
2012) indicated the β-lactams as the most significantly prescribed antimicrobials
(72.7% of all surveyed dogs). Interestingly, the authors also indicated a signifi-
cant proportion of the dogs surveyed (55.6%) had been prescribed at least one
antibiotic within 12 months of admission; which the authors conclude contributes
to the co-selection of AMR traits and propagation of MDR.
Despite the frequency and scale of reports investigating the epidemiology of
AMR in food producing animals, less is known about the presence of AMR in
companion animals. Most of the the reports of the incidence of veterinary AMR
and MDR are from individual institutions.
1.2.7 MDR and β-Lactam Resistance in Dogs
AmpC andor MDR E. coli both present clinical challenges in the care of dogs.
However, the degree to which either is a problem is difficult to assess. AmpC and
ESAC mediated AMR functionally overlap (in terms of their resistance profile)
with many of the other ESBL and β-lactamases. Though ESBL mediated resis-
tance is reported, not all of the reports attempt to distinguish ESBL from ESAC
resistance. A large proportion of the published literature of either AMR preva-
lence, or AmpC/ESBL resistance comprises reports of either clinical outbreaks of
MDR or passive surveillance from hospital bacteriology departments (table 1.1).
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Table 1.1: Available literature detailing ESBL and beta-lactam resistance in dogs,
in nosocomial and community settings.
Some of the reports summarized here do not specifically address the issue of
AmpC resistance in dogs. Earlier studies tend to report only the results of an-
tibiogram susceptibility testing, which provides only basic phenotypic resistance
of the isolates. Where the reports have included clinical breakpoints, and more
extensive phenotypic screening of suspected ESBL isolates; further diagnostic
testing may not have been conducted to confirm either ESBL or ESAC resistance
determinants. Also, the studies tend to be small (either in isolates, or numbers
of dogs surveyed), isolated from each other (spatially and temporally) and biased
towards isolates that have been clinically selected for resistance. Despite this, the
correlation of incidence and recurrence of E. coli UTI, with regards to increasing
AMR, is notable (Ball et al., 2008).
Throughout the reports, E. coli resistance to various β-lactams was highly
variable. Resistance to the cephalosporins (all generations) was not highly preva-
lent
The largest survey of clinically detected E. coli resistance was carried out
in Canada (Murphy et al., 2010). Whilst the prevalence of E. coli was low,
no antibiotic class was without detectable resistance. MDR isolates were also
detectable, mediated by the possession of pAmpC resistance genes (blaCMY-2).
Within the UK, the only canine based resistance surveillance with national cov-
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erage was carried out by (Normand et al., 2000). The authors conducted a longi-
tudinal, retrospective evaluation of resistance phenotypes (using clinical records)
from across the UK, over an eight year period. The report does not specifically
address E. coli, but identified rising trends in resistance to amoxicillin-clavulanate
and streptomycin in E. coli. The method of reporting is proportionality of resis-
tance phenotypes only, no elucidation of resistance mechanisms is possible from
the data as presented.
More recent studies from the UK also highlight an underlying prevalence of
AMR. A cross-sectional community based evaluation of canine E. coli isolate
resistance in Cheshire (Wedley et al., 2011b), confirmed the presence of multiple
ESBL (blaSHV, blaTEM, and blaCTX-M) and AmpC isolates; correlated to high
levels of resistance to ampicillin, tetracycline, trimethoprim and overall MDR
status.
A survey of nosocomial E. coli isolates (patients and clinical environment)
from several veterinary hospitals (Tuerena et al., 2016), also identified a high
proportion of MDR E. coli endemic to both patient (13.1%) and environmental
(8.9%) samples collected. These isolates were also notable for high carriage rates
of ESBL and AmpC resistance; commonly mediated by blaCTX-M, blaTEM, blaSHV
and blaCMY resistance genes.
Despite the relatively low number of reports, blaCMY-2 and blaCTX-M resistance
genes have continued to be identified in isolates globally (Belas et al., 2014, Ewers
et al., 2014, Gandolfi-Decristophoris et al., 2013, Hamilton et al., 2013, Huber
et al., 2013, Sallem et al., 2013).
Though mostly focused on nosocomial resistance, there have been reports of
community-associated MDR E. coli outbreaks which have extensive resistance
towards the fluoroquinolones (important third-line antimicrobials) and the β-
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lactams; and that such resistant isolates may be capable of zoonotic transfer
and persistence in the community or the clinical setting (Warren et al., 2001).
But reports of AmpC resistance amongst E. coli isolates in companion animals
within the community remain rare. An extensive literature search using EMBASE
returned only five reports of β-lactamase resistance in companion animal or canine
E. coli isolates.
Reports from Portugal (Costa et al., 2008) and Italy (Carattoli et al., 2005a)
confirm that AmpC resistance and ESBLs are isolated from community samples.
Many of the isolates had extensive resistance to multiple antimicrobial classes;
and some isolates possessed both AmpC (blaCMY-2) and the ESBL resistance
gene blaCTX-M. Though (Costa et al., 2008) found no AmpC resistance markers
in the isolates they sampled; AMR was still detected against a number of antibi-
otic classes including tetracycline, ampicillin and streptomycin and various ESBL
genes were detected (blaCTX-M, blaOXA and blaTEM).
The reports highlight different infectious aspects of MDR E. coli such as clon-
ality, horizontal gene transfer of plasmid and integron mediated AmpC, and chro-
mosomal mutations of AmpC; important to the dissemination of MDR E. coli.
1.2.8 Urinary Tract Infections
UTIs are ascending infections of the genito-urinary tract epithelium. Bacterial
colonization of the urinary tract occurs via the periurethral epithelium, and may
be caused by a number of different bacterial species. The predominant organism
isolated from UTIs is E. coli in both humans (Nicolle, 2008) and dogs (Ball et al.,
2008).
It is estimated that 14% of dogs contract a UTI within their lifetime. As
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well as increased age and sex, there are many predisposing factors (Beutin, 1999,
Dunning and Stonehewer, 2002):
• Urinary incontinence
• Anatomical or physiological abnormalities
• Underlying disease
• Catheterization
UTI infections are diagnostically confirmed by the direct observation and cul-
ture of bacteria in urine samples obtained by free-catch or cytocentesis. Signifi-
cant bacterial presence in the urine, indicative of an active UTI, is greater than
103 bacteria per ml. Such bacterial growth can present as an asymptomatic in-
fection, or when presenting with other clinical signs, as cystitis or pyelonephritis
(Dunning and Stonehewer, 2002).
Asymptomatic UTI, cystitis and pyelonephritis are defined separately (Mobley
and Warren, 1996) as:
• Asymptomatic bacteriuria: where bacteria are present in urine at greater
than 105 detectable organisms per ml, but there are no presenting symp-
toms.
• Cystitis: infection of the bladder (possibly the urethra), presenting with
clinical signs (dysuria, pain, frequent urination). Cystitis is confirmed with
bacterial counts in urine of greater than 103 organisms per ml.
• Pyelonephritis: infection of the kidney, though it can present as a lower
UTI; associated with more severe clinical signs (pyrexia, nausea, vomiting
and pain). If left untreated pyelonephritis can progress into kidney failure
and septicemia. Pyelonephritis is confirmed with bacterial counts in the
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urine greater than 104 organisms per ml.
Each clinical presentation of UTI requires different treatment protocols, as laid
out by the International Society for Companion Animal Infectious Diseases (Scott
Weese, 2008). UTIs are often treated empirically, before culture and sensitivity
panels are carried out to identify the causative organism or potential resistance.
Amoxicillin and trimethoprim-sulfonamide combination therapy are both sug-
gested as possible empirical treatments. Amoxicillin-clavulanic acid is acceptable
for use as an empiric treatment, however, it is important to maintain as nar-
row a spectrum before an informed decision about potential resistance can be
made. It is recommended with complicated UTIs, that treatment by withheld
if at all possible, until culture and sensitivity panels have been performed. The
recommendation for cases of pyelonephritis is an immediate course of an appropri-
ate fluoroquinolone, to be re-evaluated once culture and sensitivity data become
available.
In all potential presentations of UTI, the guidelines recommend that empirical
treatment decisions are made by taking local information into account, regardless
of clinical severity. For example, the bacterial organisms most prevalent to the
setting and local resistance surveillance data. AMR and MDR may limit the
choice of appropriate antimicrobials; as can other factors (cost, risk of adverse
reaction, sub-optimal pharmacokinetic properties in the urinary tract).
The prevention of relapse, or recurrence of a UTI, is dependent on efficient
diagnosis and treatment using antimicrobials. Which is contingent on the confir-
mation of both the causative organism and its antibiotic susceptibility (Dunning
and Stonehewer, 2002).
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1.2.9 Uropathogenic E. coli
UPEC are a heterogeneous collection of E. coli isolates capable of causing in-
fection of the urinary tract in humans and in in animals; and are just one of
several established groups of pathogenic E. coli, distinguished by a pathotypic
combination of virulence factors and distinctive pathology. More broadly, UPEC
is part of the larger group of pathogenic E. coli capable of causing extra-intestinal
infection; referred to as extra-intestinal E. coli (ExPEC) (Kaper et al., 2004).
UPEC are derived from the host gut flora, and progressively colonize the
perineum and urethra before ascending to the bladder. Recurrent or persistent
UTIs are caused by the host failing to clear UPEC from the urinary tract; and
are more likely in hosts with underlying factors (underlying disease and abnormal
physiology) which predispose the host to UTI (Johnson and Russo, 2005).
Two hypotheses have been proposed for the way in which UPEC strains trans-
fer between the gastro-intestinal and urinary tracts. The prevalence hypothesis
(Turck and Petersdorf, 1962) proposes that colonization of the urinary tract is
caused by dominant E. coli clones present in the intestinal flora; which have an
increased chance of colonizing the urinary tract because of their greater preva-
lence. The specialist pathogen hypothesis (Plos et al., 1995), which identified
the P fimbriae as an important UPEC virulence marker, suggests that UPEC are
separate population of E. coli within the gut flora which are better defined by
their virulence potential.
Despite a variable developmental background, UPEC are described as having
a defined basal number of of virulence factors; type I and P pili adhesins, and
array of siderophores (iron acquisition), and various cytotoxins such as CNF1.
These make up the UPEC pathotype (Wiles et al., 2008), though the degree to
which the various markers are present can vary amongst different UPEC strains.
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This variability is thought to be representative of the different backgrounds under
which UPEC strains may be selected from (Marrs et al., 2005). For example, the
acquisition of virulence genes is more favorable in genetic backgrounds associated
with pathogenic E. coli (Tramuta et al., 2011, Wirth et al., 2006).
The distribution of virulence across the global E. coli population is not straight-
forward. The plastic nature of the E. coli genome, which may be greatly expanded
by horizontal transfer, as well as being specific to the niche that particular iso-
lates may occupy, favors different virulence factor distributions. Virulence factors
may be broadly divided into three groups, those that are transferable and may be
expressed in different genetic backgrounds (such as the various enteropathogenic
E. coli), virulence factors that are widely dispersed by individually associated
with various pathotypes (as in the specialist pathogen hypothesis), and virulence
factors only associated with a very restricted genetic background (such as the
Shiga toxin producing E. coli) (Escobar-Páramo et al., 2004, Escobar-Páramo
et al., 2009).
The host response to UPEC infections is through the innate immune sys-
tem; which includes neutrophil recruitment via the activation of Toll-like recep-
tors (such as TLR4), and the excretion of chemokines (Svanborg et al., 2006).
Other defense mechanisms include exfoliation of the uroepithelium and secretion
of Tamm-Horsfall protein, both of which disrupt the binding of invading bacteria
to the epithelium (Mulvey et al., 2000). UPEC are also thought to be capable of
immune-modulation, which increases the likelihood of developing recurrent UTI.
Moreover, the bacteria are also capable of invading the uroepithelial cells and
forming quiescent intracellular reservoirs to prevent their removal by exfoliation
(Mysorekar and Hultgren, 2006). Otherwise, the environmental conditions of a
healthy urinary tract (regular urine flow, pH and osmotic pressure) act to prevent
the colonization of the tract by bacteria.
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The basic epidemiology of UTIs in dogs is similar to that in humans. E.
coli is the predominant bacterial isolate collected from canine UTI, including
bacteriuria and pyelonephritis. UPEC isolates have been identified as originating
from a number of different clonal lineages, identifiable by their O, K and H
serological groups; and the clones frequently identified in the faecal flora (Beutin,
1999). As well as sharing many core virulence factors, human and canine UPEC
isolates also share similar phylogenetic and serological distributions; whilst it
has been assumed that canine and human UPEC populations overlap (Johnson
et al., 2001, 2003), far fewer reports exist for the characterization of canine UPEC
isolates than human isolates.
1.2.10 Uropathogenesis and AMR
Work done towards detecting the potential associations between resistance and
phylogenetic group in E. coli remains largely incomplete. Many reports of com-
panion animal resistance surveillance fail to attempt such population descriptions.
Where studies have tried to identify a link, reports have been mixed; despite
strong assertions of association in human clinical isolates. Ultimately, the suc-
cess of any particular resistance gene is reflected in the stochastic nature of host
infection; the more successful an acquired or inherited resistance marker is at in-
tegrating into a bacterial host, the more likely it is to continue to be disseminated
(Martinez et al., 2009).
E. coli AMR mediated by chromosomal ApmC has been indicated to be more
associated with phylogenetic group A isolates (Guillouzouic et al., 2009); and
has also been correlated to a loss of virulence expression (Corvec et al., 2007).
Although, this is certainly not the case amongst human clinical isolates positive
for pAmpC; where β-lactamase resistance has been associated with pathogenic
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phylogroups B2 and D (Oteo et al., 2010). One of the more difficult obstacles in
dealing with developing resistance in the Enterobacteriaceae is the development
of resistance amongst strains associated with the commensal flora. Commen-
sal isolates are abundant, but clinically silent, despite the potential for them to
harbor and transmit AMR; becoming noticeable only when they become asso-
ciated with an infection. Such an association, between commensal E. coli and
fluoroquinolone resistance has been reported (Alekshun and Levy, 2006).
The degree to which a particular E. coli isolate expresses a virulence or resis-
tance phenotype is likely representative of its life history and the context of its
environment (Mart́ınez and Baquero, 2002). The bias towards the collection of
clinical isolates, which may introduce confounding variables such as host health
and host immunity, may obscure the complexities of the interaction between vir-
ulence and resistance. So far little has been done to compare resistance and
virulence in animal models. The data that is available does suggest that MDR E.
coli isolated in the clinic are less virulent than fully susceptible isolates; confirmed
in a mouse model by (Sidjabat et al., 2009).
However, studies addressing this in companion animals are hard to come by.
That MDR may be stably maintained within community populations by E. coli
isolates belonging to successful sequence type (ST)s which may also be virulent,
suggests that there is an overlap. Furthermore, the detection of antibiotic resis-
tance genes such as pAmpC and the ESBLs indicates that the long-term impacts




Molecular Typing of Multi-Drug
Resistant Escherichia coli
2.1 Thesis Introduction
The successful treatment of a bacterial infection requires the matching of the ap-
propriate treatment to a particular infectious organism. Though many infections
are initially treated empirically. The genesis of antimicrobial resistance (AMR),
and it’s progression to multi-drug resistant (MDR), is in the inappropriate appli-
cation of non-optimal antimicrobial compounds to the infectious organism. The
rate of progression of a population of infectious bacteria from fully susceptible to
AMR can be influenced by a number of different processes:
• The misuse of antibiotics (lack of appropriate stewardship) acts to select
and promote particular resistance elements capable of acting against one or
more antimicrobial compounds.
• The predominance of a successful bacterial clonal lineage, which may be
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more closely associated with antimicrobial resistance.
• Reservoirs of transferable resistance elements within the clinical environ-
ment which the animal may become colonized with during, or after, treat-
ment.
• Reservoirs of resistance elements without the clinical environment which
the animal may become colonised with before treatment.
To further complicate this, the confluence of selection pressures which pro-
mote the spread of AMR and MDR can influence and be influenced by selection
pressures affecting different sub-populations of E. coli. As described in the gen-
eral introduction, E. coli which are MDR tend to be derived from the commensal
flora. uropathogenic E. coli (UPEC) have a definable virulence profile which may
act as a barrier toward the acquisition of AMR and MDR. The work presented in
this chapter seeks to define the association between the E. coli and their recorded
MDR phenotypes. The primary questions addressed in this chapter were:
• What resistance genotype is conferring phenotypic extended-spectrum AmpC
(ESAC) resistance?
• Do the MDR E. coli share a common genetic background, and is this genetic
background different from a group of fully susceptible E. coli?
• Does the MDR group constitute of E. coli isolates that are virulent with
respects to their ability to cause a urinary tract infections (UTI)? Or is
there evidence to suggest that an MDR phenotype is detrimental to a more
virulent phenotype?
• Is there any evidence to suggest that the resistance genotype is horizontally
transferable?
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The work presented here has been published in an academic journal (Wagner
et al., 2014), the full paper is included in the appendix. A reference table with
the strain identification numbers is included in the appendix as strain identifi-
cation numbers were changed in the published paper to conform to submission
guidelines.
2.2 Paper Introduction
Increasing numbers of reports have documented the emergence of Escherichia
col capable of producing broad-spectrum β-lactamases. This is significant since
the β-lactam antimicrobials are of therapeutic importance in humans and many
domestic animals. Furthermore, many isolates are resistant to additional antimi-
crobial classes and therefore MDR.
Carriage of extended-spectrum β-lactamase (ESBL) and AmpC producing E.
coli has been documented in many species (Bortolaia et al., 2011). Antimicrobial
use has been reported as a risk factor (Damborg et al., 2011, 2012, Maddox et al.,
2012) and there is also evidence of sharing of organisms between species living
in close proximity to each other (Dolejska et al., 2011). Considering the physical
closeness in which many humans live with their pet companions, sharing of these
organisms between humans and pets could pose a significant mutual risk.
Clinical disease associated with these organisms is well documented in humans.
Initially the pattern was of hospital-acquired infection but community-acquired
infection has become increasingly important. ESBL E. coli are associated with
a variety of clinical diseases, in particular UTI, neonatal septicemia and wound
infections (Ben-Ami et al., 2009, Pitout, 2010). Reports of similar clinical disease
associated with AmpC-producing E. coli are far fewer than those pertaining to
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ESBLs, however these also appear to an emerging problem (Oteo et al., 2010).
Although most animal studies have focused on the zoonotic risk posed by
carriage, there are increasing reports demonstrating the involvement of these or-
ganisms in clinical disease in domestic species in a variety of locations including
Europe, North America, Asia and Australia. For example, in the United States
AmpC (CMY-2) and ESBL-producing E. coli (O’Keefe, A.a, Hutton, T.A.b
, Schifferli, D.M.a, Rankin, 2010, Sanchez et al., 2002, Shaheen et al., 2011)
have been reported from canine clinical isolates. Clinical disease associated with
AmpC-producing E. coli in dogs in Australia, was first reported in 2006 (Sidjabat
et al., 2006). More recently, a survey of clinical isolates from dogs and horses in
the Netherlands demonstrated a 2% prevalence of ESBL and AmpC-producing
isolates (Dierikx et al., 2012a).
The aim of this study was to evaluate the association of ESBL or AmpC
production with MDR E. coli isolated from clinical cases of UTI in dogs from a
local patient population, over a period of time ranging form 2002 to 2011. Isolates
were further characterized in terms of phylogenetic grouping, sequence type (ST)
and virulence genotype. Plasmid replicon typing was also performed to identify
the type and diversity of plasmids involved. Comparisons were made to a group
of susceptible E. coli isolates, also associated with canine UTI and collected over
a similar time frame.
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2.3 Methods
2.3.1 Source of Clinical Isolates
All 15 susceptible and 17/18 MDR isolates were identified in clinical cases seen at
the Hospital for Small Animals, University of Edinburgh. One MDR isolate (1223)
came from a local practice serviced by the University of Edinburgh’s diagnostic
microbiology service.
2.3.2 E. coli Identification
A total of 33 clinical isolates from canine UTI were cultured on Blood and Mac-
Conkey agar. Any lactose fermenting colonies were confirmed as E. coli utilizing
biochemical testing (API 10S™strip bioMerieux).
2.3.3 Antimicrobial susceptibility testing
Susceptibility testing was performed using the disc diffusion method in accor-
dance with Clinical Laboratory Standards Institute (CLSI) guidelines. The fol-
lowing discs were used: Co-trimoxazole (25 µg); ciprofloxacin (1 µg); amoxicillin
clavulanate (30 µg); cephalexin (30 µg); gentamicin (10 µg); tetracycline (10 µg);
cefotaxime (30 µg). All discs were sourced from Mast group Ltd.
2.3.4 Control strains
The following control strains were utilized in both the phenotypic combination
disc testing and for polymerase chain reaction (PCR). ATCC 25922 ™(negative
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control); ATCC BA-199 ™(SHV-3 positive control); NCTC 13353 ™(CTX-M-15
positive control), and NCTC 13351 ™(TEM-3 positive control).
2.3.5 Combination disc method for plasmid-mediated AmpC
and ESBL detection
A commercially available AmpC and ESBL detection set (Mast group Ltd.) was
utilized. This comprised a set of 4 discs containing cefpodoxime plus or minus
AmpC and ESBL inhibitors. Interpretation was made following the manufac-
turer’s instructions.
2.3.6 PCR for ESBL and AmpC gene detection
DNA from single colonies of each isolate was prepared using the lysis method
as previously described (Perez-Perez and Hanson, 2002). Primers for the genes
blaTEM, blaSHV, blaCTX, blaCMY-1 group, blaCMY-2 group, blaOXA-1 group and
blaOXA-2 group were derived from a previously established assay (Hasman et al.,
2005) (table 2.1). For additional detection of AmpC β-lactamase genes, multiplex
PCR was performed on all samples using the methodology and primers previously
described (Perez-Perez and Hanson, 2002). PCR products were electrophoresed
in a 1% agarose gel; gel bands were excised and sequences were compared to the
NCBI database to confirm identity.
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Table 2.1: Table of ESBL and AmpC PCR primers
Primer Gene Target Primer Sequence Product Size Reference
757 blaTEM GCGGAACCCCTATTTG 964 (Perez-Perez and Hanson, 2002)
821 TCTAAAGTATATATGAGTAAACTTGGTCTGAC
1113 PampC GTGAATACAGAGCCAGACGC 343 (Hasman et al., 2005)
796 GTTGTTTCCGGGTGATGC
1436 blaSHV TTCGCCTGTGTATTATCTCCCTG 854 (Hasman et al., 2005)
1437 TTAGCGTTGCCAGTGYTCG
1354 blaCTX ATGTGCAGYACCAGTAARGTKATGGC 593 (Perez-Perez and Hanson, 2002)
1355 TGGGTRAARTARGTSACCAGAAYCAGCGG
1004 blaCMY-1 group GTGGTGGATGCCAGCATCC 915 (Hasman et al., 2005)
1005 GGTCGAGCCGGTCTTGTTGAA
1006 blaCMY-2 group GCACTTAGCCACCTATACGGCAG 758 (Hasman et al., 2005)
1007 GCTTTTCAAGAATGCGCCAGG
1062 blaOXA-1 ATGAAAAACACAATACATATCAACTTCGC 820 (Perez-Perez and Hanson, 2002)
1063 GTGTGTTTAGAATGGTGATCGCATT
1420 blaOXA-2 ACGATAGTTGTGGCAGACGAAC 602 (Hasman et al., 2005)
1421 ATYCTGTTTGGCGTATCRATATTC
1359 blaACC-1 AGCCTCAGCAGCCGGTTAC 818 (Hasman et al., 2005)
1360 GAAGCCGTTAGTTGATCCGG
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2.3.7 Multiplex PCR pyhlogenetic grouping of clinical iso-
lates
DNA from single colonies was prepared using the Qiagen DNeasy blood and tissue
extraction kit according to the manufacturer’s instructions (Qiagen, UK). Mul-
tiplex PCR methodology (table 2.2) was employed to assign the clinical isolates
to one of four phylogenetic groups (A, B1, B2 or D). Primers and methodology
have been described previously (Doumith et al., 2012a).
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Table 2.2: Table of Phylotyping PCR primers
Primer Name Primer Direction Primer Sequence Product Size Reference
gadA Forward GATGAAATGGCGTTGGCGCAAG 373 (Doumith et al., 2012a)
Reverse GGCGGAAGTCCCAGACGATATCC (Doumith et al., 2012a)
chuA Forward ATGATCATCGCGGCGTGCTG 281 (Doumith et al., 2012a)
Reverse AAACGCGCTCGCGCCTAAT (Doumith et al., 2012a)
yjaA Forward TGTTCGCGATCTTGAAAGCAAACGT 216 (Doumith et al., 2012a)
Reverse ACCTGTGACAAACCGCCCTCA (Doumith et al., 2012a)
TSPE4.C2 Forward GCGGGTGAGACAGAAACGCG 152 (Doumith et al., 2012a)
Reverse TTGTCGTGAGTTGCGAACCCG (Doumith et al., 2012a)
44
2.3.8 PCR-based plasmid replicon typing of clinical iso-
lates
DNA was isolated as described above for the phylogenetic grouping. Methodology
involved the use of the 8 multiplex reactions (table 2.3.8) in a commercial kit
(Diatheva, Italy) based on methodology described previously (Carattoli et al.,
2005a).
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Table 2.3: Table of Replotyping PCR primers
Name DNA sequence Target Gene Product Size Reference
hi1 FW ggagcgatggattacttcagtac parA-parB 471 (Carattoli et al.,
2005a)
hi1 RV tgccgtttcacctcgtgagta (Carattoli et al.,
2005a)
hi2 FW tttctcctgagtcacctgttaacac iterons 644 (Carattoli et al.,
2005a)
hi2 RV ggctcactaccgttgtcatcct (Carattoli et al.,
2005a)
I1 FW cgaaagccggacggcagaa RNAI 139 (Carattoli et al.,
2005a)
I1 RV tcgtcgttccgccaagttcgt (Carattoli et al.,
2005a)
X FW aaccttagaggctatttaagttgctgat ori 376 (Carattoli et al.,
2005a)
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X RV tgagagtcaatttttatctcatgttttagc (Carattoli et al.,
2005a)
L/M FW ggatgaaaactatcagcatctgaag repA,B,C 785 (Carattoli et al.,
2005a)
L/M RV ctgcaggggcgattctttagg (Carattoli et al.,
2005a)
N FW gtctaacgagcttaccgaag repA 559 (Carattoli et al.,
2005a)
N RV gtttcaactctgccaagttc (Carattoli et al.,
2005a)
fia FW ccatgctggttctagagaaggtg iterons 462 (Carattoli et al.,
2005a)
fia RV gtatatccttactggcttccgcag (Carattoli et al.,
2005a)
fib FW ggagttctgacacacgattttctg repA 702 (Carattoli et al.,
2005a)
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fib RV ctcccgtcgcttcagggcatt (Carattoli et al.,
2005a)
W FW cctaagaacaacaaagcccccg repA 242 (Carattoli et al.,
2005a)
W RV ggtgcgcggcatagaaccgt (Carattoli et al.,
2005a)
Y FW aattcaaacaacactgtgcagcctg repA 765 (Carattoli et al.,
2005a)
Y RV gcgagaatggacgattacaaaacttt (Carattoli et al.,
2005a)
P FW ctatggccctgcaaacgcgccagaaa iterons 534 (Carattoli et al.,
2005a)
P RV tcacgcgccagggcgcagcc (Carattoli et al.,
2005a)
fic FW gtgaactggcagatgaggaagg repA2 262 (Carattoli et al.,
2005a)
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fic RV ttctcctcgtcgccaaactagat (Carattoli et al.,
2005a)
A/C FW gagaaccaaagacaaagacctgga repA 465 (Carattoli et al.,
2005a)
A/C RV acgacaaacctgaattgcctcctt (Carattoli et al.,
2005a)
T FW ttggcctgtttgtgcctaaaccat repA 750 (Carattoli et al.,
2005a)
T RV cgttgattacacttagctttggac (Carattoli et al.,
2005a)
fiis FW ctgtcgtaagctgatggc repA 270 (Carattoli et al.,
2005a)
fiis RV ctctgccacaaacttcagc (Carattoli et al.,
2005a)
frepb FW tgatcgtttaaggaattttg RNAI/repA 270 (Carattoli et al.,
2005a)
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frepb RV gaagatcagtcacaccatcc (Carattoli et al.,
2005a)
K/B FW gcggtccggaaagccagaaaac RNAI 160 (Carattoli et al.,
2005a)
K RV tctttcacgagcccgccaaa (Carattoli et al.,
2005a)
B/O RV tctgcgttccgccaagttcga RNAI 159 (Carattoli et al.,
2005a)50
2.3.9 Identibac ®micro-array analysis
A micro-array assay developed and carried out by the Animal Health Veterinary
Laboratories Agency (AHVLA) was used (Batchelor et al., 2008). The micro-
array contained a selection of oligonucleotide probes mapping to a range of re-
sistance and virulence-associated genes. Probe hybridizations resulting in signal
intensities greater than 0.4 were considered positive indicating the presence of
the gene.
2.3.10 MLST methodology
DNA was extracted using a DNeasy extraction kit (Qiagen) and performed as
to the manufacturer’s instructions. Sequencing of the DNA was carried out
on an Illumina MiSeq (ARK Genomics). Raw sequence reads were aligned to
two reference sequences: E. coli ABU83972 (NC 017631.1) and E. coli MG1655
(NC 000913.2) using BWA and Samtools (Li et al., 2009). Sequence type call-
ing (for multi-locus sequence-typing (MLST)) was performed using short read
sequence typing (SRST) (Inouye et al., 2012). Isolates which could not be typed
using SRST were called manually using sequences mapped to MG1655. Se-
quences aligning to the MLST genes in MG1655 were extracted using VCFtools
(Danecek et al., 2011) and Extractseq (Rice et al., 2000) and entered manually
into the MLST Database, hosted by University College Cork (http://mlst.ucc.
ie/mlst/dbs/Ecoli).
2.3.11 Statistical Methods
Comparisons were tested using Fisher’s exact test. The criterion for statistical
significance was taken to be P < 0.05.
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2.4 Results
2.4.1 Culture and Sensitivity
Between 2002 and 2011, 18 E. coli isolates associated with UTI in 16 dogs were
identified as MDR. Results of culture and sensitivity testing for MDR isolates
are displayed in table 2.4. Two of the dogs had recurrent UTI. One case recurred
1 month later (565 and 737) and the second case 6 months later (136 and 1088).
The criterion used to make the MDR determination was resistance to 3 or more
classes of antimicrobial on routine culture and sensitivity testing (Magiorakos
et al., 2012). All MDR isolates were resistant to amoxicillin clavulanate and
tetracycline, 83% (15/18) were resistant to cephalexin, 78% (14/18) were resistant
to co-trimoxazole, 56% (10/18) were resistant to ciprofloxacin, 22% (4/18) were
resistant to the 3rd generation cephalosporin cefotaxime. The latter was used as
an indicator of broad-spectrum β-lactamse production.
For comparison, 15 E. coli isolates were selected for study, based on the criteria
that they were susceptible to all 7 antimicrobial classes listed above. These
isolates were associated with UTI in dogs.
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Isolate Breed Age Clinical Notes
R1 Dachshund 10 Surgery to treat intervertebral disc prolapse. Prescribed amoxicllin/clavulanate for surgical prophylaxis
R2 Weimeraner 9 Prostatic abscess. Surgical drainage and antibiotics (enrofloxacin and clindamycin).
R4 Cocker Spaniel 4 Immune mediated haemolytic anaemia, which was treated with immunosuppressant drugs.
R5 Cross Breed 11 Hyperadrenocorticism. Amoxicillin/clavulanate administered for several months to manage concurrent liver disease.
R6 Boxer 9 Multiple mast cell tumours. Resection followed by cancer chemotherapy.
R7 Schnauzer 6 Mast cell tumour. Surgical management followed by cancer chemotherapy.
R8 Labrador 10 Surgery to resect intestinal adenocarcinoma. Post surgery developed pneumonia and treated with multiple antibiotics
R9 Collie 10 Diabetes mellitus, which was poorly controlled.
R10 German Shepherd 8 Prostatic infection and a perineal hernia accompanied by recurrent cystitis.
R11 Bouvier de Flandres 6 Placement of gastrostomy tube. Stoma became infected requiring antibiotics. Subsequent development of recurrent urinary tract infections.
R12 Bearded Collie 1 Pyelonephritis; initially treated with amoxicillin/clavulanate.
R13 Cocker Spaniel 7 Pancreatitis.
R14 Golden Retriever 5 Ectopic ureters possibly acting as a predisposing factor for urinary tract infection.
R15 Yorkshire Terrier 11 Concurrent urolithiasis.
R16 Boxer Cross 7 Detrusor muscle atony decreasing the ability to empty the bladder during urination.
Table 2.4: MDR case summaries: This table details the available clinical information for the dogs from which the MDR isolates were
obtained; including age, dog breed and a brief synopsis of the clinical treatment at time of infection.
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2.4.2 AmpC β-lactamase phenotype and genotype
To identify the contribution of either ESBL or AmpC β-lactamase to the MDR
phenotype, all isolates (both MDR and susceptible groups) were tested using the
4 disc test as described in materials and methods. All susceptible isolates were
negative (data not shown). A total of 67% (12/18) of MDR isolates were positive
for AmpC production. ESBL production was not detected.
Using ampC multiplex PCR, 9/12 isolates phenotyically AmpC positive were
genotypically positive for pAmpC (CITM group). Further simplex PCR identified
PCR identified 8 of these to be specifically associated with CMY-2 gene. Identibac
®micro-array also detected a CMY gene signal in 8/9 isolates tested (1283, 127,
1223, 1428, 746, 144, 1943, 1201 and 317) (table 2.5).
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Isolate Isolation Date Resistance Profile 3rd Gen. Resistance Mast Pheno. pAmpC PCR Phylotype Sequence Type Replicon Type
1283 9/2006 AMC/ CEF / COT / CIP / TET / GEN R AmpC CMY-2 A 10 FII I1
127 1/2008 AMC / CEF / COT / TET R AmpC CMY-2 n/t 46 FII I1
1223 9/2010 AMC / CEF / COT / CIP / TET R AmpC CMY-2 A 744 FII I1
1428 10/2010 AMC / CEF / TET R AmpC CMY-2 D 648 FII I1
746 3/2010 AMC / CEF / TET R AmpC CMY-2 D 963 FII I1
144 2/2011 AMC / CEF / COT / TET R AmpC CMY-2 D n/t FII I1
1943 12/2007 AMC / CEF / COT / CIP / TET R AmpC CMY-2 B1 539 B/O I1
1176 9/2011 AMC / CEF / COT / CIP / TET / GEN Susceptible AmpC B1 23 FII FIB
1201 9/2011 AMC / CEF / COT / TET R AmpC + B1 101 I1
317 3/2002 AMC / CEF / COT / CIP / TET R AmpC + B2 167 FII FIA I1
136 2/2010 AMC / CEF / COT / TET R + - D 10 -
1088 8/2010 AMC / CEF / TET R + - D 372 -
1049 7/2006 AMC / CEF / COT / TET / GEN S - n/d D 372 I2
1258 8/2009 AMC / COT / CIP / TET S - n/d A 10 FII FIA
1271 8/2008 AMC / COT / CIP / TET S - n/d A 10 -
585 4/2009 AMC / CEF / COT / CIP / TET S - n/d A 998 -
565 4/2011 AMC / CEF / CIP / TET / GEN R - n/d B1 23 FII B/O
737 5/2011 AMC / COT / CIP / TET / GEN S - n/d B2 23 FII FIB
Table 2.5: Incorporates the resistance typing of the MDR isolates: Kirby-Bauer disk typing (Resistance Typing), MAST 4-disk
testing (Mast Pheno), plasmid-mediated AmpC resistance gene typing PCR (pAmpC PCR), and phenotypic extended-spectrum
resistance (3rd. Gen. Resistance). Also descriptive genotyping for E. coli population segregation and plasmid burden: phylotyping
PCR (Phylotype), multi-locus sequence-typing scheme (Sequence Type), plasmid-based replicon typing (Replicon Type).
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2.4.3 Phylogenetic group and ST designation
PCR-based phylogenetic grouping was performed to assign the isolates to one of 4
phylogenetic groups, namely A, B1, B2 or D. Phylotpyes A and B1 are considered
to be associated with commensal status or intestinal pathotypes, while B2 and
D are more commonly associated with strains causing extraintestinal infections
(Tenaillon et al., 2010). Among the susceptible isolates B2 was the predominant
phylogenetic group (10 isolates, 67%) with no isolates in group A, 2 isolates (13%)
in the B1 grouping and 3 isolates (20%) in group D. In contrast, the MDR group
showed a more even distribution among all 4 phylogentic groups (1 isolate could
not be typed), with B2 comprising the smallest category. The distribution for A,
B1, B2 or D was 28%, 22%, 11% and 33% respectively. The proportion of MDR
isolates identified as phylotype B2 differed significantly from the proportion of
susceptible isolates identified as B2 (P < 0.001).
MLST identified 18 ST types among E. coli isolates. Within the MDR group
these were: ST10 (n=4); ST23 (n=3); ST372 (n=2); ST46 (n=1); ST744 (n=1);
ST648 (n=1); ST963 (n=1); ST539 (n=1); ST101 (n=1); ST167 (n=1); and
ST998 (n=1). The two MDR isolates belonging to phylogenetic B2 belonged to
ST 167 and 23. The overall association of ST and phylogenetic group is listed in
table 2.5.
Within susceptible group STs identified were: ST73 (n=4); ST12 (n=2);
ST641 (n=1); ST127 (n=1); ST10 (n=1); ST625 (n=1); ST929 (n=1); and
ST3005 (n=1). A total of 3 isolates from the susceptible group and 1 from the
MDR group did not map to existing STs (table 2.6. None of the isolates belonged
to ST131.
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Isolate Isolation Date Phylotype Sequence Type Replicon Type
162 1/2003 B2 73 -
1365 0/2011 B2 73 -
1568 11/2001 B2 12 -
1660 11/2001 B2 73 -
1711 11/2001 B2 N -
73 1/2001 B1 641 X1
1290 10/2002 B2 12 I2 R
1389 10/2001 D N FIA
78 1/2003 B2 127 FIB
1766 12/2001 B2 10 FII
1489 12/2000 B2 73 FII FIB
1333 10/2011 D N FII FIB
58 1/2002 D 625 FII FIB B/O
1105 8/2001 B2 929 FII I1
1190 9/2001 B1 3005 B/O I1
Table 2.6: Descriptive genotyping for E. coli population segregation and plasmid burden: phylotyping PCR (Phylotype), multi-locus
sequence-typing scheme (Sequence Type), plasmid-based replicon typing (Replicon Type) for the Susceptible isolates.
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2.4.4 Identibac ®micro-array analysis
A panel of 11 specific probes was extracted from a much larger panel. These
represent probes for which any isolate, wither susceptible or MDR, demonstrated
a positive result. The full list of probes against which isolates were tested can be
found in the supplementary materials.
The virulence marker panel results are summarized in table 2.7. Although
the number of isolates examined was limited, there were significantly higher (P
< 0.05) levels of carriage demonstrated for 7/11 specific virulence markers in the
susceptible group compared to the MDR group.
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Isolate Phylogroup ireA iroN iss mchB mchC mchF mcm perA prfB senB sfaS
1283 (R) A
127 (R) n/t
1223 (R) A X X




1176 (R) B1 X X X X X X




1049 (R) D X X




737 (R) B2 X X X X X
162 (S) B2 X X X X X X X
1365 (S) B2 X X X X X X X X
1568 (S) B2 X X X X X X X X
1660 (S) B2 X X X X X X X
1711 (S) B2 X X X X X X X X
73 (S) B1 X X X X X X
1290 (S) B2 X X X X X X
1389 (S) D X X X X X
78 (S) B2 X X X X X X
1766 (S) B2 X X X X X X X X X X X
1489 (S) B2
1333 (S) D X X X X
58 (S) D X X X X
1105 (S) B2 X X X X X X X X X X
1190 (S) B1
FE Sig. X X X X X X X
Table 2.7: Identibac virulence micro-array results for the MDR and susceptible isolates. R = MDR isolate, S = susceptible isolate;
n/t = non-typable; X = presence of gene; reA = siderophore receptor; iroN = enterobactin siderophore receptor; iss = increased
serum survival; mchB = microcin H47 (colicin H); mchC = MchC protein; mchF = ABC trasnporter protein; mcm = microcin M
(colicin H); perA = eneteropathogenic E. coli adherence factor; prfB = P-fimbriae regulation; senB = plasmid encoded enterotoxin;
sfaS = S-fimbriae subunit; FE Sig. = Significant difference for MDR versus susceptible by Fisher’s Exact test.
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2.4.5 Plasmid Replicon Typing
In the susceptible group (table2.6) plasmid replicons could not be identified in 5
of the isolates. In the remaining 10 isolates, 6 isolates had 2 or more replicons
and 4 isolates carried single replicons. The FII replicon was present in 5 isolates
and the FIB replicon was present in 4 isolates. Overall 8 different replicon types
were identified in this group.
In the MDR group (table2.5), plasmid replicons could not be identified in 4 of
the isolates. A total of 12 of the remaining 14 carried 2 or more replicons and only
2 isolates carried single replicons. The FII replicon was present in 11 isolates and
the I1 replicon was present in 9 isolates. A total of 6 isolates carried the FII and
I1 replicons together (these 6 isolates were all phenotypically and genotypically
positive for pAmpC). Overall 6 different replicon types were identified in this
group.
2.5 Discussion
These findings demonstrate clinically significant MDR E. coli in canine UTI. The
antibiogram phenotype of isolates (table 2.5) shows that treatment options are
limited. All MDR isolates were resistant to the recommended first line treat-
ment amoxicillin clavulanate and more than half of the isolates were resistant to
fluoroquinolones, a third line option (Weese et al., 2011).
MDR strains were analyzed in some detail. Comparisons were made to a
susceptible group of canine UTI isolates from the same locality and indirectly to
significant human clonal lineages. The latter is particularly important in light
of concerns regarding the transfer of organisms between humans and domestic
animals, and the potential for either to act as a reservoir of infection for the
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other.
AmpC rather than ESBL-producing E. coli were commonly identified among
the MDR isolates. This is interesting because, in human UTIs associated with
MDR E. coli, ESBLs (particularly the CTX-M group) seem to be the predominant
enzymes responsible for broad-spectrum resistance to β-lactams. Although this
study has a low number of isolates, other studies have also identified the presence
of AmpC producing E. coli in dogs associated with both fecal carriage and clinical
disease (Damborg et al., 2012, Dierikx et al., 2012b, Murphy et al., 2009, Shaheen
et al., 2011, Sidjabat et al., 2006, Tamang et al., 2012, Wedley et al., 2011a).
Furthermore, routine screening in our laboratory has continued to identify AmpC-
producing isolates causing UTI (10 isolates from January 2012 to November 2013).
Although this represents a relatively low local incidence, these cases are still
clinically significant and therapeutically challenging.
The phylogenetic profile differed between the two groups of isolates. The sus-
ceptible group of UTI isolates predominantly belonged to the B2 phylogenetic
group, as predicted from previous studies in humans and dogs (Johnson et al.,
2003, Mao et al., 2012, Thompson et al., 2011). The MDR group meanwhile
demonstrated a more even distribution across all four phylo-groups, with signifi-
cantly less representation of the B2 phylo-group. It is worth noting that a more
recent methodology has been able to assign E. coli to 8 rather than 4 phylo-groups
(Clermont et al., 2013), which could have altered the profile of the isolates in this
study, and future work should employ the revised methodology to provide greater
detail and depth of characterization. In the context of the results from this study,
isolates already assigned to B1 or B2 would be unlikely to change classification,
so the difference between groups in the proportions of isolates in the phylotype
B2 should still be valid.
The virulence marker profile also differed between the two groups, suggesting
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a reduced virulence genotype in the MDR isolates compared to the susceptible
ones. Previous studies have indicated that, in MDR isolates associated with UTI
in both humans and dogs, there may be a shift away from the dominance of
the B2 phylogenetic group and a decrease in certain virulence genes (Moreno
et al., 2006, Vila et al., 2002). The reason for this pattern is unclear. Other
researchers have speculated that less pathogenic phylogenetic groups are more
receptive to the acquisition of the MDR phenotype (Johnson et al., 2004), or
that acquisition of the MDR phenotype results in a trade off, with a loss of
virulence traits. Whatever the order of events, it would seem logical that less
pathogenic phylogenetic groups, with an MDR phenotype, would require certain
conditions under which to cause clinical disease.
Sequence typing did not provide evidence for clonal spread of isolates in either
group. Considering the extended sampling time this is probably not surprising.
More pertinent perhaps was the fact that ST131 was not identified amongst any
of our isolates. The O25b-ST131 clonal lineage is one of the most important
uropathogenic E. coli groups in humans. It belongs to the B2 phylogentic group,
is a MDR (almost always resistant to fluoroquinolones and often resistant to 3rd
generation cephalosporins), is often, but no always, an ESBL producer (CTX-
M-15) and is highly virulent (Oteo et al., 2010, Thompson et al., 2011). Total
reports of ST131 in domestic animals are still extremely low and although there
is some support for interspecies transfer of ST131, it is unclear if animals are a
major reservoir or incidental host of this extra-intestinal E. coli (ExPEC) clonal
lineage, or indeed if humans act as an animal reservoir (Platell et al., 2011).
Certainly within the limitations of our study we found no evidence for this.
One MDR isolate (1428) was typed as ST648 phylogenetic group D. Strains of
this clonal lineage that carry ESBLs, have been associated with bacteraemias in
human patients in the Netherlands and New Delhi metallo-β-lactamase (NDM)
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carbapenamases in human patients in the United Kingdom and Pakistan (Tamang
et al., 2012).
Plasmid replicon typing was performed in order to establish the range and
diversity of plasmids amongst both the MDR and susceptible isolates. Most of
the plasmid replicons correspond to incompatibility groups. In the susceptible
group replicon types could not be assigned to 5 of the isolates. This is perhaps
not surprising, as the assay is designed to detect resistance plasmids. In the MDR
group there were 4 isolates that were not assigned replicon types. Interestingly
2 of these (136 and 1088) were phenotypically AmpC-producing, but it was not
possible to detect plasmid-associated genes. We speculate that AmpC production
in these isolates could be attributed to chromosomal mutations in the ampC
promoter. Further analysis of these isolates will be required to confirm this. In
the remainder of the MDR isolates the FII and I1 replicon types were the most
highly represented. We observe a cluster compromising 6 isolates (1283, 127,
1223, 1428, 746, 144) (table 2.5) all AmpC-producing and carrying IncFII/IncI1
plasmids. Since IncFII and IncI1 plasmids are two of a number of plasmid types
that are particularly successful in their ability to spread MDR (Carattoli, 2011),
further characterization and comparison of the plasmids from these isolates would
be of particular interest.
With the exception of one case for which we have no history, all cases caused by
MDR E. coli had underlying disease involving suppression of the immune system
(e.g. hyperadrenocorticism, cancer chemotherapy), an anatomical abnormality
of the genitourinary tract (e.g. detrusor muscle atony, ectopic ureters), and/or
a history of prior antimicrobial treatment. Clinical details are summarized in
table 2.4. This is not a surprising finding since it can be envisaged that such
factors will increase the potential of isolates, which we speculate may be less
virulent, to cause clinical disease. What will be of interest is to follow the natural
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history of infections caused by these organisms in companion animals. It is highly
probable that future changes in the epidemiology of MDR E. coli infections in
dogs, will reflect those seen in the human population, where there has been a
shift from hospital-acquired infection, analogous to what we have observed in
this study in dogs, to a community-acquired infection, where they are associated
with uncomplicated urinary tract disease.
2.6 Thesis Discussion
The methods applied in this chapter are powerful descriptive tools in identifying
genotypic and phenotypic commonalities amongst E. coli in general. PCR typ-
ing of AmpC β-lactamase resistance markers identified a common genotype for
theMDR isolates; with a clear bias towards plasmid mediated ESAC resistance.
blaCMY-2 was the predominant detected β-lactamase resistance marker. The pres-
ence of the blaCMY-2 genotype also correlated strongly with an IncI1/IncFII plas-
mid replicon type; not significantly detectable in the susceptible isolates. This
strongly suggests that both the blaCMY-2 genotype and MDR phenotype may be
horizontally acquired amongst the MDR E. coli.
However, neither method provides a basis to link the presence of blaCMY-2 or
MDR phenotype, with one of the detected replicon types; or whether either is
present chromosomally in the MDR isolates. More fundamentally, it is also not
desirable to perform PCR analysis to dissect the genotypic basis of the MDR
phenotype as has been done for the ESAC resistance.
Any attempt to fully describe the resistance genotype for the MDR by PCR
alone would be hindered by the large and still growing number of resistance
genes and resistance gene families; some of which may not be reliably typeable
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by PCR. In a similar manner, the degree of genetic relatedness between the
MDR and susceptible can only be partially defined by the work presented in
this chapter. Phylotyping indicated a shift towards a more common commensal
(A/B1) background in the MDR group, and a strong shift to pathogenic (B2/D)
phylotypes in the susceptible group. Both trends were further emphasized by
the presence and absence of the limited set of E. coli virulence markers included
in the Identibac micro-array. However, both are limited by the small number of
markers used, and the low numbers of isolates in both the susceptible and MDR
groups, to extrapolate the phenotypic potential of the E. coli isolates; and both
are surrogate measures of overall virulence and uropathogenic potential. There
is no experimental knowledge of a potential virulence phenotype for isolates in
either group; beyond that they were isolated from active urinary tract infections.
A virulence phenotype for the MDR and susceptible isolates would increase the
validity of the association of either group with a virulent or avirulent background;
and to correlate against recorded phylotypes.
MLST is capable of providing a detailed measure of clonal relatedness between
sub-populations of E. coli. However, there is no obvious clonal relationship be-
tween many of the isolates in either group; despite having been collected at the
same location (the Small Animal Hospital). Not only were some of the isolates
un-typable by this method, intra and inter-group detected STs were equally vari-
able. Given such variation, which is compounded by the relatively low sample
size of the project, very few comparisons can be made between the isolates in this
study to the STs of E. coli recorded from other studies.
Though not talked about in the paper it is interesting to not that several
(4/15) susceptible isolates (162, 1365, 1660 and 1489) were typed as ST73 by
MLST (table 2.6). The ST73 clonal group, along with other pandemic clonal
ExPEC lineage ST131 and ST69, is associated with virulent UTIs in humans
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(Tartof et al., 2005, Wirth et al., 2006); and is also prevalent in the UK (Lau
et al., 2008). ST73 isolates are associated with expanded virulence profile (not in
the case of isolate 1489) and is also associated with ESBL resistance (Fam et al.,
2011, Oteo et al., 2009) and the is linked with the dissemination of balCTX-M
resistance genes. ST73 strains have been isolated from animal sources (Manges
et al., 2015) and the discovery of ST73 isolates in the susceptible group (which
may indicate a local endemism in the outpatient dog population at the Small
Animal Hospital) certainly warrants further inquiry.
To address the shortcomings of the work presented so far, a more detailed
genetic understanding of the MDR and susceptible isolates is needed. This would
ideally include a greater diversity of samples from different locations (i.e. other
hospitals) and greater depth of sampling (i.e. more samples or improved longitu-
dinal sampling); though this was not achieved during this project.
First the MDR and susceptible isolates will be sequenced to allow for more ac-
curate genotypic comparisons. With the wide-spread availability of next-generation
sequencing, it is now possible to sequence and assemble large numbers of bacte-
rial genomes. Short-read, whole-genome sequencing allows for the MDR and
susceptible strains to be compared with a much higher degree of accuracy. whole
genome sequencing (WGS) provides an opportunity to assess both core-genomic
sequences (single nucleotide polymorphism (SNP) phylogeny) and pan-genomic
sequences in silico; which is entirely impractical by other molecular techniques.
The large number of high-quality assembled and published E. coli genomes, which
can be easily included in such comparisons, can add greater context to any in-
ferences arising from sequence data; and may help to address the limitations of
a narrow (geographically and chronologically) dataset. WGS would also help
assess the genetic linkage of identified resistance markers to either transferable
genetic elements (horizontally acquired), or with the E .coli chromosome (vertical
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inheritance).
In order to better correlate broad differences in virulence marker presence
an infection model capable of testing virulence in a larger number of E. coli
isolates will provide a more adequate assessment of phenotypic virulence. Detailed
infection models do exist for uropathogenic E. coli, but are not easily applied to
more than a few strains of E. coli. Galleria mellonella larvae have successfully
been used as an infection model using a number of different pathogenic bacteria.
Variations in lethality and innate immune responses elicited by the larvae against
bacterial challenge provide strong in vivo phenotypes that can be to evaluate
difference in virulence potential. The infection model has been applied to UPEC
previously (Alghoribi et al., 2014); but like with WGS data there is inherent
comparative value in applying the model to previously untested E. coli strains.
The infection model will be evaluated using previously well characterized UPEC







Work in the preceding chapter identified a strong commensal association to the
multi-drug resistant (MDR) group of isolates, but no strong clonal relatedness
amongst any of the isolates in either the susceptible or MDR groups. Work in
this chapter is focused on refining the population structure of both groups of E.
coli.
Since the first whole-genome shotgun sequencing of Haemophilus influenzae
in 1995 (Fleischmann et al., 1995), the continued development of next-generation
sequencing (NGS) techniques has allowed increasingly large scale sequencing
projects of prokaryotic and eukaryotic organisms. E. coli is the paradigm model
organism in microbiology. Because of this, NGS has been applied to numerous
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different strains from a variety of environmental backgrounds. Short-read NGS
is both more powerful than other molecular epidemiological tools and ca also be
applied more efficiently to a far greater number of samples.
The development of bioinformatic tools to help process the growing abundance
of sequencing data is useful in both clinical and research settings. The progres-
sion of sequencing technology has steadily replaced molecular epidemiological
tools such as multi-locus sequence-typing (MLST), pulsed-field gel electrophore-
sis (PFGE) and 16s rRNA gene sequence analysis with bioinformatic tools that
are both more tolerant and more flexible to genetic variation; and are more easily
adapted to incorporate novel genomic loci (Laing et al., 2011). Such flexibility is
particularly desirable with E. coli ; where MLST (Noller et al., 2003) and PFGE
(Pei et al., 2008) have been found to underestimate sequence diversity amongst
E. coli strains.
Whole-genome comparisons of E. coli from different environmental backgrounds
indicate that the core set of gene sequences, common to all E. coli, account for
no more than 20% of the total genome. By contrast, the remaining 80% of the
identifiable gene content is variably associated to E. coli strains of different envi-
ronmental niches; and is strongly linked to horizontal gene transfer (HGT) and
genetic recombination (Touchon et al., 2009, Lukjancenko et al., 2010). Such
genetic diversity is not unexpected given that E. coli is a widely distributed, yet
niche driven pathogenic and commensal component of the microbiota in a diverse
range of hosts.
Pathogenic E. coli are capable of causing a spectrum of diseases which in-
clude intestinal infections: enteroheamorrhagic E. coli (EHEC), enterotoxigenic
E. coli (ETEC), enteropathogenic E. coli (EPEC) and diffuse entero-aggregative
E. coli (DEAEC); as well as extra-intestinal infections (extra-intestinal E. coli
(ExPEC)): uropathogenic E. coli (UPEC) and neonatal meningitis E. coli (NMEC)
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infections. The partitioning of E. coli into these various pathotypes is done by
the detection of virulence factors that are characteristic of a particular pathology
(Kaper et al., 2004). Because these virulence factors are exclusively pan-genomic,
and not core to all E. coli, whole genome sequencing (WGS) can be used to predict
the pathotype and pathogenic potential of an E. coli isolate in silico.
Despite a moderately conserved core genome, it has been proposed that ExPEC
lineages are independently derived from the convergence of different clonal lin-
eages of E. coli (Kaas et al., 2012). To date, there are multiple complete assem-
bled genomes for UPEC isolates. These included UPEC strains: CFT073, UTI89,
and 536; the asymptomatic UPEC strain: ABU83972; and the MDR pathogenic
UPEC strain JJ1886. With the exception of CFT073 and ABU83972, which are
highly related strains of E. coli (Wassenaar et al., 2015), these UPEC strains
have been isolated from differing genetic backgrounds.
As discussed in the general introduction, the aetiology of urinary tract infec-
tions (UTI)s is strongly influenced by a number of different environmental factors,
such as: host health status and age; which cannot be accounted for by sequencing
E. coli. Despite this, core-genomic phylogeny provides another means of predict-
ing, in silico, the pathogenic potential, as well as the genetic lineage of previously
unsequenced E. coli strains.
Based on the work in the previous chapter, it was hypothesized that there is a
clear difference in the pathogenic potential of the MDR and susceptible isolates.
WGS allows these strains to now be directly compared to E. coli isolates from
across a range of pathotypes and niches; by comparing both the core and pan-
genome of different E. coli isolates.
As well as using in silico WGS comparison studies of E. coli to obtain estimates
of potential virulence it is desirable to have a means to test the virulence of
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previously uncharacterized E. coli in vivo. Galleria mellonella larvae have been
used as an infection model for a number of different bacterial pathogens, including
EPEC, UPEC and commensal E. coli (Alghoribi et al., 2014). The Galleria
mellonella model can also be ethically applied to a much larger number of samples
than other infection models; and larvae can be incubated at 37° C, which is
optimal for E. coli.
3.2 Methods
3.2.1 DNA Extraction
Illumina sequencing was performed by Edinburgh Genomics, using an Illumina
Hi-Seq 2500 sequencer. Nextera XT libraries were prepared by Edinburgh Ge-
nomics, yielding 100bp paired-end reads. E. coli strains were grown overnight
at 37°C, 170 rpm, in lysogeny broth (LB). DNA was extracted using a Qiagen
DNeasy extraction kit. DNA was isolated from 1ml of bacterial culture, and
performed to the manufacturer’s specifications.
3.2.2 Sequence Assembly
Raw sequence reads were assessed using FastQC (Andrews, 2010) before assembly
to ensure successful sequencing. Sequence reads were then assembled using the
velvetOptimiser script, from Velvet (v1.2.08) (Zerbino and Birney, 2008). A kmer
size range of 47 to 67, with size increments of 2, was used. Reads were filtered
before assembly using Sickle (Joshi and Fass, 2011), with a minimum read quality
score of 30, and a minimum read length of 50bp. The sequence reads were then re-
shuffled, using the shuffleSequences fastq.pl script. De novo assembly used both
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paired reads and singletons. The quality of assembled genomes was evaluated
using Quality Assessment Tool (QUAST) (Gurevich et al., 2013).
3.2.3 Sequence Annotation and Analysis
Sequence annotation was performed with both the Rapid Annotations based on
Subsystem Technology (RAST) annotation server (Aziz et al., 2008), Prokka (See-
mann, 2014) and the Sanger genome pipeline: Roary (Page et al., 2015). AMR
and virulence marker genes were detected using tools developed by the Center
for Genomic Epidemiology: ResFinder (Zankari et al., 2012) and VirulenceFinder
(Joensen et al., 2014). SeqFinder (Stanton-Cook et al.) was used to identify vir-
ulence gene sequences in the assembled genomes. Virulence gene sequences were
obtained from Virulence Factor Database (VFDB) (Chen et al., 2012).
Phylogenetic analysis was performed using RealPhy (Bertels et al., 2014).
ClonalFrameML (Didelot and Wilson, 2015) was used to estimate core sequence
phylogeny and recombination estimation analysis. E. coli reference sequences
were obtained from the NCBI RefSeq collection. Sequence alignment input files
and the guide-tree were generated suing the Harvest suite (Treangen et al., 2014).
Roary was used to generate maximum-parsimony core and pan-genomic sequence
comparisons.
3.2.4 Galleria mellonella infection model
E. coli strains were grown aerobically, overnight in 10 ml of LB at 37°C, and
170 rpm. Cultures were re-suspended in phosphate buffered saline (PBS) and
standardized to an optical density (OD) of 1.0 at 600nm. Strains were then
further diluted ten-fold in PBS. Moth larvae were injected with µL of bacterial
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suspension or PBS control. Galleria mellonella larvae were obtained from a local
pet supply store.
PBS sham injection and no-injection control groups of 10 larvae were used to
control for adverse outcomes due to injection methodologies. CFT073 (pyelonephri-
tis) and ABu83972 (asymptomatic) E. coli strains were used to assess baseline
virulence thresholds for the model.
Each injection group consisted of 10 individual larvae. Once successfully inoc-
ulated, larvae were incubated at 37°C for the remainder of the experiment. Larvae




FastQC indicated successful sequencing runs for all of the isolates; all sequences
exceeded minimum quality scores for the metrics assessed by FastQC. Genome
coverage was estimated at roughly 100 fold for all of the isolates. A strain key is
provided to allow for the conversion between sequencing ID numbers and isolate










































Table 3.1: The table shows the sequence identification number, strain ID and
group (MDR or susceptible) for each of the isolates sequenced in this study.
E. coli is notorious for being difficult to sequence; with many large repeat
regions which prevent contig assembly from short-read sequencing (Koren et al.,
2013). This was reflected in the assemblies for some of the isolates in both groups
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(table 3.2 and table 3.3).
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Table 3.2: MDR Isolate assembly statistics
Assembly Contings Largest contig Total length GC (%) N50 L50 Misassemblies N’s per 100 kbp Predicted genes
0863N0001 220 601008 5238071 50.64 134269 11 123 150.34 4982
0863N0002 2836 66017 6030714 49.46 13298 118 68 1216.24 7175
0863N0003 168 218582 4924698 50.53 119627 16 124 176.13 4640
0863N0005 1458 348391 5769029 49.77 97177 19 136 1053.61 6195
0863N0006 2481 68786 5910575 49.24 11713 135 68 1165.49 6914
0863N0007 4548 48276 6669129 49.09 4613 348 56 923.18 9217
0863N0009 142 575686 5046680 50.46 149922 11 137 120.34 4821
0863N0013 157 409246 4884392 50.57 123183 12 53 134.94 4650
0863N0027 203 306918 4845242 50.69 154835 11 101 137.66 4677
0863N0030 1617 139495 5577249 49.77 41339 41 47 1501.49 6243
0863N0031 303 416737 5089827 50.57 149667 11 79 295.22 4916
0863N0032 148 254918 4835557 50.66 135417 13 63 188.23 4597
0863N0033 217 241195 4978694 50.55 73672 20 67 110.37 4870
0863N0035 207 343758 4948962 50.64 152716 12 81 125.42 4724
0863N0036 36 922974 4954102 50.44 554752 4 165 78.54 4621
0863N0039 133 355361 4745737 50.52 147596 11 53 139.45 4484
Multi-drug resistant isolates Illumina sequence assembly statistics. Isolates were sequenced using and Illumina Hi-Seq, with read
lengths of 100bp. All statistics are based on contigs of size ≥200 bp, except for contig number (which includes all assembled
contigs). N50: the length (N) of the assembled genome which is accounted for by 50% of all bases; i.e the median length of a genome
assembly. L50: The number (L) of assembled sequences, whose total length is ≥50% of the total length of all assembled sequences.
Missassemblies: Identified base positions (breakpoints) within assembled contigs that i) contain flanking sequences that are greater
than 1kb apart, ii) contain flanking sequences that align to opposing strands to one another, iii) contain flanking sequences that
overlap by more than 1kb. Assembly metric calculated by Quast using GeneMarkS, GeneMark-ES and GlimmerHMM.
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Table 3.3: Susceptible isolate assembly statistics
Assembly Contigs Total length Largest contig GC (%) N50 L50 Misassemblies N’s per 100 kbp Predicted genes
0863N0004 251 5008482 335955 50.56 92111 16 106 135.14 4849
0863N0008 454 5180380 378129 50.32 90872 18 135 312.61 5028
0863N0014 3046 6112082 59795 49.87 13206 115 87 851.16 6848
0863N0015 15813 8830244 38211 50.09 939 2072 59 331.07 15294
0863N0016 2836 5914209 101272 49.32 16047 85 116 438.18 6544
0863N0018 257 5259655 561432 50.45 196103 10 149 161.27 5038
0863N0019 270 5196946 383048 50.35 199842 10 143 124.50 4981
0863N0021 1525 5248840 129172 50.11 20112 70 79 1056.34 5538
0863N0022 2862 6256527 71277 50.05 15360 114 80 907.71 7227
0863N0024 900 5072766 109332 50.69 14693 97 68 653.06 5415
0863N0025 309 5079177 215128 50.38 64559 23 121 674.21 5041
0863N0026 217 5042893 457115 50.53 206926 8 138 254.70 4808
0863N0029 232 5086073 755992 50.50 217054 7 148 175.74 4813
0863N0034 3092 5229062 22748 50.18 4477 346 45 2042.98 6874
0863N0038 234 5109919 577914 50.49 278007 7 139 185.84 4827
Susceptible isolates Illumina sequence assembly statistics. Isolates were sequenced using and Illumina Hi-Seq, with read lengths of
100bp. All statistics are based on contigs of size ≥200 bp, except for contig number (which includes all assembled contigs). N50: the
length (N) of the assembled genome which is accounted for by 50% of all bases; i.e the median length of a genome assembly. L50:
The number (L) of assembled sequences, whose total length is ≥50% of the total length of all assembled sequences. Miss-assemblies:
Identified base positions (breakpoints) within assembled contigs that i) contain flanking sequences that are greater than 1kb apart,
ii) contain flanking sequences that align to opposing strands to one another, iii) contain flanking sequences that overlap by more
than 1kb. Assembly metric calculated by Quast using GeneMarkS, GeneMark-ES and GlimmerHMM.
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The National Center for Biotechnology Information (NCBI) RefSeq collection
of completed E. coli genomes provides a rough benchmark to compare genome
assemblies against. E. coli has a median total genome length of 5.17 mega bases
(Mb) (min 3.98Mb, max 5.87Mb) , with a median number of 5040 annotated
protein coding sequences (min 4017, max 6377) and a median guanidine-cytosine
(GC) content of 50.6%. The draft assemblies for the isolates sequenced in this
project broadly conform to these values; with a few exceptions (MDR: fig. 3.1,
fig. 3.3. Susceptible: fig. 3.2, fig. 3.4).
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Figure 3.1: The cumulative length of all assembled contigs for each sequenced multi-drug resistance isolate. Contigs are plotted from
largest to smallest on the x-axis. The baseline genome length used for this plot is the reference sequence Escherichia coli MG1655,
which has a chromosome length of 4.64Mb. The current size range for listed NCBI RefSeq E. coli genomes is between 4.48Mb and
5.87Mb.
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Figure 3.2: The cumulative length of all assembled contigs for each sequenced susceptible isolate. Contigs are plotted from largest
to smallest on the x-axis. The baseline genome length used for this plot is the reference sequence Escherichia coli MG1655, which
has a chromosome length of 4.64Mb. The current size range for listed NCBI RefSeq E. coli genomes is between 4.48Mb and 5.87Mb.
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Figure 3.3: The percentage guanidine, cytosine nucleotide composition of the assembled multi-drug resistance isolate genomes. GC%
is plotted on the x-axis. The assembled genomes are divided into non-overlapping 100bp windows, and the number of windows for
each GC% is plotted on the y-axis. The reference genome Escherichia coli MG1655 is indicated on the plot by the dashed line.
E. coli isolates typically have a GC% of 50%. Monoculture sequences (i.e. uncontaminated samples) typically display a Gaussian
distribution about the mean. Contaminated samples show multiple peaks.
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Figure 3.4: The percentage guanidine, cytosine nucleotide composition of the assembled susceptible isolate genomes. GC% is plotted
on the x-axis. The assembled genomes are divided into non-overlapping 100bp windows, and the number of windows for each GC%
is plotted on the y-axis. The reference genome Escherichia coli MG1655 is indicated on the plot by the dashed line. E. coli isolates
typically have a GC% of 50%. Monoculture sequences (i.e. uncontaminated samples) typically display a Gaussian distribution about
the mean. Contaminated samples show multiple peaks.
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From the MDR group (table 3.2), isolate 1176 (0863N0002) has a projected
cumulative genome length of greater than 6Mb. Along with an increased pro-
jected genome length, the contigs contain 7175 predicted genes; also much higher
than expected. Much of this is expected to be a result of a poorer than average
sequence assembly. The assembled contigs contain a ten-fold higher number of
un-sequenced bases (1216.24 N’s per 100kilo base pairs (kbp)), along with a com-
paratively poor N50 score (13298) and much higher number of assembled contigs
(1458).
Isolate 1428 (0863N0005) also contains an expanded number of predicted genes
(6195), without being an outlier in terms of estimated cumulative genome length
(5.8Mb). Like 1176, the N50 (97177), N’s per kbp (1053.61) and total number of
contigs (1458) indicate that this is likely due to sequence assembly error.
Isolates 1943 (0863N0006) (predicted genes: 6914, total length: 6.9Mb) and
317 (0863N0030) (predicted genes: 6243, total length: 5.6Mb) also show small
projected expansions of genomic content, also with relatively poor assembly met-
rics: N50 (11713, 41339) and number of assembled contigs (2481, 1617).
Isolate 1271 (0863N0007) shows a particularly large predicted gene content
(9217) and genome length (6.7 Mb). However, the N50 score (4613) and total
number of contigs (4548) indicate an exceptionally fragmented assembly; com-
pared to the other isolates. Though estimated mis-assemblies (56) and N’s per
100 kbp are not much higher than the other isolates.
The remaining MDR isolates have assemblies which are not worse than ex-
pected for E. coli (Koren et al., 2013); and compare favorably to the E. coli
RefSeq sequences.
The susceptible isolates were less variable, in terms of assembly metrics and
compared favorably to expected genome size and predicted genome content (table
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3.3. However, isolate 58 (0863N0015) is a significant outlier in almost every
assessed metric. Total number of assembled contigs (15813, hundred fold higher
than other isolates), N50 (939, excessively short for 200bp paired-end reads) and
L50 (2072) all point to a poor genome assembly. This is expected to account for
the drastically expanded predicted genome (total length: 8.8Mb, predicted genes:
15294).
3.3.2 Assembly Mapping to Reference Genome
In concurrence with relatively good assembly metrics for the majority of the
isolates in both the MDR and susceptible groups, and favorable comparisons to
published RefSeq sequences; the sequenced isolates show good sequence alignment
to E. coli MG1655. Both the MDR (fig. 3.5) and susceptible alignments (fig. 3.6)
show aligned contiguous sequences along the majority reference sequence; with
few gaps. This includes isolate 58 (0863N0015), which has the strongest mapping
of contigs to the reference genome despite a poor assembly.
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Figure 3.5: Multi-Drug Resistance isolate genome assemblies, as aligned to the reference genome of Escherichia coli MG1655 (NCBI
accession:NC000913.3). Green blocks identify contigs that are aligned to the reference genome. Red blocks identify contigs that are
aligned to the reference genome that contain ≥1 missassemblies. Blank space indicates an area of the reference genome to which
none of the assembled contigs have aligned.
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Figure 3.6: Susceptible isolate genome assemblies, as aligned to the reference genome of Escherichia coli MG1655 (NCBI acces-
sion:NC000913.3). Green blocks identify contigs that are aligned to the reference genome. Red blocks identify contigs that are
aligned to the reference genome that contain ≥1 mis-assemblies. Blank space indicates an area of the reference genome to which
none of the assembled contigs have aligned.
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3.3.3 Resistance Markers
The MDR isolates (table. 3.4) showed strong mapping to a variety of resistance
gene markers. The β-lactam and extended-spectrum cephalosporin resistance
phenotype is largely attributable to a blaCMY-2 resistance genotype across the
MDR isolates; with only a couple of exceptions.
Isolate 317 (0863N0030) possesses a blaCMY-7 resistance gene which accounts
for the extended-spectrum AmpC (ESAC) resistance. An additional β-lactamase
resistance maker blaTEM-1B was also detected in the 317 assembly.
Isolate 565 (0863N0031), also phenotypically positive for ESAC resistance,
contained no detectable ESAC resistance genotype.
Isolate 127 (0863N0033) was positive for blaTEM-33 resistance marker; which
is an extended-spectrum β-lactamase (ESBL) rather than an ESAC resistance
gene.
Isolate 1088 (0863N0009), despite showing phenotypic resistance to cefalexin,
ampicillin, tetracycline and extended-spectrum resistance, contained no detectable
resistance markers.
Aminoglycoside resistance markers were detected in 8 of the MDR isolates;
despite only 4 of the isolates being phenotypically positive for gentamycin resis-
tance. Though many of the detected resistance markers convey resistance against
other aminoglycosides ( strA strB, aad (streptomycin), aph (hygromycin)) and
variably against gentamycin (aac); the isolates were only tested for gentamycin
resistance so detectable resistance cannot necessarily correlated with phenotypic
resistance.
Phenotypic resistance to co-trimoxazole (potentiated-sulfonamide) was preva-
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lent amongst the MDR isolates (14/18). Correspondingly, resistance markers
were identified in the majority of the MDR isolates. Only one MDR isolate,
565 (0863N0031) (sul1, dfrA1 ) showed positive identification of potentiated-
sulfonamide resistance markers with no evidence of phenotypic resistance.
Tetracycline was the second most common resistance (15/18). With few ex-
ceptions, the resistance phenotype can be attributed to the widespread identifica-
tion of tetA and tetB resistance marker genes. Though 1943 (0863N0006), 1088
(0863N0009), 1201 (0863N0027) and 127 (0863N0033) were all positive for pheno-
typic resistance, but contained no detectable resistance makers in their sequence
assemblies.
Phenotypic resistance to chloramphenicol resistance markers (cat, floR) were
identified in 8/18 of the isolates; though as the isolates were not tested for phe-
notypic resistance the two cannot be correlated.
Similarly, isolates 1176 (0863N0002), 1223 (0863N0013), 565 (0863N0031) and
737 (0863N0035) all contain a singular resistance marker (mphA or mphB) tar-
geting macrolide antibiotics; but no phenotypic resistance testing was carried out
for any of the macrolides.
Despite 8/18 isolates being positive for phenotypic resistance against ciprofloxacin,
no fluoroquinolone resistance markers were detected in any of the MDR isolates.
Fluoroquinolone resistance is primarily achieved through point mutation to DNA
gyrase and topoisomerase genes; though resistance can be acquired by plasmid
mediated qnr genes (Jacoby, 2005). ResFinder cannot identify such point muta-
tions from the sequence data; and is only capable of identifying the acquired qnr
resistance genes. No work was done to attempt to identify any point mutations
in the isolates that may contribute towards the observed ciprofloxacin resistance
(which is the most likely explanation).
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The susceptible isolates contained almost no detected resistance markers. With
the exception of isolate 58 (0863N0015) and 1190 (0863N0024) (table 3.4). The
β-lactamase resistance gene blaTEM-1D was detected in the sequence assembly for
1190, despite no detectable phenotypic resistance to either cefalexin or amoxi-
cillin.
Isolate 58 possessed an extensive resistance genotype. Aminoglycoside (aadA1,
aph(3’)-1c, strA, strB), macrolide (mphB), sulfonamide (sul2 ) and trimethoprim
(dfrA1 ) resistance markers were all detected in the sequence assembly. The isolate
had been previously tested against a standard panel of antibiotics (not carried
out in this project) and found to be fully susceptible. The detectable resistance
markers are assumed to be an artifact of poor sequence assembly and the isolate
has not been re-typed.
Table 3.4: ResFinder detected resistance markers
















0863N0001 MDR blaCMY-2 sul2 3rd/2nd gen. CEF AMC
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0863N0002 MDR aph(4)-1a aac(3)-Iva aph(3)-1c aadA1
blaTEM-1A mph(B) catA1 floR sul1
tet(A) dfrA1
1st gen. CEF AMC CO-TRIM CIP TET
GENTA
0863N0003 MDR sul2 tet(B) 3rd/1st gen. CEF AMC COT TET
0863N0005 MDR blaCMY-2 tet(B) 3rd/1st gen. CEF AMC TET
0863N0006 MDR blaCMY-2 catB3 dfrA1 3rd/1st gen. CEF AMC CO-TRIM CIP
TET
0863N0007 MDR strA strB aadA1 blaTEM-1A floR sul2
tet(B) dfrA1
1st gen. CEF AMC CO-TRIM TET
0863N0009 MDR 3rd/1st gen. CEF AMC TET
0863N0013 MDR aph(3’)-1a aadA5 blaCMY-2 mph(A)
catA1 sul1 tet(B) drfA17
3rd/1st gen. CEF AMC CO-TRIM CIP
TET
0863N0027 MDR blaCMY-2 dfrA5 3rd/1st gen. CEF AMC CO-TRIM TET
0863N0030 MDR aadA2 strA strB aadA2 blaTEM-1B
blaCMY-7 sul1 sul2 tet(A) dfrA12 dfrA1
3rd/1st gen. CEF AMC CO-TRIM CIP
TET
0863N0031 MDR aac(3)-Iva aph(4)-1a aadA1 aph(3’)-1c
blaTEM-78 mph(B) catA1 floR sul1 tet(A)
dfrA1
3rd/1st gen. CEF AMC CIP TET GEN
0863N0032 MDR strA strB blaCMY-2 sul2 tet(A) dfrA14 3rd/1st gen. CEF AMC CO-TRIM CIP
TET
0863N0033 MDR aadA5 aph(3’)-1a strA strB blaTEM-33
catA1 sul2 sul1 dfrA1 dfrA17
3rd/1st gen. CEF AMC CO-TRIM TET
0863N0035 MDR aadA1 aph(3’)-1c blaTEM-1A mph(B)
catA1 sul1 tet(A) dfrA1
AMC CO-TRIM CIP TET GEN
0863N0039 MDR aadA1 strB strA blaTEM-1A floR sul2
tet(B) dfrA1
1st gen. CEF AMC CO-TRIM CIP TET
0863N0036 MDR 1st gen. CEF AMC CO-TRIM CIP TET
0863N0028 MDR 3rd/1st gen. CEF AMC CO-TRIM TET
0863N0037 MDR 1st gen. CEF AMC CO-TRIM TET GEN
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Shows the detected in silico resistance markers for both the susceptible and
multi-drug resistance isolate assemblies. Resistance alleles include beta-lactamase
(blaCMY, blaTEM), tetracycline resistance (sul, dfrA, tet), fluoroquinolone (floR,
catA, catB), aminoglycoside(aadA, aph, strA, strB), and macrolide (mphB) re-
sistances. The in silico resistance profile is then compared with the recorded
phenotypic resistance: 3rd gen (extended-spectrum AmpC phenotype), AMC
(ampicillin), CEF (cefalexin), COT (co-trimoxazole), CIP (ciprofloxacin), TET
(tetracycline), GEN (gentamycin).
3.3.4 Virulence Markers
Two different in silico methods were used to assess the presence of different
virulence genes in the MDR and susceptible isolates. VirFinder uses reference
virulence gene sequences from E. coli from across the different pathotypes (table
3.5). It does not provide an opportunity to expand the curated databases of
virulence markers beyond a limited selection; but can be used to confirm the
Identibac results from Chapter 2.
SeqFinder was used to better identify urovirulence genes from a more compre-
hensive database of E. coli virulence markers from VFDB. SeqFinder provides
a more complete set of genetic markers to help differentiate the susceptible and
MDR isolates.
In general, the attempted separation of the isolates by presence or absence
of virulence markers was not successful. Initial typing using VirFinder (table
3.5) and Identibac suggested that there was an increased presence of virulence
markers in the susceptible isolates. Whilst the result produced by SeqFinder (fig.
3.7) is concurrent with some of the results, increasing the number of virulence
markers used to type the isolates does indicate more general inter and intra-group
differences amongst the isolates.
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Overall, SeqFinder identified a much stronger toxin presence than either VirFinder
or Identibac. Haemolysin (hly) (14/31) and vacuolating toxin (vat) were identified
in both susceptible and MDR isolates. SeqFinder does identify two sub-groups
of isolates, based on their virulence profile. The first group (11/31) is comprised
mostly of susceptible isolates (7/11). These isolates do possess a strong urovir-
ulence profile; including: fimbrial proteins (pap, fim (type-1 fimbriae) and foc
(F1C fimbriae)), hly (haemolysin), and multiple siderophore gene families (iro,
ybt, chu). The second group (12/31) is almost exclusively MDR (10/12) and
is mostly bereft of virulence markers, with the exception of: fim, ecp (E. coli
common pillus) and some siderophores (iut, ybt, sit).
With both groups trending towards either susceptible or MDR status, the re-
maining small group of isolates do not cluster; and have more unique virulence
profiles (presence of toxins vat, sat and pic). Though the inability of SeqFinder
to successfully cluster these isolates is better explained by the inconsistent iden-
tification of genes that better define the two clusters.
Table 3.5: VirFinder detected virulence markers
ID Group Virulence Genes Galleria melonella
lethality
0863N0004 Susceptible iss mchB mchC lpfA mchF mcmA 90-100%
0863N0008 Susceptible pic vat iss cnf1 iroN mchC mcmA mchB prfB 90-100%
0863N0014 Susceptible ireA mcmA vat astA mcmA mchB mchC sfaS prfB iroN
cnf1
70-80%
0863N0015 Susceptible senB mchB mchC iroN mcmA mchF iss f17G cnf1 mchF
prfB lpfA astA
0863N0016 Susceptible mcmA iss mchF pic iroN vat mchC prfB ireA mchB cnf1 20-90%
0863N0018 Susceptible ehxA cnf1 mcmA mchF f17A iroN iss mchC vat prfB
mchB senB
0-10%
0863N0021 Susceptible mchB iroN mchC vat iss gad prfB mchF mcmA cnf1 90-100%
0863N0022 Susceptible vat iss mcmA ireA prfB mchC cnf1 mchB iroN sfaS astA 90-100%
0863N0024 Susceptible prfB 80-100%
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0863N0025 Susceptible iss vat sfaS mcmA iroN pfrB cnf1 90-100%
0863N0026 Susceptible prfB pic iss sat vat iha senB 20%
0863N0029 Susceptible iroN sfaS mcmA ireA vat mchF gad iss mchC cma mchB
cba cnf1 prfB
100%
0863N0034 Susceptible mchC iroN pic mchF iss senB mcmA prfB iha vat gad
0863N0038 Susceptible astA iss mcmA sfaS vat iroN prfB 70-100%
0863N0001 MDR cba cma prfB gad 75-100%
0863N0002 MDR mchF mcmA prfB f17G astA iss tsh lpfA iroN 90-100%
0863N0003 MDR ireA iss prfB 50-75%
0863N0005 MDR iss prfB lpfA gad iss 100%
0863N0006 MDR lpfA iss prfB mcmA 75-80%
0863N0007 MDR mcmA prfB mchC mchB cnf1 iss 100%
0863N0009 MDR mcmA vat iroN iss mchB mchC mchF prfB gad
0863N0013 MDR mchF iss iroN prfB 10-30%
0863N0027 MDR lpfA iss prfB mchF iroN iss 0%
0863N0030 MDR prfB gad iss 0-25%
0863N0031 MDR mchF astA mcmA lpfA prfB tsh iss f17G iroN 100%
0863N0032 MDR prfB 0-100%
0863N0033 MDR iss prfB 0-25%
0863N0035 MDR iroN tsh iss astA mchF mcmA lpfA prfB 100%




Shows the detected in silico virulence markers for both the susceptible and
multi-drug resistance isolate assemblies. Virulence markers detected include: mi-
crocins(mchA, mchB, mchC,mcmA), toxins (pic, vat, cnf1, senB, astA), fimbrial
proteins (lpfa, sfaS, f17A), metabolic related proteins (prfB, gad, tsh), cellular
adherence (iha), haemolysis (ehxA), colicins (cba, cma), innate immune evasion
(iss) and haem-utilization(iroN, ireA). The in silico virulence profile is then com-
pared to in vivo resistance in the Galleria mellonella infection model; as equated
by the proportion of the moth larvae killed by the final day of infection.
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Figure 3.7: SeqFinder analysis of urovirulence gene presence using CFT073 virulence genes obtained from VFDB. Black = gene
presence, green square = susceptible isolate, red square = MDR isolate. Included virulence genes: P-fimbriae (pap), type 1 fimbriae
(fim), FIC (foc), vat (toxin), sat (toxin), pic(toxin), haemolysin (hly), enterobactin (iro), Yersiniabactin (ybt), sit (siderophore),
chu (siderophore), E. coli common pillus (ecp). SeqFinder identified two clusters of similar virulence gene profiles. Group 1 are
highlighted in red on the cladogram. Group 2 are highlighted in green on the cladogram. Blue branches on the cladogram indicate
strains with unique virulence gene profiles.
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3.3.5 Galleria mellonella Virulence Model
The Galleria mellonella infection model does not show a trend towards more
virulence, or more asymptomatic isolates in either the MDR or susceptible groups.
The number of virulence markers detected did not correlate at all with moth
larvae lethality (table 3.5).
Sham injected (PBS) and non-injected (NI) control group larvae showed no
lethality throughout. The asymptomatic bacteriurea control strain ABU83972
showed no lethality. In contrast the urovirulence control strain (CFT073) showed
consistently high mortality of 80% (8/10) (fig. 3.8, fig. 3.9).
In general there was good consistency across both the MDR (fig. 3.10, 3.11)
and susceptible (fig. 3.8, fig. 3.9). Only 1283 (MDR) and 162 (susceptible)
showed large inconsistencies.
1283 showed complete lethality (100%) in the first round of infections, but
showed no larvae lethality in the second round of infections.
162 showed a large increase in lethality within the first 24 hours post-injection
of the second infection. This resulted in a 3 fold increase in the proportion of
larvae killed by the end of the infection (90%) in comparison to the first round
of infections (30%).
As well as showing no increased or decreased virulence between the two groups
of isolates, when assessed collectively (fig. 3.12); there was a lack of increasing
lethality across the time period of infection for any of the isolates. With few
exceptions of minor increases in proportion of larvae dead across the time period
of infection; the proportion of larvae dead did not generally increase after the
first 24 hours post-injection.
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Figure 3.8: First repeat of the Galleria mellonella larvae infection model for the
susceptible group isolates. NI = no injection control, PBS = PBS sham injection
control, ABU = asymptomatic bacteriurea strain, CFT = virulent UPEC strain.
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Figure 3.9: Second repeat of the Galleria mellonella larvae infection model for the
susceptible group isolates. NI = no injection control, PBS = PBS sham injection
control, ABU = asymptomatic bacteriurea strain, CFT = virulent UPEC strain.
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Figure 3.10: First repeat of the Galleria mellonella larvae infection model for
the MDR group isolates. NI = no injection control, PBS = PBS sham injection
control.
98
Figure 3.11: Second repeat of the Galleria mellonella larvae infection model for


























Figure 3.12: Combined Galleria mellonella survival curves for the MDR and
susceptible groups. Moth mortality across the 4 day time points is calculated as
the proportion of larvae alive across all isolates within the group.
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3.3.6 Core and Pan Genome Analysis
Core-genomic and pan-genomic sequence constructions do indicate different ge-
netic backgrounds for the MDR and susceptible group isolates; though it is im-
portant to note the genetic variability between isolates is still high. Core-genome
single nucleotide polymorphism (SNP) comparisons, combined with pan-genomic
sequence presence or absence does show distinct backgrounds fro the susceptible










Figure 3.13: Core genomic phylogenetic estimation of MDR, susceptible and RefSeq E. coli sequences. E. fergusonii was used
to root the tree as the closest common ancestor. Pathogenic (EHEC, UPEC, EPEC, APEC, and ExPEC) and non-pathogenic
(Environmental and Commensal/Probiotic) E. coli RefSeq sequences were included in the sequence comparisons.
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Phylogenetic analysis of the MDR isolates, susceptible isolates and RefSeq
sequences for E. coli of different pathotypes (fig. 3.13) suggest a wide ranging
variability in genetic background. Which is concurrent with previous estimates of
genetic relatedness with MLST. There is some closer relatedness to UPEC Ref-
Seq sequences ABU83972 and CFT073 with a small group of susceptible isolates
(1489, 1365, 1660 and 162); but the remainder of the isolates sequenced in this
project are widely dispersed and form no distinct grouping.
Given the dispersal of the strains across the tree, it is not possible to correlate
many MDR or susceptible strains to any one pathotype. Even amongst the UPEC
RefSeq sequences (JJ1886, 536, CFT073, ABU83972, UTI89 and IAI39) there is
no clustering, which reflects the more heterogeneous background of UPEC in
general. Though there are exceptions; most notably EHEC and K-12 derived
sequences.
A potential source of variability in the phylogenetic reconstruction is likely
recombination. Genomic recombination (the transfer of genetic material between
different bacteria) can greatly impact phylogenetic estimations and generate spu-
rious relationships between isolates; based on regions of recently shared DNA
(Didelot and Wilson, 2015).
There is significant recombination between all the isolates sequenced in this
project (fig. 3.14); and this may be, in part due to sub-optimal assemblies.
Sites of recombination frequently include repeat regions of DNA, which sequence
assembly is vulnerable to; and E. coli commonly contains very large repeat regions










































































Figure 3.14: ClonalFrameML core genome phylogeny and recombination estimation analysis. Red circle = MDR isolate, green circle
= susceptible isolate. Sites of recombination identified by ClonalFrameML are noted by horizontal dark blue bars.
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3.4 Discussion
3.4.1 Next-generation Sequence Assembly
The differences in the MDR and susceptible strains from the results of chapter
2 required further exploration. Illumina NGS was used as it allows for better
contextualisation of both the MDR and susceptible isolates. The de novo assem-
bly of the sequenced MDR and susceptible isolates also allowed more detailed
analysis of virulence genotype, antimicrobial resistance (AMR) genotype, core
and pan-genomic sequence comparisons; but also highlighted the vulnerabilities
of NGS to the complexities of the E. coli genome.
While the quality of the sequence reads (unassembled) met expected qual-
ity standards (FastQC); assembly of those sequencing reads into contiguous se-
quences was less straightforward. None of the assemblies, for either MDR or
susceptible isolates, is likely to contain the whole genome; many remain highly
fragmented and probably without regions of potential interest. Critically, short-
read NGS methods are particularly vulnerable to repetitive regions (often associ-
ated with horizotal genetic elements (HGEs)) of the genome that are longer than
the maximum insert size of the sequence read pairs; that therefore cannot be as-
sembled (Koren et al., 2013). These repeat regions can often contain the genomic
sequences of interest, and collectively drive much of the functional adaptation
and variation seen across different E. coli (Welch et al., 2002). Moreover, repeti-
tive sequences can also introduce miss-assemblies and sequence errors which may
prevent the correct annotation of genes and other downstream sequence analysis.
For the MDR isolates, sequence assembly and annotation quickly identified a
range of AMR gene which potentially contribute to the MDR phenotype. This
had not been achievable with the results of the AMR gene Identibac panel (Chap-
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ter 2). The identified AMR genes mapped well to the phenotypic resistance ob-
served for the MDR isolates (table 3.4) and confirmed that the observed ESAC
phenotype was attributable to CMY-2.
NGS methods cannot easily assemble plasmid and other horizontally-transferable
DNA sequences. Like chromosomal sequences, phages, transposable elements and
plasmids contain large repetitive regions of DNA sequence. HGEs, which are
important vectors of transmission for both virulence and AMR genes, may be de-
tectable but cannot be fully assembled from NGS data alone (Koren et al., 2013,
Lanza et al., 2014). The annotation of protein sequences, from the assembled
genomes (data not shown), confirmed the presence of IncI1 and IncF plasmid
replicon sequences; as predicted using the replicon typing PCR in Chapter 2.
RAST annotation showed a number of plasmid contigs, as well as transposable
element sequences throughout the MDR isolates. However, contigs that could be
identified as being of potential plasmid origin contained only sequences associated
with the plasmid replicon. Because of this (i.e. fragmented assemblies), it was
not possible to associate annotated virulence or AMR genes to any of the plasmid
replicons.
Identibac virulence typing (Chapter 2) showed a greater number of virulence
markers present in the susceptible isolates, as compared to the MDR. This was
confirmed in the sequence assembly data by the virulence genes detected by Iden-
tibac in both groups (microcins and haem-utilization). Neither VirFinder, or
Identibac specifically assess potential uropathogenesis; but instead include more
general E. coli virulence markers. To expand on these results, sequence assembly
data for the MDR and susceptible isolates was compared using a larger collec-
tion of UPEC specific virulence genes present in the genome of CFT073 (VFDB,
fig. 3.7). Primarily, the results show a greater variability between the MDR and
susceptible isolates; than indicated by VirFinder or Identibac. However, for both
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the susceptible and MDR isolates, few of the virulence gene families have been
fully annotated; particularly fim, chu and ybt genes.
The detection of a virulence gene in an assembled contig relies on: 1) the
presence of the virulence gene sequence in an assembled contig, and 2) correct
identification of the gene sequence in an assembled contig. Failure to detect
virulence genes could be the result of 1) the virulence gene is not present in the
assembled E. coli genome; 2) the virulence gene sequence cannot be assembled; 3)
the sequence assembly contains a virulence but contains too many miss-assemblies
or errors to be identified; and 4) the virulence gene is present but is too divergent
from the reference gene sequence to be detected. Without a complete genome
assembly it is not trivial to attribute the absence of a particular virulence gene
to any one of those scenarios. This is a significant vulnerability in declaring any
of the isolates in this study uropathogens, or otherwise.
The genetic flexibility of E. coli further complicates the prediction of pathogenic
potential and the hypothesis proposed; that because the susceptible isolates had
not been exposed to antibiotic chemotherapy they therefore may have a greater
pathogenic potential due to a difference in genetic background. SeqFinder (fig.
3.7) and VirFinder (fig. 3.5) virulence typing do suggest that susceptible isolates
carry a somewhat higher burden of virulence markers; which would certainly aid
in the colonization of the urinary tract. However, some of the key UPEC vir-
ulence genes are absent from susceptible and MDR isolates. Given the highly
plastic nature of the E. coli genome, a large degree of variability is reasonably
expected. Much of the published literature characterizing and exploring the E.
coli genome has relied on the limited collection of E. coli isolates that have been
sequenced to date. Efforts to characterize new strains of E. coli have focused
predominantly on strains of clinical and academic focus; and there is undoubt-
edly a much greater diversity amongst wild-type E. coli isolates than has been
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described to date (Touchon et al., 2009).
There are many definable pathotypes of E. coli, characterizable by: their clini-
cal presentation, genetic relatedness to other pathogenic strains and possession of
canonical virulence makers. ExPEC, and more specifically UPEC, remain difficult
to adequately define. Moreover, pathogenic E. coli and their virulence markers,
often defined by their absence from healthy gastro-intestinal flora; may actually
make up a sizable component of healthy flora. The focus on disease causing
strains of E. coli may overemphasize the contribution of certain virulence mark-
ers and limit their usefulness as true predictors of pathogenicity (Dobrindt, 2005,
Dobrindt and Hacker, 2008).
Ultimately, because of the small number of isolates and the incomplete nature
of the sequence assembly presented here, the SeqFinder and VirFinder results
merely expand the descriptive data available for the susceptible and MDR isolates.
It is unlikely that the NGS data is predictive of uropathogenic potential.
3.4.2 Core and Pan Genomic Analysis
Attempts to classify diversity amongst pathogenic E. coli have traditionally only
focused on a very small component of the wider genomic diversity. Pathotypic
typing schemes have focused predominantly on virulence makers as a surrogate
measure of the pathological differences exhibited by discrete sub-lineages of E.
coli. Much of the generated diversity amongst pathogenic E. coli is conferred
via horizontal acquisition of these virulence markers into favorable genetic back-
grounds; via plasmids, genomic islands, transposons or bacteriophages (Chen,
2003, Groisman and Ochman, 1996, Hochhut et al., 2006, Kaper et al., 2004).
Estimation of pathotypic tendency using core-genome sequencing doesn’t seem
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to be capable of indicating the virulence or pathogenic background of a given E.
coli isolate (fig. 3.5). Work done to detail genomic comparisons between CFT073
(pyelonephritis causing strain), ABU83972 (asymptomatic bacteriurea strain) and
Nissle 1917 (a gut commensal with probiotic potential) revealed a startling ge-
nomic similarity; with all three strains grossly varying in their infectious phe-
notype. Despite both ABU83972 and Nissle 1917 posessing the majority of the
virulence markers present in the CFT073 genome (including toxins and adhesive
fimbriae), both ABU83972 and Nissle 1917 are completely asymptomatic (Do-
brindt et al., 2010). Even with accurate and detailed annotation and phylogeny,
detailed modeling of in vivo expression of virulence highlights the inability viru-
lence markers alone to be completely predictive pathogenicity (Leimbach et al.,
2013, Vejborg et al., 2010).
This is certainly not an observation that is confined to UPEC. Much of the
pathotypic characterizations require the assumption that typable strains are ob-
ligate, and not facultative pathogens; and such a scheme does not adequately
encompass the spectrum of niche distribution that E. coli is capable of. There-
fore, commensal or pathogenic specialism is not just a divergent genotypic trait,
but also a convergent one (Vejborg et al., 2010, Leimbach et al., 2013). In all
likelihood any classification system capable of predicting the pathogenic potential
would need to encompass a much richer list of genetic markers than any of the
current schemes. Even typing schemes with expanded panels of markers have
been able to identify greater heterogeneity, beyond commensal and pathogenic
behavior.
Along with the paucity of available commensal E. coli and the lack of a clear
definition of what an E. coli commensal is; these bias any pathogenic prediction
from sequence information towards an overly narrow definition of pathogenic E.
coli. Especially as there is a prevalence of many virulence factors from across
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the different pathotypes, in commensal isolates (Touchon et al., 2009). There
may be no such thing as an obligate commensal; particularly in conjunction with
antimicrobial chemotherapy, where persistence and growth in an environment can
be considered virulence in their own right (Blango and Mulvey, 2010, Escobar-
Páramo et al., 2004, Leimbach et al., 2013, Narciso et al., 2012).
Ultimately the sequence assembly data generated here is not sufficient for such
detailed comparisons between the susceptible and MDR isolates; there is simply
is not enough data. Moreover, no effort was made to isolate commensal E. coli
isolates (i.e. faecal) from healthy dogs, which would have greatly strengthened
the comparisons between susceptible and MDR isolates.
Furthermore, the degree of recombination and sequence disparity identified by
ClonalFrameML (fig. 3.14) limits the confidence with which conclusions of genetic
relatedness can be drawn. While both the mapping of sequence contigs (fig.
3.5, fig. 3.6) and ClonalFrameML analysis indicate good coverage across both
a reference genome (MG1655) and amongst the MDR and susceptible isolates
(fig. 3.14), it is very likely that some of the sequence diversity used to calculate
phylogenetic relationships has been influenced by ambiguous base calls made
during assembly. Though it is still likely these isolates are not closely related
(MLST and maximum-likelihood analysis are in agreement), it would be desirable
to re-sequence these isolates to gain more confidence in the results presented here.
3.4.3 Galleria mellonella Infection Model
The Galleria mellonella larvae infection model has been used to compare gen-
eral virulence of pathogenic E. coli (Alghoribi et al., 2014), as well as detailed
comparisons of host immune responses to virulent and attenuated strains of E.
coli. The work published by Alghoribi et al. (2014), looked at a group of 71
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uncharacterized UPEC strains of mixed genetic background. By correlating phe-
notypic virulence against detected virulence genes they observed greater killing
with increased virulence gene presence. Though they did not detect significant
difference between strains of different phylogroups.
That even the more overtly virulent markers, such as the cytotoxins do not
necessarily correlate to increased virulence in the moth infection model presented
here, could be a product of the expressed phenotype of the E. coli isolate, or an
aberration of the model. Whilst there may be a slight overall trend of increased
detected virulence markers in the susceptible isolates, this does not translate into
increased virulence in the Galleria mellonella infection model (fig. 3.5).
Moreover, the heterogeneity of canine host status prior to, and throughout
the course of infection, cannot be accounted for with the isolates. It is assumed
that the MDR group isolates will have been isolated from hosts with decreased
susceptibility to UPEC infection in comparison to the susceptible group. But
this has not been quantified in any way; any of the MDR or susceptible infections
could have been asymptomatic or more virulent but this data was not available.
As has been stated previously, the canine patients from which the MDR iso-
lates were obtained from received a significant level of clinical intervention. It is
assumed that these hosts are likely to have had increased susceptibility towards
infection given their general health state. Though this does not seem to have had




The designation of any E. coli isolate as pathogenic or commensal is greatly com-
plicated by the evolutionary selective pressures exerted by antimicrobial chemother-
apy. There is not enough data to conclusively say whether the combined cost of
acquired virulence and acquired AMR are mutually exclusive phenotypes for the
isolates sequenced in this study. Even though, in terms of a reduced virulence
genotype (VirFinder, SeqFinder) do point to a separate background for the MDR
and susceptible isolates; the variability in the phylogenetic reconstructions (Re-
alphy, Clonalframe) and Galleria mellonella infection model make any assertion
difficult.
Work published by others has speculated that the increased metabolic cost of
expanded virulence and resistance, without concerted adaptation towards a more
metabolically efficient genotype was presumed is too costly to be optimal for any
given bacterial isolate. However, this view has shifted somewhat as the mecha-
nisms by which AMR can be inherited have come to be better defined (Mart́ınez
and Baquero, 2002). Recently, focus has shifted towards host microbial flora.
Indeed some of the most notorious MDR bacteria, such as community-associated
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Ente-
rococcus (VRE) are derived from the gut flora.
Phylogenetic evaluation of resistance acquisition in E. coli suggests that phy-
logroup A isolates are more closely linked to the acquisition of horizontally trans-
ferable resistance (Tenaillon et al., 2010). This a trend that has been readily
identified in a number of clinical reports of veterinary MDR (Gibson et al., 2010,
2011).
Despite the various assertions that MDR favors more commensal type E. coli,
there are also reports of MDR associated with more pathogenic E. coli. This in-
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cludes 025b:H4-ST131, belonging to phylogroup B2, which has a well documented







The work outlined in this chapter seeks to investigate the genetic basis of plas-
mid mediated multi-drug resistant (MDR) and extended-spectrum β-lactamase
(ESBL) or extended-spectrum AmpC (ESAC) carriage; using single-molecule
real-time sequencing (SMRT) sequencing with MDR ESBL resistant and fully
susceptible community-associated E. coli. This works builds upon the correlation
between blaCMY-2 resistance and IncI1 plasmid incompatibility types identified in
the previous chapters and in (Wagner et al., 2014).
MDR is an increasingly prevalent, global phenomenon. MDR Enterobacteri-
aceae producing ESBL infections pose a particular challenge. Such infections are
often resistant to first and second line β-lactams, as well as third-line extended-
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spectrum cephalosporins. The prevalence of ESBL resistance is increasing in
both nosocomial and community-acquired infections (Giske et al., 2008, Paterson,
2006). ESBL infections increase both patient morbidity and mortality. Success-
ful treatments against such infections increasingly rely on last-line carbapenem
treatments (Livermore et al., 2011).
E. coli is an important member of the microbial flora as a commensal, but
also causes a number of intestinal and extra-intestinal infections (Kaper et al.,
2004). Clinically, ESBL resistant E. coli is seen in both emerging epidemics, as
seen globally with E. coli ST131 (Petty et al., 2014), as well as antibiotic usage
selecting for endemic, opportunistic infections associated with the commensal
flora (Alekshun and Levy, 2006).
The mobilisation of ESBL resistance to horizotal genetic elements (HGEs),
such as plasmids and transposable elements, has greatly affected the dissemina-
tion of ESBL’s and MDR (Pitout, 2012). Plasmids and transposable elements
have a diverse bacterial host range, conferring resistance markers between bac-
terial species; generating a large potential resistance reservoir allowing anthro-
ponotic and zoonotic transfer (Guardabassi et al., 2004).
As sequencing technologies have developed, an increasing number of resistant
E. coli strains have been sequenced and analyzed. To date, much of the sequence
reconstruction has relied upon read mapping and short-read de novo assembly.
In reality, both methods are unlikely to resolve HGEs successfully without prior
isolation and subsequent re-sequencing. As a consequence, the availability of high
quality sequence data relating to horizontally acquired resistance remains poor.
Given the close contact of companion animals to other animals and humans, a




MDR isolates 127, 1223, 1283, 1428, 144, 317, 746 and 1943 (all positive for
ESAC (blaCMY-2) and the IncI1/IncFII replicon type) and a susceptible isolates
1190 and 1105 (also positive for the IncI1 replicon type) were selected fro SMRT
sequencing; performed using the PacBio platform.
Briefly, E. coli were inoculated into 10 ml of lysogeny broth (LB) and incu-
bated overnight at 37°C, 170 rpm. Extracted DNA was prepared for PacBio se-
quencing using AMPure®Beads (AMPB), with a target insert size range of 10kb
or greater. DNA was sheared using a Covaris®g-TUBE®. Sheared DNA was
purified and concentrated using AMPBs. Samples were eluted form the AMPBs
using PacBio Elution Buffer, and single stranded fragments were removed with
ExoVII restriction enzyme. DNA was repaired using the PacBio DNA Damage
and Repair Ends buffers, as per the PacBio protocol.
Processed DNA was further purified using AMPBs; then blunt end sequence
adapters were ligated, and ExoIII and ExoVII restrictions enzymes were used
to removed failed ligation products. Successfully ligated sequences fragments
were then concentrated by three successive AMPB purification steps. Final DNA
concentration for all of the samples exceeded 5µg.
DNA was sequenced on the PacBio RSII sequencing platform.
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4.2.2 Plasmid Sequence Comparison
SMRT analysis was used to generate a fastq file from the PacBio reads and error-
corrected reads were adjusted using PCcR, with self-correction (Koren et al.,
2013). The longest 20x coverage reads were assembled with Celera Assembler 8.1
and polished using Quiver (Chin et al., 2013).
Annotated genomes (Do-It-Yourself-Annotator (DIYA) (Stewart et al., 2009))
were imported into Geneious (Biomatters LTD., Auckland, New Zealand) (Kearse
et al., 2012) and duplicated sequences removed from the 5’ and 3’ ends to generate
the circularized chromosomes and plasmids.
The origin of replication was approximated using Ori-Finder (Luo et al., 2014)
and the chromosome reoriented; using as base 1.
4.2.3 Plasmid Sequence Comparison
Broad sequence comparisons between the SMRT sequenced plasmids were per-
formed using CCTViewer (Grant et al., 2012), and progressiveMauve (Darling
et al., 2010). CCTViewer was used to visualize both sequence and coding do-
main sequence BLAST, using isolate 1428 plasmid sequence p96 as a reference
sequence for the IncI1 plasmid comparisons, and isolate 144 plasmid sequence
p134 as the reference sequences fro the IncF plasmid comparisons. Progressive-
Mauve alignment of genbank sequences was performed with default parameters.
Plasmid multi-locus sequence-typing (MLST) was performed using the plasmid
MLST website (https://pubmlst.org/plasmid/) and sited at the University of
Oxford (Jolley and Maiden, 2010). Resistance genes and virulence genes were
identified using ResFinder (Zankari et al., 2012) and BLAST Koala (Kanehisa
et al., 2016).
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4.2.4 Plasmid Core and Pan Genomes
Core sequence homology between the plasmid sequences was detected with get homologues
(Contreras-Moreira and Vinuesa, 2013). Homologous clusters of coding domain
sequences were detected using bi-directional best-hits (BDBHs), clusters of orthol-
ogous groups (COGs), and orthoMCL algorithms; through the get homologues
script.
Clusters were aligned by amino acid sequence with Muscle aligner. Amino
acid alignments were then translated back into nucleotide sequences using the
pal2nal script (Suyama et al., 2006). Fasta file headers were modified to provide
unique sequence identification for each of the individual sequences, using an in
house script.
The homologous clusters were then concatenated to provide an aligned se-
quence in fasta format. The Galaxy Web Server fasta width formatting, set to
width 0, was used to format the fasta file before converting sequence formats. The
catafasta2phyml.pl script (https://github.com/nylander/catfasta2phml) was
used to generate a phyml format input for RaXML phylogenetic estimation.
RaXML (Stamatakis, 2014) was used to reconstruct a phylogenetic estimation
(with a GTRGAMMA model, with 100 bootstrap replicates).
The get homologues clusters were also used for the pan genome analysis.
The PARS program from the PHYLIP package was used to perform maximum-
parsimony analysis.
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4.2.5 Conjugation Recipient Strains
Spontaneous rifampicin resistant MG1655 E. coli mutants were generated as
marked recipient strains for plasmid conjugation experiments. MG1655 mutants
were isolated from overnight cultures on LB agar plates containing 100µg/ml ri-
fampicin at 37°C. A single resistant colony was re-streaked onto rifampicin plates
and re-cultured overnight at 37°C, to ensure purity of culture. The mutants
were then compared to wild-type strains grown on LB agar in the absence of the
antibiotic to ensure comparable strain fitness.
4.2.6 Plasmid Conjugation
Donor and recipient strains were inoculated into 10ml of LB and incubated
overnight at 37°C, 170rpm. 500µL of donor and recipient cultures were inoculated
into 5ml of 10mM MgSO4. Cultures were then filtered (Millipore, HAWP02500)
and the filter paper placed onto an LB agar plate and incubated overnight at
37°C. The filter paper was then vortexed in 550µL of LB, and serial dilutions
(10, 100, and 1000 fold) dilutions made of the bacterial suspension. 100µL of the
100 and 1000 fold dilutions was plated, in triplicate, onto LB agar and incubated
overnight.
Candidate colonies were then streaked onto LB plates (100µg/ml rifampicin/100µg/ml
ampicillin) and incubated overnight at 37°C. Colonies resistant to rifampicin and
ampicillin were then incubated in 10ml of 100µg/ml rifampicin, 100µg/ml ampi-
cillin LB at 37°C, 170 rpm for glycerol stocks and storage at −70°C storage.
Conjugants were also screened using antibiotic sensitivity testing, replicon typ-
ing PCR (Carattoli et al., 2005a) and phylotyping PCR (Doumith et al., 2012b).
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4.2.7 Antibiotic Sensitivity Testing
Kirby-Bauer disk diffusion was used to detect phenotypic antimicrobial resistance
for both conjugant and wild-type strains. Briefly, E. coli strains were incubated
in nutrient broth (Oxoid) at 37°C, and then diluted to a MacFarland standard in
sterile saline solution. This was then plated on to Mueller-Hinton agar (Oxoid),
and incubated overnight at 37°C. Antibiotics used were: amoxicillin-clavulanic
acid 30µg (Oxoid CT0223B), cephalexin 30µg (Oxoid CT0007B), ciprofloxacin
5µg (Oxoid CT0425B), gentamicin 10µg (Oxoid CT0024B), doxycycline 30µg
(Oxoid CT0018B) and tetracycline 30µg (Oxoid CT0054B).
4.3 Results
The aim of the work in this chapter is to understand the genetic context of
antibiotic resistant alleles in the collection of MDR E. coli clinical isolates; defined
by ESAC blaCMY-2. Previous work had correlated this resistance with carriage of
an incI1-FII replicon type plasmid.
4.3.1 Sequencing and Plasmid Carriage
In order to try and obtain plasmid sequences, the Illumina sequence data was
filtered against reference E. coli sequences to remove chromosomal sequence (as-
sembled de novo) and resulting contigs compared against published plasmid se-
quences using BLAST. However, this was largely unsuccessful as was direct de
novo assembly of unfiltered sequence reads. To resolve this, a subset of MDR
isolates, focusing on the IncI1-FII were selected for sequencing by SMRT. These
included 8 MDR isolates and 2 susceptible isolates.
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SMRT sequencing of the MDR isolates revealed multiple extra-chromosomal
contigs per isolate, with good agreement in relation to the initial replicon typing
PCR; total detected plasmid carriage per isolate is depicted in (fig. 4.1). Se-
quencing revealed the complex and multi-replicon capacity of the majority of the




















































Figure 4.1: Schematic representation of the plasmid carriage of the E. coli isolates in this study. Boxes represent each isolate;
and referred to by their isolate ID. Depicted sequences are not to scale. Plasmid sequences are identified and distinguished by
their sequence length. Plasmid encoded resistance, where detected by BLAST search, is indicated by color coding on the plasmids.
Plasmid incompatibility type, where typable, is indicated (IncF or IncI1). Chromosomal sequences are not depicted.
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While 7/8 MDR strains had the anticipated replicons, isolate 317 only con-
tained an InCF plasmid according to the SMRT sequencing, despite both PCR
and Illumina sequence data indicating the presence of IncF and IncI1 replicons.
One of the susceptible isolates, 1105, was PCR positive fro the incI1 geno-
type, but neither Illumina or SMRT sequence data detected nucleotide sequences
associated with the replicon type.
MDR isolate 746 contained an IncI1 contig, but potentially two IncF contigs.
While this should not be possible, both sequences show marked similarity, despite
discrepancies with their size (10kb difference).
SMRT sequencing also detected numerous extra-chromosomal contigs with no
discernible replicon type. Some of these sequences carry resistance markers, and
are of clinical relevance. These sequences would not have been detectable without
SMRT sequencing.
In the MDR isolates, the IncI1 plasmid associated exclusively with the blaCMY-2
ESAC resistance gene. The resistance maker is associated with an insertional
element (IS91) and contains the backbone of a resistance cassette (blaCMY-2-blc-
sugE ) that is associated with the dissemination of resistance in E. coli (Fang
et al., 2015) and Salmonella enterica (Fricke et al., 2009).
Plasmid sequence sizes ranged from 85-96kb, with between 106-113 coding
domain sequences; many of which have no homology with proteins of identified
function and therefore designated hypothetical proteins (table 4.1).
All but two of the IncI1 plasmids belong to the same MLST clonal complex
(CC-2), determined in silico, based on the presence and sequence similarity of
repI1, ardA, trbA, sogS and pilL genes to previously published IncI1 pMLST pro-
files. Remarkably, despite their considerable size and number of coding regions,
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it is not possible to discern from the nucleotide sequence any further functional
contribution of the plasmids to the host strain beyond the blaCMY-2 resistance
gene cassette.
The IncF plasmids were much more heterogeneous in size (100-147kb), num-
ber of coding regions (105-150) and the number and classifications of various
resistance markers (table. 4.1). Aminoglycoside, chloramphenicol, potentiated-
sulfonamide and β-lactamase (not AmpC or ESAC associated) resistance markers















127 p95 105 IncI1:ST2
(CC 2)
CMY-2 -
127 p91 100 nt - -




127 p39 48 nt - fimD, hha,
virD, virB
1223 p147 150 FII:18 - iss, iroN,
mchF
1223 p87 97 IncI1:ST23
(CC 2)
CMY-2 dot
1283 p109 128 IncF:36/31 tet(A) TC.FEV.OM3,
sit
1283 p92 101 IncI1:ST2
(CC 2)
CMY-2 dot
1283 p31 41 nt - hha, virD,
virB




1283 p3 3 nt - -





1428 p96 113 IncI1:ST43
(CC -)
CMY-2 dot
1428 p66 108 FII:4 tet(B) -
1428 p48 65 nt - -







144 p92 105 IncI1:ST2
(CC 2)
CMY-2 -
317 p100 105 FII:43 - ABC.LPT.P,
TC.OOP,
raxB
746 p95 106 IncI1:ST2
(CC 2)
CMY-2 dot
746 p72 116 FII:52 ** - -
746 p62 102 FII:2 ** - -
1943 p85 90 IncI1:ST55
(CC -)
CMY-2 dot
1943 p80 86 FIB:1 - sit, iuc




Basic descriptive information on plasmid sequences derived from this study. nt =
not typable, CC = clonal complex, - = none detected, ** = probable split contig
Despite the greater number of resistance markers shared amongst the plasmids,
four of the plasmids contained no detectable resistance markers. Virulence genes,
mostly associated with iron uptake and metabolism, were detected on many of the
IncF plasmids. This suggests a possible metabolic contribution towards bacterial
host function.
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By predicted in silico replicon typing, the IncF plasmids are of mixed lineage.
127 p123, 1223 p147, 1283 p109, 1428 p111 and 144 p134 all possess IncFII
and IncFIB replicon type sequences. The remaining strains containing replicon
type sequences were: 317 p100, 1428 p66, 746 p62 and 746 p72, which were all
exclusively IncFII; 1953 p80 was of the IncFIA replicon type.
4.3.2 IncI1 Comparative Analysis
Sequence comparisons of the strains indicates a strong underlying genetic rela-
tionship between the IncI1 plasmids. Nucleotide and coding domain sequence
BLAST comparisons show greater than 90% sequence similarity for the bulk of
the sequences. Multiple co-linear blocks, with high synteny and sequence simi-
larity and large-scale rearrangements were identified using progressiveMauve (fig.
4.2).
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Figure 4.2: Core sequence alignment of IncI1 replicon type plasmid sequences, using 1428 p96 as the index sequence. Comparisons
were performed using BLAST Atlas searches using the CCT comparison tool. Both the whole nucleotide sequence (smaller ring)
and coding domain specific (larger ring) BLAST comparisons were carried out. ProgressiveMauve was also used to compare the
plasmids. Local co-linear blocks, detected by progressiveMauve have been annotated onto the BLAST comparisons
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The IncI1 plasmids were compared against 42 plasmid sequences obtained
through GenBank, which were identified by BLAST as being similar to the plas-
mids sequenced in this study. Pan-genomic analysis detected 305 homologous
gene clusters across all sequences. Wagner parsimony phylogenetic estimations of
a binary matrix of homologous cluster presence or absence indicates a close phy-
logenetic relationship between all of the IncI1 plasmids sequenced in this study;
and places the IncI1 plasmid from the susceptible isolate 1190 ancestrally to the
MDR isolate plasmids.
Pan-genomic analysis showed a region of conservation amongst the MDR, sus-
ceptible and GenBank plasmid sequences. Ten homologous gene clusters: traL,
M, nikB, traO, traJ, traF, traE, traT and traX ; all relating to plasmid transfer

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.3: Maximum-parsimony analysis using detected presence or absence of h m l g us g e cl ste s f m the an genome of
PacBio IncI1 replicon sequences and comparator IncI1 sequences obtained from t NCBI nucl o id dat bas . Plasmid sequences
from this study lie with the red box. Conserved genes (used for maximum-likelihoo analysis) are hig lighted in the blue box.
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These sequences were extracted from the pan-genomic analysis and aligned, for
maximum-likelihood core genome phylogenetic analysis (fig. 4.4). The analysis
of these core genes also indicates close phylogenetic relationships between the
majority of the IncI1 plasmids; with moderate bootstrap support for the majority
of the identified clades. Unlike the maximum parsimony tree, the plasmids from
1943 and 1428 are no longer monophyletic to the remaining canine IncI1 plasmids.
There is considerable genetic distance between susceptible isolate 1190’s plasmid
and the MDR group plasmids. Despite only moderate bootstrap support overall,
the phylogenetic tree is congruent with the predicted in silico MLST groups;
though 1190 and KJ484640 could not be typed by in silico IncI1 MLST (fig.
4.4).
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Figure 4.4: Alignment and maximum-likelihood phylogenetic analysis of core IncI1 plasmid sequences. IncI1 replicon PacBio
sequences were used to identify other putative IncI1 plasmids from the NCBI nucleotide database. The sequences have been
annotated with predicted plasmid multi-locus sequence types (clonal groups). The bacterial and animal hosts, from which the
plasmid sequences were extracted, have also been annotated where available from submitted sequence metadata. Isolates from this
study are identified by black squares.
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Clades show multiple bacterial and mammalian hosts for the IncI1 sequences.
IncI1 plasmids are notable for their extensive host-range within the Enterobacte-
riaceae. However, human-associated sequences are largely absent from the tree;
suggesting limited zoonotic potential for the plasmids.
The majority of the canine sequences form a monophyletic clade, with chicken
and porcine associated plasmid sequences being the closest ancestrally. Of note,
CP009566 and KF434766 are two reference IncI1 plasmids are both associated
with canine E. coli infections; the first isolated in the USA (Bortolaia et al., 2014)
and the second in Scandinavia(Bogaerts et al., 2015). These are clonally related to
the plasmids sequenced in this study despite their isolation being geographically
and temporally distinct. While CP009566 was isolated from and E. coli isolate in
Arizona, KF434766 was isolated from a Salmonella Newport strain in Denmark.
Despite the mulitplicity of E. coli sequences which dominate the tree, multiple
bacterial hosts are present within each clade on the tree. This suggest that
intra-species transmission of the IncI1 plasmids present on the tree is a common
occurrence; which has been previously reported for the IncI1 plasmids (Carattoli,
2011).
Where the information was available, the animal host of origin has also been
annotated on the tree with the noted comparative absence of human hosts despite
the heavy bias of human isolate plasmid sequences available on the GenBank
database.
4.3.3 IncF Comparative Analysis
In comparison to the IncI1 plasmids, much less sequence similarity was detected
by BLAST coding domain sequence, nucleotide alignments, or by progressive-
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Mauve sequence comparisons. The single region conserved amongst these plas-
mids is related to plasmid replication machinery. The remaining regions of local-
colinearity have little synteny, or support across all the plasmid sequences (fig.
4.5).
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Figure 4.5: Core sequence alignment of IncF replicon type plasmid sequences, using 1428 p96 as the index sequence. Comparisons
were performed using BLAST Atlas searches using the CCT comparison tool. Both the whole nucleotide sequence (smaller ring)
and coding domain specific (larger ring) BLAST comparisons were carried out. ProgressiveMauve was also used to compare the
plasmids. Local co-linear blocks, detected by progressiveMauve have been annotated onto the BLAST comparisons
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GenBank BLAST searches identified 9 sequences similar to the IncFII/IncFIB
plasmids. Pan-genomic maximum-parsimony analysis of both reference and Inc-
FII/IncFIB plasmids indicates a mixed phylogeny (fig. 4.6). Many of the plasmids
are individually monophyletic, with few clades describing more than a couple of
plasmid sequences. Most of the plasmids show a mixed predicted replicon type,
with FII/FIA the most commonly identified. All of the reference sequences used




   
   
   
   
  
   
   
  
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Figure 4.6: Top: Maximum-parsimony analysis of pan-genomic homologous gene clusters for IncFII replion sequences. Similar NCBI
nucleotide sequences, with detectably diverse replicon types were included. Isolates sequenced in this study are indicated by the
red boxes. Bottom: Maximum-likelihood analysis of aligned core homologous sequences. Sequences have been annotated with their
detected replicon type.
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A singular clade of plasmids, exclusively IncFII, show greater sequence homol-
ogy than the remaining plasmid sequences. Despite the closeness of these plas-
mid sequences to one another, they cannot be compared by maximum-likelihood
analysis. 1428 p66, 746 p62, 746 p72 and 1943 p80 could not be included as
no homologous clusters, between all of the plasmid sequences, could be detected
when they were included in the analysis. All other IncF type plasmid sequences
were used to generate a core genome of 8 homologous gene clusters.
Like the IncI1 plasmid comparisons, these genes were mostly associated with
plasmid maintenance and replication: traA, traL, traE, traB, traX and X-polypeptide.
Maximum likelihood phylogenetic analysis of the IncFII, IncFIA and IncFIB repli-
con types show a dispersal of all sequences of different replicon types throughout
the tree (fig. 4.6). None of the PCR typed IncFII plasmids sequenced in this
study are members of the same clade; moreover, 317 p100 is a significant outlier
from the rest of the IncF-type plasmid sequences.
Given that the E. coli isolates included in the work presented in this thesis
were chosen based their extended-spectrum β-lactamase (ESAC) phenotype (as-
sociated only with IncI1 plasmids); a lack of distinct genetic relatedness amongst
the IncF-type plasmids is not surprising.
746 p62 and 746 p72 are somewhat baffling. Plasmids incompatibility should
dictate that no two plasmids of the same type should exist in the same isolate.
Pan-genomic analysis indicates mostly similar gene content between, which does
not necessarily indicate mis-assembly (i.e. that the contigs are both part of a
larger contiguous sequence). Similarly, 1428 p111 and 1428 p66 share a predicted
IncFII replicon type.
There are multiple potential explanations for the contigs both being present
in the same isolate. Firstly, their may be two plasmids within the same bacterial
137
population that are split between bacterial hosts. Secondly, it is possible that the
10 kb difference in sequence length represents an insertion sequence that cannot be
sequenced across using the SMRT sequencing protocols used here. Finally, these
sequences could represent the mis-annotation of the plasmid replicon sequences.
4.3.4 Other Plasmids
Numerous other extra-chromosomal contigs were detected by PacBio sequencing.
IncI1, IncFII, IncFIA and IncFIB replicon types only account for a fraction of the
plasmid sequences. The nature of SMRT sequencing and analysis make it unlikely
that these sequences are part of the main chromosome, or the plasmids with well
defined replicon-types. Whilst many of these sequences do not contain identifiable
resistance markers, some do. Many of these sequences do not have established
replication and transfer machinery encoded onto them, so their transfer capacity
is unknown; but may represent small replicons that can be co-inherited with other
transfered plasmids or possibly other methods.
Though these plasmid sequences contain few coding regions, the majority of
which are of unknown function (hypothetical), it was not assessed as to whether
any of these regions may play a role in the inheritance of the plasmids. Such other
methods of transfer include: partition systems that contribute towards replica-
tion, incompatibility and long-term stability (and may be encoded for on the
chromosome), genetic addiction and post-segregational killing of daughter cells
which do not contain a plasmid (though no toxin/anti-toxin systems were an-
notated), DNA site-specific resolution systems which involve chromosomal genes
encoded in all E. coli (such as OriC ) and the increased likelihood of transmission
based on plasmid copy number (not assessed in this work), and even the native
advantage that smaller DNA molecules associate more closely together (super-
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coiling) which increases the likelihood of replication events during normal cellular
function (Barbara and Gregory, 2004).
4.3.5 Plasmid Conjugation
Successful conjugation of the IncI1 plasmids was achieved from wild-type strains
to E. coli MG1655. Conjugants were confirmed using PCR and Kirby-Bauer disk
diffusion to type donor and recipient strains. Phenotypic resistance to amoxicillin-
clavulanic acid, cephalexin and extended-spectrum cephalosporin resistance was
conferred to conjugants in line with transfer of the IncI1 plasmids containing the
CMY-2 resistance gene.
4.4 Discussion
It is critical to understand the genetic context and reservoirs of antimicrobial
resistance genes in order to stem the selection of MDR bacteria. In this study
both Illumina and SMRT sequencing, of a defined set of clinical isolates, was
applied to investigate resistance gene alleles and their context in the reservoir
organism.
Illumina data from both MDR and susceptible E. coli strains allowed their
phylogenies to be determined and enabled sub-selection of strains for SMRT se-
quencing (8 MDR and 2 susceptible) and this revealed the extensive repertoire
of plasmids that can be present within individual isolates; with a subset shown
to contribute to the resistance phenotypes.
A focus of this study was the ESAC resistance; encoded predominantly by
blaCMY-2 in this set of strains; though interestingly isolate 127 contained a plas-
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mid, p43, encoding blaTEM-33 which also confers ESAC resistance (Bush and Ja-
coby, 2010). CMY-2 was shown to be encoded on IncI1 replicon plasmids and
these formed a closely related phylogenetic cluster despite the strains having
been collected over a 10 year period. The association of IncI1 plasmids with
extended-spectrum β-lactamase resistance has been documented in members of
the Enterobacteriaceae; but it is more unusual for them to be associated with
blaCMY-2 (ESAC) resistance (Bortolaia et al., 2011, Diestra et al., 2009, Folster
et al., 2010, Hradecka et al., 2008, Leverstein-van Hall et al., 2011, Liu et al., 2007,
Marcade et al., 2008, Su et al., 2008, Tato et al., 2007). The strains possessed
an blaCMY-2 harboring IncI1 plasmid in combination with many other plasmids
contributing to an MDR genotype; in particular IncF replicons that harbored
multiple resistances.
As indicated from our preliminary studies, the majority of the MDR strains
containing these plasmid combinations (IncI1/IncF) are associated with com-
mensal phylogroups. The IncI1 plasmids indicate a level of endemism within the
commensal population of the urinary tract infections (UTI) isolates. There is cur-
rently little information in the published literature describing the prevalence of
plasmid incompatibility groups present in nosocomial, or community-associated
canine populations. Interestingly, in this study, extended-spectrum β-lactam re-
sistance has not been detected in a bacterial isolate that is not also MDR. This
would suggest that the acquisition of other resistance alleles, in particular on IncF
type plasmids, concertedly to the acquisition of the IncI1 ESAC plasmids.
The MDR stains in this study often associated with animals that have had
a complex treatment history; and all they strains were isolated after they had
successfully invaded the urinary tract. It is interesting to note that the IncF
plasmids carry a much higher proportion of the resistance alleles and putative
virulence-associated genes. It is therefore interesting to speculate that the acqui-
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sition of these plasmids, in part due to antibiotic use, then drive the emergence
of strains that may be more virulent.
The E. coli isolates do represent a model of the genetic and phenotypic re-
sponses of E. coli to the current clinical practices in modern care. A combination
of prophylactic use of antibiotics, for surgical or other treatments, combined with
patient vulnerability has provided an environment for the selection of at least
two plasmid replicon groups; with numerous other horizontally-transferable DNA
molecules also under selection.
In contrast to this study, previous comparisons of IncI1 resistance plasmids
isolated from enterotoxigenic E. coli (ETEC) showed greater sequence diversity,
rather than sequence conservation (Johnson et al., 2011). The majority of the
MDR isolate IncI1 plasmids sequenced in this study share a closest common
ancestor. This may be due to: i) limited sequence divergence or ii) sequence
convergence. Given the genetic distance between the susceptible IncI plasmids,
the absence of any dominant E. coli clone associated with the IncI1 plasmids, the
lack of any indication of potential bacterial host range of the plasmids (other than
E. coli) and the discordance of sequence similarity with the chronological sequence
of the E. coli isolates; it becomes very difficult to approximate either scenario with
the work presented here. The reliability of any estimation of rates of divergence
between different plasmids is questionable; though the identification of a similar
plasmid backbone in Denmark and the USA (Bogaerts et al. (2015); (Bortolaia
et al., 2011)) does suggest an underlying core plasmid sequence stability capable
of maintaining the blaCMY-2 resistance cassette.
Fecal carriage of β-lactamase resistance markers in healthy canines has been
reported in relatively high abundance (Baede et al., 2015, Okubo et al., 2014,
Rocha-Gracia et al., 2015); and IncI1 plasmids sharing the pMLST clonal type
have also been detected in healthy canines (Haenni et al., 2014). The genetic
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similarity, despite geographic dispersion of the canine specific IncI1 clade, is highly
suggestive of stable persistence of horizontally-transferable extended-spectrum
β-lactam resistance in community associated canine E. coli strains; with global
circulation.
In comparison with the IncI1 plasmids, the IncF plasmids are much more dis-
parate in both core and pan-genomic sequence content. This may, in part, be
a consequence of experimental design. The isolates for this study were collected
based on their status as being MDR including an ESAC phenotype; the ESAC
resistance is not encoded by the IncF plasmids. This may over emphasize the
relationship between circulating IncI1 plasmids and underestimate the degree of
relationship between circulating IncF plasmids. However, fewer sequences could
be identified in the NCBI database sharing nucleotide similarity and very few
of the resistance markers appear to be conserved between one IncF plasmid and
another. This may be an indication that vertical inheritance may be a more
important means of plasmid transfer for this group of plasmids. It is difficult to
consider a strong hypothesis as to whether sequences reflect progressive diver-
gence, or weak convergence. They are at least much more capable of undergoing
extensive genetic rearrangement.
Detailed sequence comparisons and descriptions for plasmids harboring clini-
cally relevant antimicrobial resistance (AMR) are currently rare. Despite detailed
knowledge of the mechanisms of replication, inheritance and transfer; much has
been extrapolated from small-scale studies (Barbara and Gregory, 2004). Suc-
cessful infection control practices rely on appropriate and targeted surveillance
measures. Whilst PCR and short-read sequencing have provided a means for es-
timating the underlying contribution of plasmids to AMR; their impact has been
limited.
Much of the resistance phenotype of the bacterial isolates sequenced here can
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be attributed to the multiplicity of the resistance markers found on the plasmids.
The dispersion of resistance genes across different plasmids, in many of the iso-
lates, suggests sequential acquisition by the bacterial isolates; it is unlikely that
the transfer of multiple plasmids would occur as a singular event. It is likely
that these MDR strains have emerged in the flora of the gastrointestinal tract
during treatments; and this also helps explain the genetic diversity of the isolates
backgrounds. Commensal strains have been implicated in other studies as being
a significant component of the AMR reservoir (Alekshun and Levy, 2006, Bailey
et al., 2010, Marshall et al., 2009).
As sequencing techniques have developed it has become apparent that it is not
unusual for E. coli isolates to contain multiple plasmid sequences simultaneously.
A simple search of RefSeq E. coli genomes reveals numerous examples. But
the long-term stability of the plasmids, within their host bacterial genomes, is
unknown. It is assumed that the acquisition of so much extra-chromosomal DNA
is energetically costly to the bacterial host; and because of this many of the
plasmids may not be stably maintained without antibiotic selective pressure, or
active plasmid maintenance systems (such as toxin/antitoxin plasmid addiction
systems).
Despite this blaCMY-2, which accounts for a small proportion of the total coding
domain sequences encoded on the IncI1 plasmids, appears to be a sufficiently
strong selectable marker to allow the plasmid to remain endemic across a range
of E. coli isolates affecting canine patients.
Fully contiguous sequences for each plasmid within each E. coli isolate would
likely not have been achievable with SMRT sequencing. This includes plasmids
that do not contain a marker for either incompatibility or replicon typing schemes,
and are not detectable by PCR or sequence annotation. While some of these se-
quences are devoid of any immediately obvious contribution to either the MDR
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phenotype, or pathogenic potential of the E. coli host; it is possible that they
may still play a role. Though basic sequence comparisons reveal some similari-
ties amongst this group of plasmids; their functional contribution has not been
assessed in anyway in this project. More over, the abundance of smaller plasmids
(with no typeable replicon) remains completely unknown in the wider MDR E.
coli group (other than the 8 isolates sequenced in this chapter). SMRT sequenc-
ing and core genome comparisons also revealed numerous plasmids with mixed
replicon sequences; which was not detected by PCR, or by Illumina sequencing.
Zoonotic transmission of antibiotic resistance from companion animals has
been previously reported (Damborg et al., 2009, Guardabassi et al., 2004). The
zoonotic potential of the MDR genotypes, by transmission of the plasmids (IncI1,
IncF or other), is not known for any of the sequences described here. Maximum-
likelihood and parsimony analysis of the plasmid sequences did not indicate a
strong evolutionary relationship between the sequenced plasmids and any refer-
ence sequence plasmids associated with human infections. However, there has
been much concern in the scientific literature over the global spread of MDR E.
coli clones, such as ST131 (Petty et al., 2014). The identification of a resistance
plasmid with wide dispersion with E. coli and an unknown host-range is also
concerning. With a strong match between plasmids located in Edinburgh and
found in dogs, to plasmids seen in the USA and Denmark, suggests that dispersal
and maintenance of closely related plasmid lineages is a possibility.
The concern over the usage of multiple antibiotics in high-risk groups, leading
to MDR, is not a new one. But the potential for change and the scale of such
transition, from fully susceptible to MDR, is alarming. Population analysis of the
E. coli isolates has not indicated a particular genetic background associated with
any of the plasmids. It seems more likely that the concerted selective pressure
of changing antibiotic treatments has acted to select particular plasmids, rather
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than particular strains of E. coli.
Little is known about the fundamental interaction between members of a com-
plex bacterial community upon challenge with multiple antibiotics. SMRT se-
quencing suggests that not only are there complex interactions between host flora
and antibiotic challenge; the mobilization of multiple plasmids and other HGEs
to this diverse background of strains, creates a daunting genetic complexity.
These isolates remain a rarity and MDR is not seen in uncomplicated UTIs.
Neither the clinical environment, or the canine patients can be ruled out as po-
tential reservoirs for the horizontal elements carrying the resistance gene markers.
The E. coli from the set of UTIs, presented in this thesis, was isolated from canine
patients that had been provided a significant level of clinical care. Evolving MDR,
resulting from longer-term clinical interventions, appears provides a selective en-
vironment for the development of multiple DNA elements with the potential to
be stably inherited and maintained within a clinical population; with remarkably
few resistance markers.
While the order in which the plasmids were acquired cannot be stated without
a more detailed understanding of the chronology of the treatments each patient
received; it is suggested that the mobilization of multiple resistance markers on
the IncF plasmids allows for better persistence in a complex clinical environment,
and more aggressive treatment protocols (including extended-spectrum β-lactams
and combinatorial β-lactam/inhibitor chemotherapies) have selected for a singu-
lar, clinically associated IncI1 plasmid.
In this regard, the findings here indicate the importance and relevance of the




5.1 Veterinary Care and Derived antimicrobial
resistance (AMR)
Experimental findings:
• The prescription of antibiotics in complex veterinary care does lead to the
selection of multi-drug resistant (MDR) isolates similar to those seen in
human clinical settings.
This research project was undertaken to gain a better understanding of the
differences in MDR strains of E. coli in dogs. Much of the work presented here
is focused on basic descriptive data, applied to previously unknown susceptible
and MDR E. coli isolates.
The primary aim was to evaluate MDR, characterized by extended-spectrum
AmpC (ESAC) resistance, and provide insight into the carriage of this resistance
in multiple strains of E. coli.
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Fortunately such infections remain rare and the Small Animal Hospital, Uni-
versity of Edinburgh; though the low number of isolates that could be included
in this project greatly limits the interpretation of the results presented in early
chapters.
The continued isolation of MDR E. coli at the Small Animal Hospital is the
result of the level of clinical intervention being applied to the animals in care.
This closely mirrors what is being recorded in the human clinical setting; even
though the resistance profiles of the E. coli isolates is different.
Beyond the locality of the Small Animal Hospital, the paucity of available
information on the prevalence of MDR in veterinary clinical settings creates a
bias of focus towards infection and resistance control measures and how these
apply to human clinical care.
The isolates described in the work presented here make a limited contribution
towards addressing the comparative lack of available data on the prevalence of
MDR in companion animal veterinary care. These isolates do confirm that dogs
undergoing complex, long-term treatments may be may act as a reservoir for po-
tentially transferable MDR (IncF plasmid mediated) and ESAC (IncI1, blaCMY-2
mediated) resistance; which is capable of persisting. Unfortunately, the scale of
the project, with only 18 MDR isolates (all from the same hospital), prevents
the findings of the work being extrapolated beyond a very limited geographical
setting (the Small Animal Hospital); even to the local community (Edinburgh).
Long-term antibiotic chemotherapy, exposure to multiple antibiotics and poor
host health status are all known selective pressures which favor the dissemination
of MDR. Unfortunately the available clinical records did not contain enough
information to allow the prescription of antibiotics to be correlated to the MDR
E. coli ; which were all isolated as secondary urinary tract infections (UTI)s.
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Therefore, it was not possible to assess the progression of AMR to MDR in the
individual patients. Enhanced communication between clinicians and researchers
could enable future studies on AMR infection progression, and acquisition of
horizontally-acquired resistance by E. coli.
Future work could also include studies into determine whether the detected
AMR or MDR persists within the wider clinical environment; for example, are pa-
tients colonized with resistance before treatment, or is there an external reservoir
for the MDR, or ESAC phenotype that can be identified?
Such information is necessary to better understand how the transmission of
AMR between E. coli, and between dogs, may be occurring. There is evidence
that suggest that MDR and ESAC, derived from infections in animals may pose
a threat to the control of AMR. This was beyond the scope of the current project
to address. It is not known what the long term stability of the MDR E. coli is
when not continuously exposed to antibiotic treatment.
Future Work:
• Is MDR resistance detectable in E. coli and other bacteria in healthy dogs?
• Is MDR resistance detectable only in a clinical environment?
• Is AMR/MDR maintained in the clinical environment?
• How does the MDR profile of the isolates in this study compare to the
resistance seen in humans?
• How does the use of antibiotics at the Small Animal Hospital influence the
incidence of MDR?
In order to best address these questions a better epidemiological understanding
of AMR and MDR a longitudinal study (i.e active surveillance); tracking in-
148
patients from point of admission, with sentinel samples from healthy dogs in the
community (no just fully susceptible).
With the genetic resolution afforded by next-generation sequencing (NGS)
techniques, coupled with a more accurate sampling and treatment time line, a
much more accurate model of transmission for these MDR isolates could be devel-
oped; and answer questions over the source of resistance (clinical or community)
and the longer term stability of the various resistance markers.
NGS and detailed sampling have already been used to detail hospital and
community transmission in Staphylococcus aureus (Harris et al., 2013, Holden
et al., 2004), and large scale intra-city and inter-continental transmission studies
in Klebsiella pneumoniae (Holt et al., 2015); to great effect.
The sampling could also be expanded to include human samples, to better
understand the zoonotic potential of the resistances detailed.
5.2 Extended-Spectrum AmpC and MDR
Experimental Findings
• blaCMY-2 derived ESAC phenotype
• Strong genetic linkage of blaCMY-2 mediated resistance to a well conserved
plasmid backbone.
• Mixed MDR genotypic profile.
• Genetic linkage of remaining MDR resistance markers to a separate plasmid
backbone.
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Despite the lack of an active surveillance program, the results presented in
this thesis have captured the successful propagation of ESAC resistance amongst
very different MDR E. coli.
The focus of this project has been on the ESAC (blaCMY-2) mediated resistance,
yet it is clear for many of the isolates that consistent use of multiple antibiotics
(not just the β-lactams), over a variable time-frame has selected for two, or more,
significant horizontal acquisition events (IncF and IncI1 plasmids).
While the use of particular β-lactam antibiotics has selected for an IncI1 with
a very targeted resistance, the majority of the MDR phenotype is carried by other
IncF-type plasmids.
It would be interesting to know if either of the IncI1 or IncF plasmids are
community associated or limited to the clinical environment where adequate an-
tibiotic selective pressure is maintained. From a veterinary care perspective, this
is important as both the IncF and IncI1 are capable of impacting the effective
treatment of infections. However, it was beyond the scope of this project to
determine the wider prevalence of either the MDR (IncF) or ESAC (blaCMY-2)
resistance beyond the small number of isolates already collected from the clinical
setting.
Future work:
• How common is the incidence of plasmid-linked ESAC and MDR resistance
beyond the Small Animal Hospital?
• Is there evidence for a reservoir, or increased prevalence for either ESAC or
MDR, in dogs or other animals (community or clinical)?
It was postulated in Chapter 4 that the acquisition of the resistance plasmids
was likely to be sequential; and that the order in which the IncI1 and IncF
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plasmids are acquired and transmitted has implications for better infection control
at the Small Animal Hospital.
As suggested previously, a more comprehensive and active surveillance pro-
gram, targeted towards the resistance genotypes described in this thesis would
help to answer these questions.
Now that there is a much better descriptive understanding of the ESAC and




• Classical urovirulence markers do correlate with pathogenic-type isolates.
• MDR E. coli are more associated with commensal phylogroups; and sus-
ceptible E. coli more associated with pathogenic phylogroups.
• MDR and susceptible E. coli strains do not share underlying genetic relat-
edness.
A further aim of the project was to attempt to contextualize MDR isolates
against a background of more routine out-patient E. coli infections. It was not
known if the MDR isolates were of nosocomial origin, or whether there was any
evidence of community-derived infections and resistance elements.
Furthermore, it was not known if virulence phenotype, or genotype could dis-
cern whether or not the MDR isolates had a distinctive genetic background of
commensal origin.
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The pathotypic variability of E. coli is well defined for a number of disease
states. Each pathogenic group is defined using canonical strains of E. coli which
produce obvious and characteristic infections from which controlled experiments
can be conducted to elucidate the genetic basis of the observed virulence pheno-
type (Kaper et al., 2004, Wirth et al., 2006).
Such typing schemes have focused on sets of virulence genes, which by their
presence or absence can be used to infer pathogenic ability. However, the ap-
plication of such predictive pathotyping to the isolates in this study was not so
straight forward.
The results of virulence genotyping (Identibac, SeqFinder, VirFinder) and the
comparisons of the MDR and susceptible isolates to archetypal uropathogenic
E. coli (UPEC) strains (phylotyping, MLST and phylogeny) may or, may not
suggest a trend towards greater uropathogenicity in the susceptible isolates.
Many of the virulence factors that define UPEC are missing from the sus-
ceptible and MDR isolates. While some of the variability may be a product of
incomplete annotation, and sub-optimal sequence assemblies; extra-intestinal E.
coli (ExPEC) and UPEC are highly flexible in terms of their virulence (Hill, 2012,
Wirth et al., 2006). Either way, it is not likely that pathogenic potential can be
reliably predicted for some of the isolates in this study.
Even for isolates which possess a more full complement of urovirulence markers,
the actual expression of these markers has not been quantified in any way. To do
so would require more detailed and in vitro work to assay particular groups of
virulence markers to try and discern potential differences; which is well beyond
the scope of this project.
Uropathogenesis has been defined as a distinct pathotype, yet there is still
large variability in the presence and expression of many core virulence genes;
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even amongst very closely related UPEC strains (Vejborg et al., 2010). CFT073
is a highly virulent uropathogen, expressing a number of virulence factors (Do-
brindt et al., 2016). Despite this highly pathogenic genetic background CFT073
is the ancestral parent strain fro both ABU83972 (asymptomatic) and Nissle 1917
(probiotic) E. coli strains. All three strains belong to the B2 phylogroup, possess
a number of urovirulence genes and yet are highly variable in their ability to cause
disease. Only detailed in vitro comparisons between CFT073 and ABU83972 re-
vealed other mechanisms such as immuno-modulation, persistence and metabolic
growth advantages targeted to the urinary and gastrointestinal tracts that could
better account for the pathogenic variability seen in these strains (Dobrindt and
Hacker, 2008, Dobrindt et al., 2016, Vejborg et al., 2010).
This spectrum of virulence and pathogenesis is also observed in MDR UPEC.
The ST131 clonal lineage is closely associated with rapid expansion of the extended-
spectrum β-lactamase (ESBL) blaCTX-M-15 and uropathogenesis (Petty et al.,
2014). Despite their clonal relatedness and pathogenic phylogrouping (B2), there
is variability of virulence between ST131 isolates; which is attributable to variable
carriage of ExPEC virulence markers as well as loss or acquisition of genomic loci
associated to virulence markers not specific to a particular pathovars (Alghoribi
et al., 2014, Petty et al., 2014).
The small number of isolates, combined with a lack of underlying genetic relat-
edness to one another make such detailed comparisons of virulence very difficult.
Should such disparate E. coli isolates be expected to be uniform in their viru-
lence types? Or, do the results reflect the overall heterogeneity of the ExPEC
and UPEC pathotypes?
Both questions require both a broadening of the number and type of isolates
sequenced here, coupled with more detailed in vitro assays of virulence capable of
discerning genuine differences of urovirulence beyond just the presence, or absence
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of a small list of virulence factors.
To complicate the interpretation of any results further; assessing only the
pathogenic potential by virulence genes may also underestimate the effect of com-
mensal traits which may contribute towards the colonization of the urinary tract.
Persistence in an otherwise sterile and immune-controlled environment, metabolic
advantages (superior growth rates) and the ability to progressively colonize the
gastrointestinal tract, as well as the urinary tract are often neglected in virulence
typing schemes (Hill, 2012).
Even resistance itself may be considered a virulence factor as long as the
selection pressure is strong enough to overcome other environmental conditions;
like resource competition from other gut flora bacteria.
Just as pathotype and commensal niche adaptation drive genomic diversity in
E. coli, so to do antimicrobials. Many of the IncF sequences detailed in this body
of work contained virulence markers as well as resistance markers; suggesting
multiple selection pressures favoring the maintenance of the plasmid (including
expanded virulence).
The prescription of an antibiotic, though targeted at a single bacterial pop-
ulation, impacts all bacterial populations which the antibiotic is active against.
Therapeutic compounds that are active against pathogenic E. coli are active
against all other populations of E. coli which the host is colonized by; whether
they are commensal, asymptomatic, or pathogenic. By providing novel evolution-
ary pressure, such treatments may augment existing pathogens such as ST131,
or drive opportunistic acquisition of AMR in commensal populations (Alekshun
and Levy, 2006).
E. coli commensalism is not easily defined by the presence or absence of vir-
ulence markers. Commensalism is better defined and contextualised by core-
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genomic sequence comparisons. As such, commensalism and its relationship to
the isolates focused on in this study, is likely a convenient place holder label for
an isolate who’s pathogenic potential, or environmental niche, has not been fully
evaluated under the right conditions (Tenaillon et al., 2010).
Future Work:
• What is the minimal requirement for uropathogenesis?
• What is the distinction between an opportunistic E. coli isolate and a com-
mensal E. coli isolate?
• Are core genomic sequences adequate for determining the uropathogenic
potential of E. coli isolates?
• How much does the pan-genome contribute to determining uropathogenic
potential?
The variability in the predicted virulence markers seen in the work presented
here may well represent real differences between the strains; but ultimately this is
a far from complete understanding of the adaptation of the MDR and susceptible
isolates to either a pathogenic or commensal niche background.
The strongest indicator of uropathogenic potential for the isolates, presented
in this body of work, is their presence and isolation from an active UTI; but this
observation is not without complications.
For the MDR isolates, it is likely that there was a greater underlying suscepti-
bility to infection given the level of treatment the dogs were receiving; compared
to the susceptible isolates, due to the disease status of the host. To confirm this,
the host immune status prior to infection, and host response to an active UTI
between the dogs in both groups would be required.
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A more detailed understanding of the changes to the gut flora, in response to
antibiotic treatment would help to answer the question of whether the observed
MDR strains are more likely to originate from commensal or pathogenic popu-
lations of E. coli. The change in E. coli populations, post antibiotic treatment,
would indicate which populations (commensal or pathogenic) persist better dur-
ing antibiotic chemotherapy; which are then more likely to develop AMR and
MDR.
Questions of minimal virulence requirement and commensal trait markers are
better answered by expanding the current work to include a much more diverse
range of E. coli. As previously stated, UPEC isolates display a wide-spectrum
of virulence (including avirulence); defined not just by the presence of virulence
markers, but also each strains unique expression of these markers. While this
may not be completely predictive, as long as enough is known about the isolate
(i.e. was it isolated from an active UTI), this will provide a better approximation
of what baseline virulence markers are required to invade the urinary tract.
The work should also be expanded to include faecal isolates to better under-
stand commensal type E. coli in a healthy dog. Colonization of the gut, which is a
key stage in the development of a UTI, needs to be better understood so that the
genetic markers which favor colonization can also be used to better distinguish
potential virulence between the MDR and susceptible isolates.
Finally, it is also important to expand and improve the work started on defin-
ing the pan-genomic sequences which distinguish the various isolates from one
another. Core-genome phylogeny, whilst undoubtedly useful in providing more
accurate evolutionary estimations, relies on only a fraction of the total genome
of E. coli (20%) (Tenaillon et al., 2010).
At the most basic level (how it is used here), it provides another means to
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test the evolutionary relatedness amongst different strains. By expanding it, and
dissection the pan-genome further, it is a powerful tool for identifying genes that
may be positively selected for in the different populations of E. coli of interest
here (commensal, MDR, UPEC etc.) (Mainda et al., 2016).
5.4 Phenotypic Virulence
Experimental Findings
• Galleria mellonella may be valuable for comparing virulence between UPEC
strains.
• Urovirulence markers do not correlate with greater virulence in an infection
model.
• MDR phenotypes did not correlate with reduced virulence in an infection
model.
Galleria mellonella is a promising infection model which has already been ap-
plied to E. coli (Alghoribi et al., 2014), and a number of other pathogenic bacteria
(Aperis et al., 2007, Jarrett and Stephenson, 1990, Mylonakis and Moreno, 2005,
Peleg and Jara, 2009, Seed and Dennis, 2008).
The application of the infection is validated by the reproducibility of the dif-
ference in lethality between asymptomatic ABU83972 and pathogenic CFT073
control strains. Though there is clearly much scope for refinement of the model.
For example, ABU83972 and CFT073 are closely related strains of UPEC
and it would be desirable to expand the current infection model to include more
reference UPEC strains; to better assay the potential variability of both UPEC
157
strains and the infection model. The model currently only uses larvae death as
a surrogate value to summarize all virulence. The probability of larval death is
much more likely to be the result of complex multi-factorial influences of various
virulence genes (such as toxins); which should be assessed.
It is also unlikely that individual virulence gene families contribute equally
to the killing phenotype. In order to generate a more robust model, it would
be useful to determine which urovirulence genes contribute the most towards
virulence in the larvae.
Furthermore, the larvae in this work were exposed to a single infectious does.
While this was optimal for reproducing the effects seen in the control strains,
it is very probable that individual E. coli strains will be more or less virulent
when this concentration is altered; and concentration-dependent killing provides
another useful metric to measure variability in virulence. Titrating the infectious
dose of E. coli and quantifying virulence in terms of both number of bacteria
injected, as well as the proportion of moth larvae killed, would allow much more
powerful comparisons to be made between strains.
When using the model to investigate the virulence of MDR strains, it would
also be desirable to expand the model to investigate the effects of antibiotic dosing
during an infection. By introducing antibiotics, it may be possible to quantify
the effect of the expression of antibiotic resistance, positive or negative, on the
expression of virulence during infection.
Overall, the results produced here did not show any correlation between the
number of virulence factors and moth lethality. This incongruence might result as
a by-product of the infection model; though the strong link to an asymptomatic
bacteriurea strain and no lethality, and a virulent UPEC strain to higher lethality
does make this less likely. This may also be due to a stronger nascent pathogenic
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potential amongst commensal type E. coli than has been previously estimated.
Future work:
• How many virulence makers illicit an immune response in a Galleria mel-
lonella infection model?
• Are reference UPEC strains virulent in Galleria mellonella virulent in a
Galleria mellonella infection model?
• Are reference commensal and probiotic E. coli strains virulent in a Galleria
mellonella infection model?
• Can antibiotics be used in the infection model?
5.5 Plasmids and MDR
Experimental Findings:
• IncI1 associated with singular blaCMY-2 resistance.
• IncFII associated with various virulence and resistance.
The focus of the project has been on ESAC resistance, which creates a bias
in the reported genotypes for both resistance markers and the plasmids carrying
these resistance markers. However, there is no doubt of their contribution towards
the MDR status of the isolates.
If the IncF plasmid sequence variation seen in the isolates in this study is a
true reflection of the wider E. coli population-level genetic background, it would
suggest a closer relationship between the IncF plasmids and their host isolates.
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Such a relationship would be in important in helping to determine the progression
of the resistance state of the isolates.
Does the acquisition of an IncI1 plasmid carrying a singular resistance marker
drive the acquisition of further resistance markers carried by the IncF plasmid?
Or does the acquisition of a broader MDR phenotype allow persistence and a
progressive adaptation towards and extended-spectrum resistance?
Also important in determining the relationship between the plasmids and their
E. coli hosts; what is the long-term stability of resistance markers and elements,
in the wider pool of resistance?
The indication of phylogenetic comparisons to other plasmid backbones sug-
gests a tendency towards persistence and conservation of these markers in isolates
with wide geographic distributions. Furthermore, that the plasmids, which are
in temporally isolated infections at the Small Animal Hospital, would suggest
that transferability between disparate bacterial populations is certainly possible.
This would also be helpful in asserting whether a potential transfer of resistance
markers between the clinic and the community is driven by one or the other.
Currently the observed differences between the genetic backgrounds of the
susceptible and MDR isolates, and the much closer genetic relatedness between
the plasmids conferring resistance, suggests that it is the conservation of horizotal
genetic elements (HGEs) that is driving ESAC resistance at the Small Animal
Hospital.
Rather than a clonal expansion of particularly virulent, or infectious E. coli
isolates; it is likely that the dissemination of resistance is the product of the trans-
ferability of the plasmids. Given the mixed results of the phenotypic and geno-
typic virulence typing of the MDR isolates, this may indicate a reduced impact
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of ESAC and MDR acquisition. This may be due to acquisition in a favourable
E. coli host background (commensal, not pathogen), a functional contribution of
the plasmids that extends beyond just resistance phenotype (metabolic, virulence
etc.), or finally an artifact of canine host status (reduced host immune pressure
on the E. coli isolates).
Given the persistence of the IncI1 blaCMY-2 plasmid it would be of considerable
value to know its distribution amongst E. coli, or indeed other bacterial species, at
the Small Animal Hospital. Is it being actively maintained by antibiotic selective
pressure in a clinical setting? Or, given the reported presence of the plasmid
backbone internationally, is it distributed in the wider community?
Due to the focus on UTIs (which are overwhelmingly caused by E. coli), the
focus on E. coli may be disproportionately biased; especially given the indication
that the plasmid backbone is found in a number of other Enterobacteriaceae.
These questions would be answered with an expanded active surveillance pro-
gram (as suggested earlier); and answering would greatly improve the understand-
ing of the transmission dynamics of ESAC and MDR within the Small Animal
Hospital.
5.6 Work in Progress
Further Work:
• Is AMR plasmid acquisition favorable in all E. coli genetic backgrounds?
• Expression and control of AMR phenotype.
• Expression and control of virulence profile.
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• Ascribing further function to the hypothetical coding information.
• What is the long-term stability of the resistance elements?
One of the more striking differences between the MDR and susceptible isolates
is their plasmid burden. Whereas the MDR isolates are characterizable by a
consistent IncI1 and IncFII replicon type, the susceptible isolates show little to
no such consistency and less replicon detection overall.
Very little is known about the baseline plasmid burden for E. coli, other than
it varies widely across a broad range of isolates. No information exists about the
expected range of plasmid replicon types associated with either pathogenic, or
commensal populations beyond well characterized strains.
For the IncI1 plasmids, the maintenance of 90kb (and larger) plasmids by a
single resistance marker, is either a product of either strong antibiotic selection
pressure, or through the mitigation of the metabolic expense of the acquisition
of such a large amount of genetic material. While strong antibiotic selection
pressure is likely in a clinical setting, the widespread presence of the IncI1 plasmid
backbone does suggest some competitive advantage or selection pressure beyond
just ESAC resistance.
This is also likely true of the IncF plasmids, which contain not just resistance
markers (some do not possess any), but virulence markers as well. In light of
this potential functional diversity, it would be desirable to know the capacity
of a plasmid to impact regular cellular function in the presence or absence of
antibiotics. Similarly, to be able to quantify the ease of transfer of these plasmids
to E. coli isolates of different genetic backgrounds may highlight further impacts
to various environmental niches.
If the plasmids cannot be transferred to highly adapted, virulent UPEC isolates
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it would confirm whether or not the resistance plasmids favor commensal E.
coli ; and would be suggestive of a negative impact of resistance carriage towards
virulence.
The conjugation of the plasmids into other reference strains allows for the
investigation of the effects the resistance plasmids may have in a different host
background.
Due to time constraints, further work to assess the effect of resistance expres-
sion on normal E. coli cellular function has since been started (but cannot be
included).
Briefly, conjugants and wild-type strains were grown in dog urine in the pres-
ence and absence of a β-lactam antibiotic and allowed to reach mid exponential
growth phase. RNA was extracted and sequenced using Illumina sequencing in
the anticipation of performing differential RNA-Seq expression analysis.
In such a way, the effect of resistance expression can by measured in both an
MDR, UPEC and K-12 background.
Looking beyond the contribution of plasmid-mediated resistance; there is very
little data available on the nature of the various populations of E. coli which
form a component of the host flora. Less information still, is available about
the baseline presence of virulence or AMR markers that are present in a healthy
animal host; and the degree to which the presence or absence of either is affected
during clinical intervention.
The observation that AMR is more likely to be associated with commensal-
type E. coli may be a product of greater susceptibility of more pathogenic E. coli
to antibiotics pressure. In other words, is there a selective advantage to be gained
by plasmids re-introducing virulence markers (UPEC specific or otherwise) into a
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more commensal type population; which go onto cause opportunistic infections?
Another, perhaps more likely scenario, is that commensal E. coli simply present
the lowest energetic barrier in expressing the acquired antibiotic resistance.
Despite the small-scale (the biggest shortcoming of this project), the results
shown here do suggest that virulence and antibiotic resistance are not mutually
exclusive. Despite the commensal associations with AMR observed here and in
other studies; there are well published examples of AMR associated with out-
breaks of virulent E. coli.
To better contextualize these questions in terms of the wider impacts of plasmid-
mediated MDR, is it necessary to attempt to control the derivation of AMR
plasmids from otherwise neutral plasmids within the flora? Or, does therapeutic
intervention need to target the transfer of nascent AMR plasmids from the wider
pool of AMR organisms to other bacteria?
Either scenario is a daunting challenge and unlikely to be completely achieved,
even within the clinical environment (Williams and Hergenrother, 2008).
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Ben-Ami, R., Rodŕıguez-Baño, J., Arslan, H., Pitout, J. D. D., Quentin, C.,
Caibo, E. S., Azap, O. K., Arpin, C., Pascual, A., Livermore, D. M., Garau,
J., and Carmeli, Y. A multinational survey of risk factors for infection with
extended-spectrum β-lactamase-producing enterobacteriaceae in nonhospital-
ized patients. Clinical Infectious Diseases, 49(5):682–690, 2009.
Benedict, K. M., Morley, P. S., and Metre, D. C. V. Characteristics of biosecurity
and infection control programs at veterinary teaching hospitals. J Am Vet Med
Assoc, 233(5):767–773, 2008.
Bertels, F., Silander, O. K., Pachkov, M., Rainey, P. B., and van Nimwegen, E.
Automated reconstruction of whole-genome phylogenies from short-sequence
reads. Molecular Biology and Evolution, 31(5):1077–1088, 2014.
Beutin, L. Escherichia coli as a pathogen in dogs and cats. Vet Res, 30(2-3):
285–298, 1999.
Blango, M. G. and Mulvey, M. a. Persistence of uropathogenic Escherichia coli
in the face of multiple antibiotics. Antimicrobial agents and chemotherapy, 54
(5):1855–63, May 2010.
Bogaerts, P., Huang, T.-D., Bouchahrouf, W., Bauraing, C., Berhin, C., El Garch,
F., and Glupczynski, Y. Characterization of esbl- and ampc-producing en-
terobacteriaceae from diseased companion animals in europe. Microbial drug
resistance (Larchmont, N.Y.), 21:643–50, Dec 2015.
Bortolaia, V., Larsen, J., Damborg, P., and Guardabassi, L. Potential pathogenic-
ity and host range of extended-spectrum β-lactamase-producing Escherichia
coli isolates from healthy poultry. Applied and Environmental Microbiology, 77
(16):5830–5833, 2011.
166
Bortolaia, V., Hansen, K. H., Nielsen, C. A., Fritsche, T. R., and Guardabassi,
L. High diversity of plasmids harbouring blacmy-2 among clinical escherichia
coli isolates from humans and companion animals in the upper midwestern usa.
Journal of Antimicrobial Chemotherapy, 69(6):1492–1496, 2014.
Bradford, P. A. Extended-spectrum beta-lactamases in the 21st century: char-
acterization, epidemiology, and detection of this important resistance threat.
Clin Microbiol Rev, 14(4):933–51, table of contents, 2001.
Buckland, E. L., ONeill, D., Summers, J., Mateus, A., Church, D., Redmond,
L., and Brodbelt, D. Characterisation of antimicrobial usage in cats and dogs
attending uk primary care companion animal veterinary practices. Veterinary
Record, 2016.
Bush, K. and Jacoby, G. A. Updated functional classification of beta-lactamases.
Antimicrob Agents Chemother, 54(3):969–976, 2010.
Bush, K., Jacoby, G. A., and Medeiros, A. A. A functional classification scheme
for beta-lactamases and its correlation with molecular structure. Antimicrob
Agents Chemother, 39(6):1211–1233, 1995.
Carattoli, A., Bertini, A., Villa, L., Falbo, V., Hopkins, K. L., and Threlfall,
E. J. Identification of plasmids by PCR-based replicon typing. Journal of
Microbiological Methods, 63(3):219–228, 2005a.
Carattoli, A. Plasmids in Gram negatives: molecular typing of resistance plas-
mids. International journal of medical microbiology : IJMM, 301(8):654–8, dec
2011.
Carattoli, A., Lovari, S., Franco, A., Cordaro, G., Di Matteo, P., and Battisti, A.
Extended-Spectrum Œ-Lactamases in Escherichia coli Isolated from Dogs and
Cats in Rome, Italy, from 2001 to 2003. Antimicrobial Agents and Chemother-
apy, 49(2):833–835, 2005b.
Chen, L., Xiong, Z., Sun, L., Yang, J., and Jin, Q. Vfdb 2012 update: toward the
genetic diversity and molecular evolution of bacterial virulence factors. Nucleic
acids research, 40:D641–5, Jan 2012.
Chen, Y. Uropathogenic virulence factors in isolates of Escherichia coli from
clinical cases of canine pyometra and feces of healthy bitches. Veterinary Mi-
crobiology, 94(1):57–69, June 2003.
Chin, C.-S., H Alexander, D., Marks, P., Klammer, A., Drake, J., Heiner, C.,
Clum, A., Copeland, A., Huddleston, J., E Eichler, E., W Turner, S., and
Korlach, J. Nonhybrid, finished microbial genome assemblies from long-read
smrt sequencing data. 10, 05 2013.
Clermont, O., Christenson, J. K., Denamur, E., and Gordon, D. M. The Clermont
Escherichia coli phylo-typing method revisited: Improvement of specificity and
detection of new phylo-groups. Environmental Microbiology Reports, 5(1):58–
65, 2013.
167
Contreras-Moreira, B. and Vinuesa, P. Gethomologues, a versatile software pack-
age for scalable and robust microbial pangenome analysis, Dec 2013.
Cornaglia, G., Garau, J., and Livermore, D. M. Living with ESBLs. Introduction.
Clin Microbiol Infect, 14 Suppl 1:1–2, 2008.
Corvec, S., Prodhomme, A., Giraudeau, C., Dauvergne, S., Reynaud, A.,
and Caroff, N. Most Escherichia coli strains overproducing chromosomal
AmpC β-lactamase belong to phylogenetic group A. Journal of Antimicro-
bial Chemotherapy, 60(4):872–876, 2007.
Cosgrove, S. E. and Carmeli, Y. The impact of antimicrobial resistance on health
and economic outcomes. Clin Infect Dis, 36(11):1433–1437, 2003.
Cosgrove, S., Kaye, K., Eliopoulous, G., and Carmeli, Y. Health and economic
outcomes of the emergence of third-generation cephalosporin resistance in en-
terobacter species. Archives of Internal Medicine, 162(2):185–190, 2002.
Costa, D., Poeta, P., Saenz, Y., Coelho, A. C., Matos, M., Vinue, L., Rodrigues,
J., and Torres, C. Prevalence of antimicrobial resistance and resistance genes
in faecal Escherichia coli isolates recovered from healthy pets. Veterinary Mi-
crobiology, 127(1Äı̀2):97–105, 2008.
Damborg, P., Nielsen, S. S., and Guardabassi, L. Escherichia coli shedding pat-
terns in humans and dogs: insights into within-household transmission of phy-
lotypes associated with urinary tract infections. Epidemiol Infect, 137(10):
1457–1464, 2009.
Damborg, P., Gaustad, I. B., Olsen, J. E., and Guardabassi, L. Selection of CMY-
2 producing Escherichia coli in the faecal flora of dogs treated with cephalexin.
Veterinary Microbiology, 151(3-4):404–408, 2011.
Damborg, P., Marskar, P., Baptiste, K. E., and Guardabassi, L. Faecal shedding
of CTX-M-producing Escherichia coli in horses receiving broad-spectrum an-
timicrobial prophylaxis after hospital admission. Veterinary Microbiology, 154
(3-4):298–304, 2012.
Danecek, P., Auton, A., Abecasis, G., Albers, C. A., Banks, E., DePristo, M. A.,
Handsaker, R. E., Lunter, G., Marth, G. T., Sherry, S. T., McVean, G., and
Durbin, R. The variant call format and VCFtools. Bioinformatics, 27(15):
2156–2158, aug 2011.
Darling, A. E., Mau, B., and Perna, N. T. progressivemauve: Multiple genome
alignment with gene gain, loss and rearrangement. PLOS ONE, 5(6):1–17, 06
2010.
Davies, J. and Davies, D. Origins and Evolution of Antibiotic Resistance. Mi-
crobiology and Molecular Biology Reviews, 74(3):417–433, 2010.
168
de Jong, A., Thomas, V., Simjee, S., Godinho, K., Schiessl, B., Klein, U., Butty,
P., Valle, M., Marion, H., and Shryock, T. R. Pan-european monitoring of sus-
ceptibility to human-use antimicrobial agents in enteric bacteria isolated from
healthy food-producing animals. The Journal of antimicrobial chemotherapy,
67:638–51, Mar 2012.
Didelot, X. and Wilson, D. J. Clonalframeml: Efficient inference of recombination
in whole bacterial genomes. PLOS Computational Biology, 11(2):1–18, 02 2015.
Dierikx, C. M., van Duijkeren, E., Schoormans, A. H. W., van Essen-Zandbergen,
A., Veldman, K., Kant, A., Huijsdens, X. W., van der Zwaluw, K., Wagenaar,
J. A., and Mevius, D. J. Occurrence and characteristics of extended-spectrum-
β-lactamase- and AmpC-producing clinical isolates derived from companion
animals and horses. Journal of Antimicrobial Chemotherapy, 67(6):1368–1374,
2012a.
Dierikx, C. M., van Duijkeren, E., Schoormans, A. H. W., van Essen-Zandbergen,
A., Veldman, K., Kant, A., Huijsdens, X. W., van der Zwaluw, K., Wagenaar,
J. A., and Mevius, D. J. Occurrence and characteristics of extended-spectrum-
β-lactamase- and AmpC-producing clinical isolates derived from companion
animals and horses. Journal of Antimicrobial Chemotherapy, 67(6):1368–1374,
2012b.
Diestra, K., Juan, C., Curiao, T., Moyá, B., Miró, E., Oteo, J., Coque, T. M.,
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Osante, N., Jouini, A., Klibi, N., Sáenz, Y., Boudabous, A., and Torres, C.
First detection of ctx-m-1, cmy-2, and qnrb19 resistance mechanisms in fecal
escherichia coli isolates from healthy pets in tunisia. Vector-Borne and Zoonotic
Diseases, 13(2):98–102, 2013. PMID: 23289399.
Sanchez, S., Stevenson, M., Hudson, C. R., Maier, M., Buffington, T., Dam,
Q., and Maurer, J. J. Characterization of multidrug-resistant Escherichia coli
181
isolates associated with nosocomial infections in dogs. Journal of Clinical Mi-
crobiology, 40(10):3586–3595, 2002.
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tas, S., Petit, M. A., Pichon, C., Rouy, Z., Ruf, C. S., Schneider, D., Tourret,
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Multidrug-resistant Escherichia coli from canine urinary tract
infections tend to have commensal phylotypes, lower
prevalence of virulence determinants and ampC-replicons
Samuel Wagner, David L. Gally, Sally A. Argyle *
Royal Dick School of Veterinary Studies and The Roslin Institute, University of Edinburgh, Roslin, Midlothian EH25 9RG, United Kingdom
1. Introduction
Increasing numbers of reports have documented the
emergence of Escherichia coli capable of producing broad-
spectrum b-lactamases. This is significant since the b-
lactam antimicrobials are of therapeutic importance in
humans and many domestic animals. Furthermore, many
isolates are resistant to additional antimicrobial classes
and are therefore multidrug-resistant (MDR).
Carriage of ESBL- and AmpC-producing E. coli has been
documented in many species (Bortolaia et al., 2011).
Antimicrobial use has been reported as a risk factor
(Damborg et al., 2011, 2012; Maddox et al., 2012) and there
is also evidence of sharing of organisms between species
living in close proximity to each other (Dolejska et al.,
2011). Considering the physical closeness in which many
humans live with their pet companions, sharing of these
organisms between humans and pets could pose a
significant mutual risk.
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A B S T R A C T
Multidrug-resistant Escherichia coli is an emerging clinical challenge in domestic species.
Treatment options in many cases are limited. This study characterized MDR E. coli isolates
from urinary tract infections in dogs, collected between 2002 and 2011. Isolates were
evaluated in terms of b-lactamase production, phylogenetic group, ST type, replicon type
and virulence marker profile. Comparisons were made with antibiotic susceptible isolates
also collected from dogs with urinary tract infections. AmpC b-lactamase was produced in
67% of the MDR isolates (12/18). Of these, 8 could be specifically attributed to the CMY-2
gene. None of the isolates tested in either group expressed ESBLs. Phylo-group distribution
was as expected in the susceptible isolates, with an over representation of the pathogenic
B2 phylo-group (67%). In contrast, the phylogenetic background for the MDR group was
mixed, with representation of commensal phylo-groups A and B1. The B2 phylo-group
represented the smallest proportion (A, B1, B2 or D was 28%, 22%, 11% and 33%,
respectively). Virulence marker profiles, evaluated using Identibac1 microarray,
discriminated between the two groups. Marker sequences for a core panel of virulence
determinants were identified in most of the susceptible isolates, but not in most of the
MDR isolates. These findings indicate that for MDR isolates, plasmid-mediated AmpC is an
important resistance mechanism, and while still capable of causing clinical disease, there
is evidence for a shift towards phylogenetic groups of reduced inferred virulence potential.
There was no evidence of zoonotic potential in either the susceptible or MDR urinary tract
isolates in this study.
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Clinical disease associated with these organisms is well
documented in humans. Initially the pattern was of
hospital-acquired infection but community-acquired
infection has become increasingly important. ESBL E. coli
are associated with a variety of clinical diseases, in
particular urinary tract infections, neonatal septicaemia
and wound infections (Ben-Ami et al., 2009; Pitout, 2010).
Reports of similar clinical disease associated with AmpC-
producing E. coli are far fewer than those pertaining to
ESBLs, however these also appear to be an emerging
problem (Oteo et al., 2010).
Although most animal studies have focused on the
zoonotic risk posed by carriage, there are increasing
reports demonstrating the involvement of these organisms
in clinical disease in domestic species in a variety of
locations including Europe, North America, Asia and
Australia. For example, in the United States AmpC (CMY-
2) and ESBL-producing E. coli (O’Keefe et al., 2010; Sanchez
et al., 2002; Shaheen et al., 2011) have been reported from
canine clinical isolates. Clinical disease associated with
AmpC-producing E. coli in dogs in Australia, was first
reported in 2006 (Sidjabat et al., 2006). More recently, a
survey of clinical isolates from dogs and horses in the
Netherlands demonstrated a 2% prevalence of ESBL and
AmpC-producing isolates (Dierikx et al., 2012).
The aim of this study was to evaluate the association of
ESBL or AmpC production with multidrug-resistant E. coli
isolated from clinical cases of urinary tract infection in
dogs from a local patient population, over a period of time
ranging from 2002 to 2011. Isolates were further
characterized in terms of phylogenetic grouping, sequence
type and virulence genotype. Plasmid replicon typing was
also performed to identify the type and diversity of
plasmids involved. Comparisons were made to a group of
susceptible E. coli isolates, also associated with canine
urinary tract infection and collected over a similar time
frame.
2. Materials and methods
2.1. Source of clinical isolates
All 15 susceptible and 17/18 MDR isolates were
identified in clinical cases seen at the Hospital for Small
Animals, University of Edinburgh. One MDR isolate (R3)
came from a local practice serviced by the University of
Edinburgh’s diagnostic microbiology service.
2.2. E. coli identification
A total of 33 clinical isolates from canine urinary tract
infections were cultured on Blood and MacConkey agar.
Any lactose fermenting colonies were confirmed as E. coli
utilizing biochemical testing (API 10S1 strip bioMerieux).
2.3. Antimicrobial susceptibility testing
Susceptibility testing was performed using the disc
diffusion method in accordance with Clinical Laboratory
Standards Institute (CLSI) guidelines. The following discs
were used: Co-trimoxazole (25 mg); ciprofloxacin (1 mg);
amoxicillin clavulanate (30 mg); cephalexin (30 mg); gen-
tamicin (10 mg); tetracycline (10 mg); cefotaxime (30 mg).
All discs were sourced from Mast group Ltd.
2.4. Control strains
The following control strains were utilized in both the
phenotypic combination disc testing and for polymerase
chain reaction. ATCC 25922TM (negative control); ATCC BA-
199TM (SHV-3 positive control); NCTC 13353TM (CTX-M-15
positive control), and NCTC 13351TM (TEM-3 positive
control).
2.5. Combination disc method for plasmid-mediated AmpC
and ESBL detection
A commercially available AmpC and ESBL detection set
(Mast group Ltd) was utilized. This comprised a set of 4
discs containing cefpodoxime plus or minus AmpC and
ESBL inhibitors. Interpretation was made following the
manufacturer’s instructions.
2.6. PCR for ESBL and AmpC gene detection
DNA from single colonies of each isolate was prepared
using the lysis method as previously described (Pérez-
Pérez and Hanson, 2002). Primers for the genes blaTEM,
blaSHV, blaCTX, blaCMY-1 group, blaCMY-2 group, blaOXA-1
group and blaOXA-2 group were derived from a previously
established assay (Hasman et al., 2005). For additional
detection of AmpC b-lactamase genes, multiplex PCR was
performed on all samples using the methodology and
primers previously described (Pérez-Pérez and Hanson,
2002). PCR products were electrophoresed in a 1% agarose
gel, gel bands were excised, and sequences were compared
to the NCBI database to confirm identity.
2.7. Multiplex PCR phylogenetic grouping of clinical isolates
DNA from single colonies was prepared using the
Qiagen DNeasy blood and tissue extraction kit according to
the manufacturer’s instructions (Qiagen, UK). Multiplex
PCR methodology was employed to assign the clinical
isolates to one of four phylogenetic groups (A, B1, B2 or D).
Primers and methodology have been described previously
(Doumith et al., 2012).
2.8. PCR-based plasmid replicon typing of clinical isolates
DNA was isolated as described above for the phyloge-
netic grouping. Methodology involved the use of 8
multiplex reactions in a commercial kit (Diatheva, Italy)
based on methodology described previously (Carattoli
et al., 2005).
2.9. Identibac1 microarray analysis
A microarray assay developed and carried out by the
Animal Health Veterinary Laboratories Agency (AHVLA)
was used (Batchelor et al., 2008). The microarray contained
a selection of oligonucleotide probes mapping to a range of
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resistance and virulence-associated genes. Probe hybridi-
zations resulting in signal intensities greater than 0.4 were
considered positive indicating the presence of the gene.
2.10. MLST methodology
DNA was extracted using a DNeasy extraction kit
(Qiagen) and performed as to the manufacturer’s instruc-
tions. Sequencing of the DNA was carried out on an
Illumina MiSeq (ARK Genomics). Raw sequence reads were
aligned to two reference sequences, E. coli ABU83972 and
E. coli MG1655 (Accession numbers NC_017631.1 and
NC_000913.2), using BWA and Samtools (Li and Durbin,
2009). Sequence type calling (for multi-locus sequence
typing) was performed using SRST (Inouye et al., 2012).
Isolates which could not be typed using SRST were called
manually using sequences mapped to MG1655. Sequences
aligning to the MLST genes in MG1655 were extracted
using VCFtools (Danecek et al., 2011) and Extractseq, (Rice,
2000) and entered manually into the MLST Database,
hosted by University College Cork (http://mlst.ucc.ie/mlst/
dbs/Ecoli).
2.11. Statistical methods
Comparisons were tested using Fisher’s exact test. The
criterion for statistical significance was taken to be
P < 0.05.
3. Results
3.1. Culture and sensitivity
Between 2002 and 2011, 18 E. coli isolates associated
with urinary tract infections (UTIs) in 16 dogs were
identified as multidrug-resistant (MDR). Results of culture
and sensitivity testing for the MDR isolates (R1-16) are
displayed in Table 1. Two of the dogs had recurrent UTI
infection. One case recurred 1 month later (R16a and b)
and the second case 6 months later (R11a and b). The
criterion used to make the MDR determination was
resistance to 3 or more classes of antimicrobial on
routine culture and sensitivity testing. All MDR isolates
were resistant to amoxicillin clavulanate and tetracy-
cline, 83% (15/18) were resistant to cephalexin, 78% (14/
18) were resistant to co-trimoxazole, 56% (10/18) were
resistant to ciprofloxacin, 22% (4/18) were resistant to
gentamicin and 67% (12/18) were resistant to the 3rd
generation cephalosporin cefotaxime. The latter was
used as an indicator of broad-spectrum b-lactamase
production.
For comparison, 15 E. coli isolates were selected for
study, based on the criteria that they were susceptible to
all 7 antimicrobial classes listed above. These isolates were
associated with urinary tract infections in dogs.
3.2. AmpC b-lactamase phenotype and genotype
To identify the contribution of either ESBL or AmpC b-
lactamases to the MDR phenotype, all isolates (both MDR
and susceptible groups) were tested using the 4 disc test as
described in materials and methods. All susceptible
isolates were negative (data not shown). A total of 67%
(12/18) of MDR isolates were positive for AmpC produc-
tion. ESBL production was not detected.
Using ampC multiplex PCR, 9/12 isolates phenotypi-
cally AmpC positive were genotypically positive for
pAmpC (CITM group). Further simplex PCR identified 8
of these to be specifically associated with the CMY-2 gene.
Identibac1 microarray also detected a CMY gene signal in
8/9 isolates tested (isolates relate to R1–R7, R9 and R10 in
Table 1).
Table 1
Summary of phenotypic and genotypic characterization of the MDR E. coli isolates.
Isolate Isolation date (month/year) Resistance pattern 3rd Gen AmpC Pheno pAmpC PCR Phylo ST Replicon type
R1 9/2006 AMC CEF COT CIP TET R + + A 10 FII I1
R2 1/2008 AMC CEF COT TET R + + n/t 46 FII I1
R3 9/2010 AMC CEF COT CIP TET R + + A 744 FII I1
R4 10/2010 AMC CEF TET R + + D 648 FII I1
R5 3/2010 AMC CEF TET R + + D 963 FII I1
R6 2/2011 AMC CEF COT TET R + + D N FII I1
R7 12/2007 AMC CEF COT CIP TET R + + B1 539 B/O I1
R8 9/2011 AMC CEF COT CIP TET GEN S +  B1 23 FII FIB
R9 9/2011 AMC CEF COT TET R + + B1 101 I1
R10 3/2002 AMC CEF COT CIP TET R + + B2 167 FII FIA I1
R11a 2/2010 AMC CEF COT TET R +  D 10 
R11b 8/2010 AMC CEF TET R +  D 372 
R12 7/2006 AMC CEF COT TET GEN S  n/d D 372 I2
R13 8/2009 AMC COT CIP TET S  n/d A 10 FII FIA
R14 8/2008 AMC COT CIP TET S  n/d A 10 
R15 4/2009 AMC CEF COT CIP TET S  n/d A 998 
R16a 4/2011 AMC CEF CIP TET GEN R  n/d B1 23 FII B/O
R16b 5/2011 AMC COT CIP TET GEN S  n/d B2 23 FII FIB
Resistance pattern identifies antimicrobials to which organisms were resistant: AMC = Amoxicillin clavulanate; CEF = Cephalexin; COT = co-trimoxazole;
CIP = ciprofloxacin; TET = tetracycline; GEN = gentamicin. 3rd Gen identifies which organisms were resistant (R) or sensitive (S) to the 3rd generation
cephalosporin cefotaxime. AmpC Pheno identifies which isolates were positive or negative for AmpC on the 4 disc phenotypic test. AmpC PCR identifies
those isolates where plasmid associated AmpC genes could be identified by PCR (n/d designates not done), Phylo represents phylogenetic group, ST
represents sequence type and N represents a novel ST type.
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3.3. Phylogenetic group and ST designation
PCR-based phylogenetic grouping was performed to
assign the isolates to one of 4 phylogenetic groups, namely
A, B1, B2 or D. Phylotypes A and B1 are considered to be
associated with commensal status or intestinal patho-
types, while B2 and D are more commonly associated with
strains causing extraintestinal infections (Tenaillon et al.,
2010). Among the susceptible isolates B2 was the
predominant phylogenetic group (10 isolates, 67%) with
no isolates in group A, 2 isolates (13%) in the B1 grouping
and 3 isolates (20%) in group D. In contrast, the MDR group
showed a more even distribution among all 4 phylogenetic
groups (1 isolate could not be typed), with B2 comprising
the smallest category. The distribution for A, B1, B2 or D
was 28%, 22%, 11% and 33% respectively. The proportion of
MDR isolates identified as phylotype B2 differed signifi-
cantly from the proportion of susceptible isolates identi-
fied as B2 (P < 0.001).
MLST identified 18 ST types among the E. coli isolates.
Within the MDR group these were: ST10 (n = 4); ST 23
(n = 3); ST372 (n = 2); ST46 (n = 1); ST744 (n = 1); ST648
(n = 1); ST963 (n = 1); ST539 (n = 1); ST101 (n = 1); ST167
(n = 1); and ST 998 (n = 1). The two MDR isolates belonging
to phylogenetic group B2 belonged to ST types 167 and 23.
The overall association of ST type and phylogenetic group
is listed in Table 1. Within the susceptible group ST types
identified were: ST73 (n = 4); ST12 (n = 2); ST641 (n = 1); ST
127 (n = 1); ST10 (n = 1); ST625 (n = 1); ST929 (n = 1); and
ST3005 (n = 1). A total of 3 isolates from the susceptible
group and 1 from the MDR group did not map to existing ST
types. None of the isolates belonged to ST131.
3.4. Identibac1 microarray analysis
A panel of 11 specific probes was extracted from a much
larger panel. These represent probes for which any isolate,
either susceptible or MDR, demonstrated a positive result.
The full list of probes against which isolates were tested
can be found in the supplementary materials.
The virulence marker panel results are summarized in
Table 3. Although the number of isolates examined was
limited, there were significantly higher (P < 0.05) levels of
carriage demonstrated for 7/11 specific virulence markers
in the susceptible group compared to the MDR group.
3.5. Plasmid replicon typing
In the susceptible group (Table 2) plasmid replicons
could not be identified in 5 of the isolates. In the remaining
10 isolates, 6 isolates had 2 or more replicons and 4 isolates
carried single replicons. The FII replicon was present in 5
isolates and the FIB replicon was present in 4 isolates.
Overall 8 different replicon types were identified in this
group. In the MDR group (Table 1), plasmid replicons could
not be identified in 4 of the isolates. A total of 12 of the
remaining 14 carried 2 or more replicons and only 2
isolates carried single replicons. The FII replicon was
present in 11 isolates and the I1 replicon was present in 9
isolates. A total of 6 isolates carried the FII and I1 replicons
together (these 6 isolates were all phenotypically and
genotypically positive for pAmpC). Overall 6 different
replicon types were identified in this group.
4. Discussion
These findings demonstrate clinically significant MDR
E. coli in canine urinary tract infections. The antibiogram
phenotype of isolates (Table 1.) shows that treatment
options are limited. All MDR isolates were resistant to the
recommended first line treatment amoxicillin clavulanate
and more than half of the isolates were resistant to
fluoroquinolones, a third line option (Weese et al., 2011).
MDR strains were analyzed in some detail. Comparisons
were made to a susceptible group of canine UTI isolates
from the same locality and indirectly to significant human
clonal lineages. The latter is particularly important in light
of concerns regarding the transfer of organisms between
humans and domestic animals, and the potential for either
to act as a reservoir of infection for the other.
AmpC rather than ESBL-producing E. coli were com-
monly identified among the MDR isolates. This is inter-
esting because, in human UTIs associated with MDR E. coli,
ESBLs (particularly the CTX-M group) seem to be the
predominant enzymes responsible for broad-spectrum
resistance to b-lactams. Although this study has a low
number of isolates, other studies have also identified the
presence of AmpC producing E. coli in dogs associated with
both faecal carriage and clinical disease (Damborg et al.,
2011; Dierikx et al., 2012; Murphy et al., 2009; Shaheen
et al., 2011; Sidjabat et al., 2006; Tamang et al., 2012;
Wedley et al., 2011). Furthermore, routine screening in our
laboratory has continued to identify AmpC-producing
isolates causing urinary tract infection (10 isolates from
January 2012 to November 2013). Although this represents
a relatively low local incidence, these cases are still
clinically significant and therapeutically challenging.
The phylogenetic profile differed between the two
groups of isolates. The susceptible group of UTI isolates
predominantly belonged to the B2 phylogenetic group, as
predicted from previous studies in humans and dogs
Table 2
Summary of phylogenetic group and replicon type of the susceptible
urinary tract isolates.
Isolate Isolation date (month/year) Phylo ST Replicon type
S1 1/2003 B2 73 –
S2 10/2011 B2 73 –
S3 11/2001 B2 12 –
S4 11/2001 B2 73 –
S5 11/2001 B2 N –
S6 1/2001 B1 641 X1
S7 10/2002 B2 12 I2 R
S8 1/2003 D N FIA
S9 1/2003 B2 127 FIB
S10 12/2011 B2 10 FII
S11 12/2000 B2 73 FII FIB
S12 10/2011 D N FII FIB
S13 1/2002 D 625 FII FIB B/O
S14 8/2001 B2 929 FII I1
S15 9/2001 B1 3005 B/O I1
Phylo represents phylogenetic group, ST represents sequence type and N
represents novel sequence types.
S. Wagner et al. / Veterinary Microbiology 169 (2014) 171–178174
(Johnson et al., 2003; Mao et al., 2012; Thompson et al.,
2011). The MDR group meanwhile demonstrated a more
even distribution across all four phylo-groups, with
significantly less representation of the B2 phylo-group. It
is worth noting that a more recent methodology has been
able to assign E. coli to 8 rather than 4 phylo-groups
(Clermont et al., 2013), which could have altered the
profile of the isolates in this study, and future work should
employ the revised methodology to provide greater detail
and depth of characterization. In the context of the results
from this study, isolates already assigned to B1 or B2 would
be unlikely to change classification, so the difference
between groups in the proportions of isolates in phylotype
B2 should still be valid.
The virulence marker profile also differed between the
two groups, suggesting a reduced virulence genotype in
the MDR isolates compared to the susceptible ones.
Previous studies have indicated that, in MDR isolates
associated with UTI in both humans and dogs, there may be
a shift away from the dominance of the B2 phylogenetic
group and a decrease in certain virulence genes (Moreno
et al., 2006; Vila et al., 2002). The reason for this pattern is
unclear. Other researchers have speculated that less
pathogenic phylogenetic groups are more receptive to
the acquisition of the MDR phenotype (Johnson et al.,
2004), or that acquisition of the MDR phenotype results in
a trade off, with a loss of virulence traits. Whatever the
order of events, it would seem logical that less pathogenic
phylogenetic groups, with an MDR phenotype, would
require certain conditions under which to cause clinical
disease.
Sequence typing did not provide evidence for clonal
spread of isolates in either group. Considering the
extended sampling time this is probably not surprising.
More pertinent perhaps was the fact that ST131 was not
identified amongst any of our isolates. The O25b-
ST131clonal lineage is one of the most important
uropathogenic E. coli groups in humans. It belongs to the
B2 phylogenetic group, is multidrug-resistant (almost
always resistant to the fluoroquinolones and often
resistant to 3rd generation cephalosporins), is often, but
not always, an ESBL producer (CTXM-15) and is highly
virulent (Oteo et al., 2010; Thompson et al., 2011). Total
reports of ST131 in domestic animals are still extremely
low and, although there is some support for interspecies
transfer of ST131, it is unclear if animals are a major
Table 3
Identification of virulence markers in the MDR and susceptible E. coli isolates. X indicates presence of the gene.
Isolate Phyl ireA iroN iss mchB mchC mchF mcm perA prfB senB sfaS
a a a a a a a
R1 A
R2 n/t





R8 B1 X X X X X X









R16b B2 X X X X X
S1 B2 X X X X X X X
S2 B2 X X X X X X X X
S3 B2 X X X X X X X X
S4 B2 X X X X X X X
S5 B2 X X X X X X X X
S6 B1 X X X X X X
S7 B2 X X X X X X
S8 D X X X X X
S9 B2 X X X X X X
S10 B2 X X X X X X X X X X X
S11 B2
S12 D X X X X
S13 D X X X X X
S14 B2 X X X X X X X X X
S15 B1
R = MDR isolate; S = susceptible isolate; Phyl = phylogroup; ireA = siderophore receptor; iroN = enterobactin siderophore receptor; iss = increased serum
survival; mchB = microcin H47 part of colicin H; mchC = MchC protein; mchF = ABC transporter protein; mcm = microcin M part of colicin H; perA = EPEC
adherence factor; prfB = P-related fimbriae regulatory gene; senB = plasmid encoded enterotoxin; sfaS = S fimbriae minor subunit.
a Identifies significant difference for MDR versus susceptible.
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reservoir or incidental host of this ExPEC clonal lineage, or
indeed if humans act as an animal reservoir (Platell et al.,
2011). Certainly within the limitations of our study we
found no evidence for this.
One MDR isolate (R4) was typed as ST648 phylogenetic
group D. Strains of this clonal lineage that carry ESBLs, have
been associated with bacteraemias in human patients in
the Netherlands and NDM carbapenamases in human
patients in the United Kingdom and Pakistan (Tamang
et al., 2012).
Plasmid replicon typing was performed in order to
establish the range and diversity of plasmids amongst both
the MDR and susceptible isolates. Most of the plasmid
replicons correspond to incompatibility groups. In the
susceptible group replicon types could not be assigned to 5
of the isolates. This is perhaps not surprising, as the assay is
designed to detect resistance plasmids. In the MDR group
there were 4 isolates that were not assigned replicon types.
Interestingly 2 of these (R11a and b) were phenotypically
AmpC-producing, but it was not possible to detect
plasmid-associated genes. We speculate that AmpC
production in these isolates could be attributed to
chromosomal mutations in the ampC promoter. Further
analysis of these isolates will be required to confirm this. In
the remainder of the MDR isolates the FII and I1 replicon
types were the most highly represented. We observed a
cluster comprising 6 isolates (R1–R6 Table 1) all AmpC-
producing and carrying Inc FII/IncI1 plasmids. Since IncFII
and IncI1 plasmids are two of a number of plasmid types
that are particularly successful in their ability to spread
multidrug resistance (Carattoli, 2011), further character-
ization and comparison of the plasmids from these isolates
would be of particular interest.
With the exception of one case for which we have no
history, all cases caused by MDR E. coli had underlying
disease involving suppression of the immune system (e.g.
hyperadrenocorticism, cancer chemotherapy), an anato-
mical abnormality of the genitourinary tract (e.g. detrusor
muscle atony, ectopic ureters), and/or a history of prior
antimicrobial treatment. Clinical details are summarized
in Table 4. This is not a surprising finding since it can be
envisaged that such factors will increase the potential of
isolates, which we speculate may be less virulent, to cause
clinical disease. What will be of interest is to follow the
natural history of infections caused by these organisms in
companion animals. It is highly probable that future
changes in the epidemiology of MDR E. coli infections in
dogs, will reflect those seen in the human population,
where there has been a shift from hospital-acquired
infection, analogous to what we have observed in this
study in dogs, to a community-acquired infection, where
they are associated with uncomplicated urinary tract
disease.
The main limitations of this study are the low number
of MDR isolates, and the relatively extended time over
which samples were collected. However, this reflects the
relative scarcity of such MDR isolates associated with
routine community-acquired canine urinary tract infec-
tions tested over the last decade at our laboratory, with the
majority of the MDR isolates arising from more complex
clinical cases at the small animal hospital.
5. Conclusion
MDR E. coli are a cause of a small but clinically
significant number of urinary tract infections in dogs
serviced by the veterinary microbiology service at
Edinburgh University.
Broad-spectrum b-lactamase production is an impor-
tant resistance mechanism and, unlike in human infec-
tions, AmpC rather than ESBL production predominates.
This may reflect the gut carriage of AmpC E. coli in the dog.
Amongst our isolates MDR E. coli are skewed towards less
pathogenic phylogenetic groups and have a reduced
virulence genotype. The variety of ST types does not
support clonal spread; horizontal transfer of certain
plasmid types may be a more important mechanism for
the transmission of the MDR phenotype, judging by the
frequency of the IncFII and IncI1 plasmid types. Most
importantly, ST type analysis of both susceptible and MDR
Table 4
Clinical summary of the cases from which MDR E. coli were isolated.
Isolate Breed Age (years) Summary of clinical details
R1 Dachshund 10 Surgery to treat intervertebral disc prolapse. Amoxicillin/clavulanate used for surgical prophylaxis.
R2 Weimeraner 9 Prostatic abscess. Surgical drainage and antibiotics (enrofloxacin and clindamycin).
R4 Cocker Spaniel 4 Immune mediated haemolytic anaemia, which was treated with immunosuppressant drugs.
R5 Cross breed 11 Hyperadrenocorticism. Amoxicillin/clavulanate administered for several months to manage
concurrent liver disease.
R6 Boxer 9 Multiple mast cell tumours. Resection followed by cancer chemotherapy.
R7 Schnauzer 6 Mast cell tumour. Surgical management followed by cancer chemotherapy.
R8 Labrador 10 Surgery to resect intestinal adenocarcinoma. Post surgery developed pneumonia and treated with
multiple antibiotics.
R9 Collie 10 Diabetes mellitus poorly controlled.
R10 German Shepherd 8 Prostatic infection and a perineal hernia accompanied by recurrent cystitis.
R11 Bouvier de Flandres 6 Placement of a gastrostomy tube. The stoma became infected requiring antimicrobials.
Subsequently the dog developed recurrent urinary tract infections.
R12 Bearded Collie 1 Pyelonephritis. Initially treated with amoxicillin/clavulanate.
R13 Cocker Spaniel 7 Pancreatitis
R14 Golden Retriever 5 Ectopic ureters possibly acting as a predisposing factor for urinary tract infection.
R15 Yorkshire Terrier 11 Concurrent urolithiasis.
R16 Boxer cross 7 Detrusor muscle atony decreasing the ability to empty the bladder during urination.
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isolates suggests that dogs with urinary tract infection are
not acting as a reservoir for zoonotic spread. Neither does it
provide evidence for reverse zoonosis from the human
population.
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A B S T R A C T
The purpose of this study was to determine the plasmid architecture and context of resistance genes in multi-
drug resistant (MDR) Escherichia coli strains isolated from urinary tract infections in dogs. Illumina and single-
molecule real-time (SMRT) sequencing were applied to assemble the complete genomes of E. coli strains asso-
ciated with clinical urinary tract infections, which were either phenotypically MDR or drug susceptible. This
revealed that multiple distinct families of plasmids were associated with building an MDR phenotype. Plasmid-
mediated AmpC (CMY-2) beta-lactamase resistance was associated with a clonal group of IncI1 plasmids that has
remained stable in isolates collected up to a decade apart. Other plasmids, in particular those with an IncF
replicon type, contained other resistance gene markers, so that the emergence of these MDR strains was driven
by the accumulation of multiple plasmids, up to 5 replicons in specific cases. This study indicates that vulnerable
patients, often with complex clinical histories provide a setting leading to the emergence of MDR E. coli strains in
clonally distinct commensal backgrounds. While it is known that horizontally-transferred resistance supplements
uropathogenic strains of E. coli such as ST131, our study demonstrates that the selection of an MDR phenotype in
commensal E. coli strains can result in opportunistic infections in vulnerable patient populations. These strains
provide a reservoir for the onward transfer of resistance alleles into more typically pathogenic strains and
provide opportunities for the coalition of resistance and virulence determinants on plasmids as evidenced by the
IncF replicons characterised in this study.
1. Introduction
E. coli is an important commensal organism and a significant pa-
thogen. It is associated with intestinal and extra-intestinal infections
and is a leading cause of urinary tract infections (UTIs) and bacteraemia
leading to sepsis (Pitout, 2010).
Beta-lactam antimicrobials are widely used in both human and an-
imal medicine. Due to their spectrum of activity, pharmacokinetic
characteristics and good safety profile, members of the group are a good
choice in the treatment of UTIs associated with E. coli. However, there is
increasing resistance to these antimicrobials, mediated by the ability of
Enterobacteriaceae such as E. coli, to produce plasmid mediated AmpC
(pAmpC) and extended spectrum beta-lactamase enzymes (ESBLs). This
imparts resistance to most of the Beta-lactam antimicrobials, including
the later generation cephalosporins. In addition, many are also resistant
to other antimicrobial classes rendering them multi-drug resistant
(MDR), significantly increasing morbidity and mortality (Harris, 2015).
The prevalence of pAmpC and ESBL resistance is increasing in both
hospital and community acquired infections (Nakai et al., 2016). Less
information is available for companion animals, but studies that have
evaluated this report a resistance epidemiology similar to that observed
in human clinical care (Dierikx et al., 2012; Gibson et al., 2010; Murphy
et al., 2010; Tamang et al., 2012)
Successful dissemination of resistance within MDR E. coli is attri-
butable to the fact that they are mostly located on horizontally trans-
ferable elements (HTEs) such as plasmids and transposable elements.
HTEs are often promiscuous with a diverse bacterial host range, con-
ferring resistance not just within but also between bacterial species,
generating a large potential resistance reservoir (Bortolaia et al., 2011).
It is important to determine the genetic context of resistance alleles to
understand co-inheritance of traits that may drive selection and the
potential of resistances to coalesce in single isolate backgrounds.
As sequencing technologies have advanced, an increasing number of
resistant E. coli strains, have been sequenced. Initially, much of the
sequence comparison relied upon read mapping and short read de novo
assembly. These methods often fail to accurately resolve complete
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chromosomes and other replicons due to multiple repeat regions which
are often present in mobile genetic elements. As a consequence, there is
a relative lack of availability of high quality sequence data relating to
complete bacterial plasmids encoding antibiotic resistance. The advent
of long read sequencing technologies is now leading to increased re-
presentation of these sequences in public databases.
The aim of this study was to characterise MDR E. coli associated
with urinary tract infections in dogs focusing on the use of Illumina
sequencing combined with Pacific Biosciences single molecule real time
(SMRT) sequencing to elucidate the plasmid repertoires that have been
assembled to generate MDR isolates.
2. Materials and methods
2.1. Bacterial strains
All isolates (16 MDR and 14 antibiotic susceptible (AS)) were pre-
viously characterized in terms of bacterial identification, phylogenetic
group, plasmid replicon type, MDR phenotype and ST type (Wagner
et al., 2014).
2.2. Illumina sequencing
E. coli isolates were cultured overnight at 37 °C, 170 rpm, in lyso-
geny broth (LB). DNA was extracted using Qiagen DNeasy extraction kit
(Qiagen U.K.). DNA was isolated from 1 ml of bacterial culture, ac-
cording to the manufacturer's specifications. Following integrity as-
sessment on agarose gels and quantification/quality determination by
spectrophotometry (including absorbance 260:280 nm), Nextera XT li-
braries were prepared by Edinburgh Genomics. Paired-end Illumina
sequencing was performed using an Illumina Hi-Seq 2500 sequencer
with read lengths of 100 bp to achieve an average depth of 60×.
2.3. SMRT sequencing
SMRT sequencing was performed using the PacBio platform (Pacific
Biosciences). E. coli were inoculated into 10 ml LB and incubated
overnight at 37 °C, 170 rpm. DNA was extracted using the Qiagen 100/
G extraction kit, according to the manufacturer's instructions. Extracted
DNA was prepared for sequencing using AMPure Beads (Beckman
Coulter), with a target insert size range of 10 kb or greater. DNA was
sheared using a g-TUBE™ (Covaris). Sheared DNA was purified and
concentrated using AMPure beads. Samples were eluted using PacBio
Elution Buffer, and single stranded fragments were removed with
ExoVII DNA. Fragments were then repaired using the PacBio DNA
Damage and Repair Ends buffers, as per the protocol. Processed DNA
was further purified using AMPure beads; then blunt ended sequence
adapters were ligated, and ExoIII and ExoVII restriction enzymes used
to remove any failed ligation products. Successfully ligated sequence
fragments were concentrated using three successive AMPure bead
purification steps. Final DNA concentration for all of the samples ex-
ceeded 5 μg. DNA was sequenced on the PacBio RSII sequencing plat-
form.
2.4. Sequence assembly and annotation
Illumina sequence reads were filtered using Sickle (Joshi and Fass,
2011) with a minimum read quality score of 30, and a read length of
50 bp. Reads were re-shuffled with shuffleSequences fastq.pl script
(Zerbino, 2010). De novo assembly used both paired reads and single-
tons. Illumina sequence reads were assembled with the VelvetOptimiser
script, from Velvet 1.2.08 (Zerbino and Birney, 2008) using a kmer size
range of 47 to 67.
SMRT analysis was used to generate a fastq file from the PacBio
reads and error-corrected reads were adjusted using PBcR with self-
correction (Koren et al., 2013). Then the longest 20× coverage reads
were assembled with Celera Assembler 8.1 and polished using Quiver
(Chin et al., 2013). Annotated genomes (Do-It-Yourself Annotator
(DIYA) (Stewart et al., 2009)) were imported into Geneious (Biomatters
LTD., Auckland, New Zealand) (Kearse et al., 2012) and duplicated
sequence removed from the 5′ and 3′ ends to generate the circularized
chromosomes/plasmids. Origin of replication was approximated using
Ori-Finder (Luo et al., 2014) and the chromosome reoriented using the
origin as base 1.
2.5. Core genome analysis
To construct core SNPs trees short reads were aligned with BWA
http://www.ncbi.nlm.nih.gov/pubmed/19451168 (Li and Durbin,
2009) to a reference E. coli O157:H7 Sakai strain (RefSeq assembly
accession: GCF\_000008865). Consensus sequence for each alignment
of 5,590,092 bp was produced using the majority rule and then used to
detect and remove recombination regions with Gubbins http://nar.
oxfordjournals.org/content/early/2014/11/20/nar.gku1196.short
(Croucher et al., 2015).
Resulting sequences were used to construct a Maximum Likelihood
(ML) tree with RAxML http://www.ncbi.nlm.nih.gov/pubmed/
24451623 (Stamatakis, 2014) under a GAMMA model of hetero-
geneity with 500 bootstrap replicates.
2.6. Plasmid sequence comparison
CCTViewer (Grant et al., 2012) was used to visualise SMRT se-
quenced plasmids, using 1428 p96 as a reference sequence for the IncI1
plasmids (Accession no CP023370) and 144 p134 (Accession no
CP023363) as the reference for the IncF plasmid (Table 2). Pro-
gressiveMauve (Darling et al., 2010) alignment was performed using
default parameters. ResFinder (Zankari et al., 2012) was used to con-
firm annotated antimicrobial resistance markers. BlastKOALA
(Kanehisa et al., 2016) was used to identify putative virulence factor
sequences on the plasmid.
2.7. Analysis of plasmid core and pan genomes
Plasmid replicon and clonal complex types were determined using
the pubMLST database (Jolley and Maiden, 2010). Core sequence
homology between the plasmid sequences was detected with GE-
T_HOMOLOGUES (Altschul et al., 1997) using bi-directional best-hits
(BDBHs) and orthoMCL algorithms. Protein clusters were aligned with
Muscle (Edgar, 2004). Amino acid alignments were then translated
back into nucleotide sequences using the PAL2NAL (Suyama et al.,
2006), concatenated and transformed into phyml format with catfas-
ta2phyml/catfasta2phyml.pl script to use for RaXML phylogenetic es-
timation under a GTR model and 100 bootstrap replicates (Stamatakis,
2014). GET_HOMOLOGUES was also used for the pan genome analysis,
using the PARS program from the PHYLIP package (Contreras-Moreira
Table 1
Summary of the E. coli reference strains used in this study.






ABU83972 CP001671 Asymptomatic bacteruria
JJ1886 CP006784 Multi-drug resistant
NA114 CP002797 Multi-drug resistant
uropathogenic
MG1655 NC_000913 Non pathogenic
UMNK88 NC_017641.1 Porcine enterotoxigenic
Sakai 0157:H7 BA000007.2 Human enterohaemorrhagic
APEC O78 CP004009.1 Avian pathogenic




3.1. Comparative analysis of E. coli strains
Core SNP-based phylogenetic analysis of the 30 clinical UTI asso-
ciated isolates (16 MDR and 14 AS) plus 10 reference strains (Table 1)
was carried out, and identified at least two distinct clusters that mostly
correlates well with the isolates’ MDR status (Fig. 1). Isolates were
ancestrally diverse, however there was a trend for susceptible isolates to
be more closely associated to human UPEC E. coli reference sequences
and MDR isolates clustered together with commensal E. coli reference
sequences. Whole genome sequencing (WGS) analysis of the MDR
strains confirmed previous standard phylotyping results regarding their
diverse commensal backgrounds. Isolates that possess the IncI1/IncF
plasmid genotype were well dispersed throughout the tree. Tree clades
were largely independent with respect to date of isolation.
3.2. Sequencing and plasmid carriage
Plasmid sequences could not be assembled using Illumina short read
sequence data. Therefore, 8 MDR isolates (127, 1223, 1283, 1428, 144,
317, 746 and 1943 (Supplementary Table S1)) were sequenced by
SMRT, these were selected to examine the IncI1 replicon context of the
CMY-2 (AmpC) beta-lactamase. Two sensitive isolates (1190 and 1105,
(Supplementary Table S2)) but carrying an IncI1 replicon were also
sequenced by SMRT. The plasmid combinations present in the MDR
strains are described in Table 2 and depicted in Fig. 2 along with their
contribution to MDR as defined by carriage of specific resistance alleles.
While 7/8 MDR strains had the anticipated replicons, one isolate
(317) only carried an IncF plasmid, despite PCR and Illumina sequence
data indicating the presence of IncF and IncI1 replicons. It is possible
that the plasmid was lost during the experimental process. One sus-
ceptible isolate, 1105, was PCR positive for the IncI1 genotype, but this
replicon could not be assembled from the SMRT sequence data.
3.3. IncI1 comparative analysis
In the MDR isolates, the IncI1 plasmid sequence sizes ranged from
85 to 96 kb, with between 106 and 113 coding domain sequences;
many of which still had no ascribed function. All but two of the IncI1
plasmids belonged to the same clonal complex (CC-2), determined in
silico, based on the presence and sequence similarity of repI1, ardA,
trbA, sogS, and pilL to previously published IncI1 pMLST profiles. As
anticipated, the IncI1 plasmids associated exclusively with the CMY-2
encoded pAmpC beta-lactamase resistance gene; this was located within
a resistance cassette associated with a mobile element (Figs. 2 and 3).
Significant periods of time separate isolation of the sequenced
strains; the first collected in 2001, the most recent 2011. This makes the
comparison of the IncI1 replicons unique as it provides insight into the
evolution of this resistance-encoding replicon in our local context over
this time period.
BLAST Atlas search using the CCT comparison tool for analysis of
the Incl1 replicons show greater than 90% sequence similarity for most
of the sequences. Multiple collinear blocks, with high synteny and se-
quence similarity and limited large-scale rearrangements were identi-
fied using progressive Mauve (Fig. 3).
IncI1 plasmids were compared against 42 plasmid sequences ob-
tained through GenBank, which were identified by BLAST as being si-
milar (Supplementary Fig. 1). Pan-genomic analysis detected 305
homologous gene clusters across all sequences. Phylogenetic estima-
tions using homologous cluster presence or absence indicated a close
phylogenetic relationship between all IncI1 plasmids sequenced in this
study including the IncI1 plasmid from the susceptible E. coli isolate in
this study (1190/01 Accession no CP023387). The resistance cassette
conferring CMY-2 mediated pAmpC resistance although not exclusive to
the canine resistance plasmids, was not detected in many other IncI1
sequences available on databases. Ten of the homologous gene clusters:
traL, traM, nikB, traO, traJ, traF, traE, traT, traI, and traX; all relating to
plasmid transfer and replication were core to all the IncI1 plasmid se-
quences (Fig. 4). These were extracted from the pan-genomic analysis
and aligned for maximum likelihood core genome phylogenetic esti-
mation (Supplementary Fig. 1). Despite only weak bootstrap support
overall, the phylogenetic tree is congruent with the predicted in silico
MLST plasmid groups. The IncI1 plasmids included in the analysis were
from different Salmonella serovars and E. coli isolated from different
animal hosts suggesting that interspecies transmission of the IncI1
plasmids occurs. However, IncI1 sequences associated with bacteria
isolated from humans were largely absent, despite the over re-
presentation of human isolates in databases in general. The majority of
canine sequences form a sub-cluster, with chicken- and porcine-asso-
ciated plasmid sequences being the most similar. Of note, CP009566
and KF434766 are the only two reference IncI1 plasmids associated
with canine clinical infections; isolated in Salmonella enterica serovar
Newport in Arizona in 2015 (Cao et al., 2015) and E. coli in Denmark in
2008 (Hansen et al., 2016) respectively. These were closely related to
the canine E. coli plasmids sequenced in this study even though their
host bacterial strains were obtained from different geographical areas
and at different times (Supplementary Fig. 1).
Table 2
Plasmid descriptions from isolates following Illumina and SMRT sequencing.
Name* CDS Plasmid MLST Resistance genes Virulence genes
127 p123 140 IncFII: 22 FIA: 6
FIB: 69
aadA5, aph(3′)-1a,
strB, strA, catA1, sul1,
sul2, dfrA17
–
127 p95 105 IncI1:ST2 (CC2) blaCMY-2 –
127 p91 100 nt – –
127 p43 51 nt blaTEM-33, dfrA1 hha, virD, virB
127p39 48 nt – fimD, hha, virD,
virB
1223 p147 150 IncFII:18 – iss, iroN, mchF
1223 p87 97 IncI1:ST23
(CC2)
blaCMY-2 dot
1283 p109 128 IncFII:31 tet(A) TC·FEV.OM3, sit
1283 p92 101 IncI1: ST2
(CC2)
blaCMY-2 dot
1283 p31 41 nt – hha, virD, virB
1283 p7 9 nt strA, strB, sul2,
dfrA14
–
1283 p3 3 nt – –





1428 p96 113 IncI1:ST43 (CC-
)
blaCMY-2 dot
1428 p66 108 IncFII:4 tet(B) –
1428 p48 65 nt – –
144 p134 142 IncFII:2 FIB:1 strA, strB, blaTEM-1b,
sul2, dfrA5
iroC, sit, iuc, mer
144 p92 105 IncI1:ST2 (CC2) blaCMY-2 –
317 p100 105 IncFII:43 – ABC,LPT.P,
TC·OOP, raxB
746 p95 106 IncI1:ST2 (CC2) blaCMY-2 dot
746 p72 116 IncFII:2 § – –
746 p62 102 IncFII:2 § – –
1943 p85 90 IncI1:ST55 (CC-
)
blaCMY-2 dot
1943 p80 86 IncFIB:1 – sit, iuc
1943 p54 59 nt blaTEM-1a, catB3,
dfrA1
hha, virD, virB
*Each plasmid is referred to by the isolate ID followed by the letter p and then a number
which represents the size of the plasmid in KB. nt = non typable, CC = clonal complex,
− = non identified, § = putative split contig, CDS = coding sequence, ST = sequence
type.
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Fig. 1. Maximum-parsimony tree of E. coli chromosomal sequence alignment. Isolates from this study are listed in red (MDR) or green (AS). Ref-Seq sequences are listed in black. Plasmid
replicon types are designated from left to right by the colour coded squares: FII FIA FIB I1 I2 B/O ×1 R . Phylogroup designations are colour coded in the right hand
column as follows, A = yellow, B1 = blue, B2 = red and D = green. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.).
Fig. 2. Graphical representation of the plasmid carriage of
the E. coli isolates sequenced in this study. Boxes represent
each isolate referred to by their isolate ID. Depicted se-
quences are not to scale. Plasmid sequences are identified and
distinguished by their sequence length. Plasmid encoded re-
sistance, where detected by BLAST search, is indicated by
colour coding on the plasmids. Plasmid incompatibility type,
where typable, is indicated (either IncF or IncI1).
Chromosomal sequences are not depicted.
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3.4. IncF comparative analysis
The IncF plasmids were more heterogeneous in size (100–147 kb),
the number of coding regions (105–150), and the number and classi-
fications of various resistance markers. Aminoglycoside, chlor-
amphenicol, potentiated-sulfonamide, and beta-lactam resistance mar-
kers (other than CMY-2) were associated with IncF or smaller untyped
plasmids (Fig. 2).
Despite the greater variety and number of resistance markers shared
amongst some of the IncFII plasmids, five contained no detectable re-
sistance markers. Virulence genes, mostly associated with iron uptake,
and genes associated with metabolism were detected on many of the
IncF plasmids. In silico replicon typing indicates that many of these
plasmids were of mixed lineage (Table 2). IncF plasmids showed less
sequence similarity when compared by BLAST or by progressiveMauve
sequence analysis. With one exception, all regions of local co-linearity
had little synteny, or support across all the plasmid sequences (Fig. 5).
GenBank BLAST searches identified 9 sequences similar to the IncFII/
IncFIB plasmids. Pan-genomic maximum parsimony analysis indicated
diverse content (Fig. 6a). No core genes could be identified for all the
plasmid sequences, although a subset, excluding 1428 p66, 746 p62,
746 p72, and 1943 p80, could be compared using 8 homologous gene
clusters; as with the IncI1 plasmids these genes were mostly associated
with plasmid maintenance and replication, including traA, traL, traE,
traB and traX. The different replicon sub-types are depicted in Fig. 6b,
with FII/FIB the most commonly identified. A singular clade of plas-
mids, exclusively IncFII, showed greater sequence homology than the
remaining plasmid sequences (Fig. 6a & b). Maximum likelihood phy-
logenetic analysis of IncFII, IncFIA, and IncFIB replicon types showed
dispersal of all sequences of different replicon types throughout the tree
(Fig. 6b). None of the PCR typed IncFII plasmids sequenced in this study
were members of the same clade and 317 p100 was a significant outlier
from the rest of the plasmid sequences.
3.5. Other plasmids
Numerous other extra-chromosomal contigs were detected from
SMRT sequencing. IncI1, IncFII, IncFIA, and IncFIB, were the only
Fig. 3. Core sequence alignment of IncI1 replicon type plasmid sequences, using 1428 p96 as the index sequence. Comparisons were performed using a BLAST Atlas search using the CCT
comparison tool. Both the whole nucleotide sequence (smaller ring) and coding domain sequence specific (larger ring) BLAST comparisons were carried out. ProgressiveMauve was also
used to compare the plasmids. Local co-linear blocks, detected by progressiveMauve have been annotated onto the BLAST comparisons.
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detected incompatibility types, yet account for a fraction of plasmid
sequences. The nature of the SMRT sequencing and the analysis means
that these sequences are very unlikely to be part of the main chromo-
some or the plasmids with defined replicon-types. Whilst many of these
do not contain identifiable resistance markers, some do. Many of these
sequences do not have established replication and transfer machinery
encoded on them, so their transfer capacity is currently unknown, but
they may represent small replicons that can be co-inherited with other
transferred plasmids or possibly by other methods such as transduction.
4. Discussion
MDR E. coli isolates are relatively rarely isolated from in and out-
patient samples presented for testing at the University of Edinburgh’s
small animal hospital. As previously described (Wagner et al., 2014)
MDR isolates are often associated with animals with complex medical
histories and understanding their emergence in the context of generally
sensitive E. coli isolates (AS) provides an important opportunity to de-
velop our understanding of MDR emergence in a clinical setting.
Combined use of Illumina and SMRT sequencing has allowed de-
tailed examination of individual plasmids and strain background, as
well as an overview of plasmid carriage in the context of individual
isolates.
Phenotypic beta-lactamase resistance is attributed to pAmpC, en-
coded exclusively by the CMY-2 allele on IncI1 replicon plasmids,
forming a notably closely related phylogenetic cluster, with high levels
of homogeneity in the IncI1 plasmid sequence, despite the strains
having been collected over a 10 year period. The CMY-2 allele was the
only identifiable resistance gene present on this subset of IncI1 plas-
mids. This has been reported previously in CMY-2 carrying IncI1 plas-
mids isolated from canine, feline and human hosts (Bortolaia et al.,
2014; Sidjabat et al., 2014). The majority of the MDR IncI1 plasmids
share a closest common ancestor, using maximum-likelihood analysis of
the core genome. This is either due to i) limited sequence divergence or
ii) sequence convergence. Given the genetic distance between the sus-
ceptible IncI1 plasmids, the absence of any dominant E. coli clone as-
sociated with the IncI1 plasmids, the lack of any indication of potential
bacterial host range of the plasmids (other than E. coli), and the dis-
cordance of sequence similarity with the chronological sequence of the
E. coli isolates; it is difficult to identify which. The reliability of any
estimation of rates of divergence between the different plasmids is
questionable; the identification of a similar plasmid backbone in canine
clinical isolates CP009566 and KF434766 from the USA and Scandi-
navia does suggest underlying core genome stability (Bogaerts et al.,
2015; Bortolaia et al., 2014). CMY-2 has also been identified from
faeces of healthy dogs in a number of geographical locations including
the Netherlands, Mexico, France and Japan, (Baede et al., 2015; Haenni
et al., 2014; Okubo et al., 2014; Rocha-Gracia et al., 2015) and where
determined, the plasmid context is predominantly IncI1. This may in-
dicate that the IncI1-CMY-2 is endemic to the commensal population
especially in the dog. The common use of cephalosporins such as ce-
phalexin in companion animal practice has been implicated in high
prevalence carriage particularly in canine isolates (Haenni et al., 2014).
In comparison to the IncI1 plasmids, the IncF plasmids are more
disparate, in core and pan-genome sequence content. This could be a
consequence of experimental design, as the isolates for this study were
collected based on their pAmpC production, the gene for which is
present on the IncI1 plasmid. However other studies also provide evi-
dence for the relative heterogeneity of the IncF plasmids (Villa et al.,
2010), and relatively few sequences could be identified in the NCBI
database, sharing nucleotide similarity with the IncF sequences in this
study; with little conservation of resistance markers between one IncF
plasmid and another. Another contrasting feature of the IncF plasmids,
supported by other studies, was their greater compliment of resistance
alleles and putative virulence-associated genes compared to the IncI1
plasmids. As most of the strains containing the IncI1/IncF plasmid
combination specifically were associated with commensal phylogroups,
we speculate that acquisition of IncF plasmids in combination with
IncI1 drives emergence of normally commensal E. coli strains resulting
in clinical disease in vulnerable patients, especially in the presence of
antibiotic selection. All patients from which MDR isolates were iden-
tified could without exception fall into this categorisation having sig-
nificant underlying disease, often multiple antibiotic treatments and
some receiving immunosuppressant therapies (Wagner et al., 2014).
The dispersion of resistance genes across different plasmids, in many of
the isolates, suggests sequential acquisition perhaps whilst part of the
Fig. 4. Maximum-parsimony analysis using detected presence or absence of homologous
gene clusters from the pan genome of PacBio IncI1 replicon sequences, and comparator
IncI1 sequences obtained from the NCBI nucleotide sequence database. Plasmid se-
quences from this study lie within the red box. Core genome genes (used for maximum-
likelihood analysis) are indicated by *. The CMY-2 resistance cassette, common to the
IncI1 plasmid sequences isolated in this study, is highlighted by the blue box. (For in-
terpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
Fig. 5. Core sequence alignment of IncFII replicon type plasmid sequences, using 1223
p147 as the index sequence. Comparisons were performed using a BLAST Atlas search
using the CCT comparison tool. Both the whole nucleotide sequence (smaller ring) and
coding domain sequence specific (larger ring) BLAST comparisons were carried out.
ProgressiveMauve was also used to compare the plasmids. Local co-linear blocks detected
by progressiveMauve have been annotated onto the BLAST comparisons.
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normal flora of the gastrointestinal tract; as it is unlikely that the
transfer of multiple plasmids would occur as a singular event. Com-
mensal strains have previously been implicated as a significant
component of the resistance reservoir (Marshall and Levy, 2011) whilst
other studies have clearly identified the carriage of CMY-2 in more
typical UPEC strains such as ST 131 (Dashti et al., 2014).
Fig. 6. Maximum parsimony and maximum likelihood analysis for IncFII. a) Maximum parsimony analysis of pan-genomic homologous gene clusters for IncFII replicon sequences.
Similar NCBI nucleotide sequences, with detectably diverse replicon types were included. Isolates sequenced in this study are indicated by the red boxes. b) Maximum-likelihood analysis
of aligned core homologous sequences. Sequences have been annotated with their detected replicon type. FII FIA FIB . (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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SMRT sequencing identified strains containing up to 5 plasmids
contributing up to 300KB of additional genetic information. Much of
the function of these coding regions is unknown Sequencing also re-
vealed the presence of small non-typable plasmids of which we were
previously unaware. It is assumed that the acquisition of so much extra-
chromosomal DNA may be energetically costly to the bacterial host,
and many of the plasmids may not be stably maintained in this com-
binatorial manner in these specific backgrounds without antibiotic se-
lective pressure. The long-term stability of these plasmids within their
host bacterial genomes is currently unknown, but investigation of this
in future work would be of significant value.
The MDR E. coli strains characterised in this study were isolated
from clinical cases with significant underlying disease, which had re-
ceived often multiple courses of antimicrobial chemotherapy. This re-
presents a model of the genetic and phenotypic adaptation of E. coli to
current clinical practices in both the human and veterinary setting.
Patient vulnerability and antibiotic selective pressures provide an en-
vironment for the emergence of opportunistic MDR resistant E. coli
based on the acquisition of at least two plasmid replicon groups, with
numerous other horizontal DNA molecules also under selection. It will
be of interest to evaluate the long-term stability of extra-chromosomal
DNA in relation to antibiotic selective pressure and individual plasmid
and resistance gene effects. In addition, it would also be of value to
establish the reservoir potential of isolates as a source of resistance. It
could be argued that the commensal background of the isolates requires
a confluence of several factors for disease to occur, but should the
horizontal transfer of plasmids to more pathogenic E. coli occur then the
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